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Abstract  
Deregulation of tyrosine kinases has been implicated in Philadelphia chromosome negative 
Acute Lymphoblastic Leukaemia (ALL) with a higher risk of relapse. The studies in this 
thesis sought to identify potential receptor tyrosine kinase targets and to explore the use of 
tyrosine kinase inhibitors (TKIs) in childhood ALL. 
 
Initial work describes the baseline receptor tyrosine kinase profiles of 18 primary ALLs. 
Alterations in the phosphorylation signals of Axl, EphA2, EphB2, FGFR2, FLT3, Mer and 
PDGFRβ were identified and associated with clinical and biological features. 
   
Subsequently, 5 ALL cell lines and a panel of 20 primary samples representative of 
common biological features were screened for sensitivity to a library of TKIs. Significant 
heterogeneity in sensitivity was observed in the panel of leukaemia cells. No correlation 
was evident between response to TKIs and current clinical or biological stratification 
parameters in the primary cell panel.  
 
Two candidate inhibitors, dovitinib and foretinib, were taken forward for further 
preclinical work. Potent nanomolar activity was demonstrated in cell lines and primary 
ALL. The combination of dovitinib or foretinib with conventional cytotoxics demonstrated 
significant synergy and sensitised steroid – resistant cell lines to dexamethasone. Objective 
responses were not identified to single agent TKI therapy in a murine primagraft model.   
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1 Acute Lymphoblastic Leukaemia of Childhood 
1.1 Incidence and prevalence of childhood malignancies 
Childhood cancer is an uncommon event, affecting approximately 1 in 600 children in the 
United Kingdom (1). Despite its infrequency, cancer is an important cause of morbidity and 
mortality in children under 16.  In 2008, malignancy was the second most common cause of 
death, following trauma, accounting for approximately 20% of childhood deaths (2).  
  
Of the estimated 1500 children suffering from cancer in the United Kingdom (UK) each 
year, acute leukaemia accounts for 25 – 30%, of which acute lymphoblastic leukaemia (ALL) 
is most common. The reported incidence of ALL was 46.1 cases per million children per 
year in England and Wales for the period 1996 – 2000, with an international incidence of 12 
– 59 cases per million (3, 4). While the incidence of childhood malignancy is relatively 
constant throughout Europe (4), studies from Europe and the United States of America 
(USA) have demonstrated annual increases of up to 1.4% for ALL (5, 6). In Europe, this 
increase has coincided with the westernisation of previous Eastern Bloc societies (7). In the 
Czech Republic a 1.5 fold increase was described in the age group 1 – 4 years for the period 
1980 – 1999 (8). A corresponding increase has not been demonstrated in many non – 
European developing countries, which may be a spurious finding due to under – reporting 
and the lack of robust cancer registries (9).  
 
The distribution of acute leukaemia varies with age. The peak incidence of ALL is around 
the third and fourth years, rapidly rising from birth and decreasing dramatically after 5 
years of age (10).  
 
1.2 Presentation, investigation and diagnosis of childhood ALL 
1.2.1 Presentation  
ALL is characterised by a combination of generalised systemic illness, haematological 
complications from replacement of normal haematopoietic tissue with non – functional 
malignant cells and invasion of extramedullary tissue. Leukaemic blasts may infiltrate intra 
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– abdominal and/or thoracic structures (thymus or thoracic lymph nodes), leading to life – 
threatening compression of the airways and great vessels. Patients with extensive systemic 
spread may develop central nervous system (CNS) invasion, presenting with the signs and 
symptoms of raised intracranial pressure from meningeal infiltration, focal neurological 
involvement (such as invasion of cranial nerves) or intracranial bleeds due to 
thrombocytopenia.  
 
1.2.2 Diagnostic investigations 
The baseline investigations required for diagnosis, classification and stratification of 
leukaemia include a peripheral blood film to demonstrate lymphoblasts, a bone marrow 
aspiration for morphology and immunophenotyping and a lumbar puncture to assess CNS 
involvement (11, 12).   
 
Morphological examination of bone marrow confirms the presence of abnormal cells, with 
lymphoid blasts generally small, uniform cells with homogenous chromatin. The French – 
American – British (FAB) classification system of acute leukaemias was based on 
assessment of cell size, nuclear shape, cytoplasmic amount and consistency, describing 
leukaemia cells as L1, 2 and 3 (13). The FAB classification system has been superseded by 
classification systems based combining morphology, immunophenotype, leukaemic 
cytogenetics and assessment of treatment response. The one exception is L3 morphology, in 
which cells express the surface immunoglobulin M (sIgM) and demonstrates similar 
behaviour to the more mature Burkitt’s Non – Hodgkin’s Lymphoma, requiring a different 
treatment strategy.   
 
Morphological examination is complemented by immunophenotyping of the leukaemic 
blasts by flow cytometry. Panels of monoclonal antibodies to antigens associated with 
leukaemias are used to determine lineage (see table 1.1 and fig 1.1), antibodies to CD3 or 7 
to identify T – cell ALL, CD19 (B – cell leukaemia), cytoplasmic myeloperoxidase (myeloid 
lineage).  
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Antigen  Maturity  Lineage  
CD45 (Common Leukocyte Antigen) - Myeloid/Lymphoblastic  
CD34 Immature  Myeloid/Lymphoblastic  
   
CD19  Pan – B  B – cell precursor ALL 
CD10 (common ALL antigen) Immature   B – cell precursor ALL 
Tdt (Terminal deoxynucleotidyl transferase)  Immature  Precursor B – and T – ALL  
Cytoplasmic Immunoglobulin (cyIg) Immature  B – cell precursor ALL 
Surface Marker Immunoglobulin (smIg) Mature  B – cell Mature ALL 
   
Cytoplasmic CD3 Mature  T – cell ALL 
Surface marker CD3 Mature  T – cell ALL  
CD7 Mature   T – cell ALL 
   
Cytoplasmic MPO -  Myeloid  
 
Table 1.1 List of antigens commonly used to identify lineage and maturity of acute leukaemias (14). 
 
                
Markers        
CD34 + + + +    
Tdt  + + - - - - 
CD19 - + + + + + + 
CD10 - - + + -/+ - - 
Cytoplasmic 
Ig 
- - - -    
Surface Ig - - - - - - + 
Stages Null Pro – B Common ALL Pre – B Mature B – cell ALL 
 
Figure 1.1 B – cell precursor ALL mirrors the stages identified in normal B – cell development. The 
maturity of both normal B – cells and B – cell lineage leukaemias can be determined by the expression of cell 
surface and intracellular antigens. Reproduced from Janeway’s Immunobiology (15).  
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1.3 Risk assessment of ALL and prognostic implications  
The heterogeneous nature of ALL has led to the understanding that a generic therapeutic 
strategy is not optimal.  Current protocols stratify the intensity of treatment on the basis of 
potential relapse risk. An unfortunate consequence of this focus on relapse risk is that a 
significant number of children may be over – treated on current intensive strategies. 
Current stratification strategies combine clinical and biological risk factors with the aim to 
balance the burden of chemotherapy with the intention of a favourable outcome.  
 
1.3.1 Age and white cell count 
The first attempts to establish a uniform system of stratification used age and diagnostic 
white cell count (WCC) as the stratification tools (16, 17). Although the value of these 
continuous variables has been questioned, comparisons of the hazard ratios of relapse are 
borne out when the highest and lowest quintiles of risk categorisation have been compared 
(18).    
 
The Rome/NCI classification defined WCC greater than 50x109 blasts/litre as the threshold 
to intensify therapy (16) and has been adopted by the UK Medical Research Council (MRC), 
US Children’s Oncology Group (COG) and German – based Berlin – Frankfurt – Münster 
(BFM) trial cooperatives. High WCC is associated with an increased risk of bone marrow 
relapse in B – cell precursor, but not T – cell ALL (19). WCC  greater than 100x109/L is 
associated with increased CNS relapse in T – cell ALL (20).  
 
The standard risk category for age defined by the Rome/NCI workshops is between 1 and 
10 years, which has been widely adopted. Patients outside of this range have a poorer 
prognosis (21), with particularly high rates of relapse in infant ALL (<1yr) (22, 23). 
Similarly, adolescents and young adults (AYA) have increased rates of relapse (21, 24, 25) 
although outcomes can be improved by intensifying treatment (26). Reasons for the lower 
survival rates in AYA are thought to relate a reduced frequency of leukaemias sensitive to 
current treatment strategies (27, 28) and higher treatment – related toxicity (29, 30)  
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1.3.2 Recurrent cytogenetic abnormalities and translocations  
Approximately 80% of ALL demonstrate recurrent chromosomal alterations, 
predominantly translocations, deletions, aneuploidy or amplifications (11, 31, 32). In 
general, the primary chromosomal abnormality occurs in isolation (33). More detailed 
molecular assessment of B – precursor ALL has revealed sub-microscopic abnormalities in 
cytogenetic subtypes. On average a leukaemic blast has 6.46 molecular abnormalities (34), 
with the copy number alteration (CNA) related to the cytogenetic subtype. MLL –
rearranged leukaemias usually demonstrate only 1 CNA per cell, while TEL/AML1 and 
Philadelphia – chromosome positive (Ph+) leukaemias have been revealed to possess 6 or 
more CNA per case.  The inference is the fewer the copy number alterations the more 
oncogenic the mutation. Leukaemic karyotype is a prognostic indicator independent of age 
and white cell count (35), with not only the total copy number but specific recurrent 
cytogenetic translocations impacting on the response to therapy (36).  
 
Translocation Frequency Impact on survival 
Hazard Ratios (95% CI) 
Survival for trial 
Favourable cytogenetics: 
TEL/AML (ETV6-RUNX1) 
t(12;21)(p13;q22) 
22%  0.51  
(0.38 - 0.7) 
EFS 89% 
OS 96% 
Hyperdiploid 
Chromosomes >50 
25% 0.6 (0.47 – 0.78) EFS 84% 
OS 93% 
Unfavourable cytogenetics: 
E2A-PBX1 
t(1;19)(q23;p13.3) 
5% 0.6 (0.27 – 1.35) 
 
EFS 80% 
OS 84% 
MLL rearrangements 
11q23 
(4;11,8;11,11;19) 
8% 
(Infants 70%) 
> 1 year 2% 
2.98 (1.71 – 5.2) 
 
EFS 50% 
OS 60% 
Bcr/Abl 
t(9;22)(q34;1q11.1) 
3% 3.55 (2.21 – 5.72) EFS 44% 
OS 58% 
t(17;19) <1 -  -  
iAMP21 1 – 3%  6.04(3 – 9.35) 
Improved with increased 
intensity 
HR 2.246 
EFS 26% 
OS 69% 
COG trials (37): 
4yr EFS 70.2±7% 
4yr OS 84.7±5.6% 
Table 1.2 Summary of the impact of chromosomal abnormalities and cytogenetic variation on 5yr overall 
survival for the United Kingdom ALL97/99 trial. The 5yr survival for the ALL97/99 trial was 87% (86 – 89%). 
Five year overall survival rates for childhood ALL range between 85 – 95% in large cooperative trials (33, 35, 
37). 
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1.3.2.1 Philadelphia chromosome – positive t(9;22)(q23;q11) 
Only 3 – 5% of childhood leukaemia express t(9;22) (38); the frequency increases with age, 
up to 30% in adult ALL (39) . The Philadelphia chromosome was initially identified in CML 
(40) and the molecular detail of the reciprocal translocation of the long arm of 9 (q34-ter) 
and long arm 22 (q11-ter), t(9;22)(q43;q11) was defined later (41). The minutiae of the 
translocation sites differ in the acute and chronic form of the disease. In acute leukaemia the 
breakpoint is upstream of the BCR (minor – BCR) and encodes for a smaller fusion 
oncoprotein, the p190 variant (42). The classic adult variant (p210) is rare in paediatric 
Philadelphia disease, usually described in CML, AML or biphenotypic leukaemia.  
 
1.3.2.2 ETV6/RUNX1 t(12;21) 
The cryptic ETV6/RUNX1 translocation is the most frequent recurrent abnormality (25 – 
30%) in childhood B – precursor ALL (43, 44), most commonly occurring between 1 – 10yr 
of age (45). The translocation is less frequent in adult ALL and is very rare in T – cell ALL 
(46, 47). 
The t(12;21) translocation results from the juxtaposition of exons 1 – 4 of TEL/ETV6 on 
12p13 and the coding region (21q22) of RUNX1/AML1/CBFA2 (44). Both TEL/ETV6 and 
RUNX1 encode for transcription factors, and the latter is part of the core binding factor 
alpha – 2 complex, which is important in normal haematopoiesis. The resultant fusion 
oncogene interferes with the differentiation of normal lymphoid precursors, by converting 
RUNX1 to a transcriptional repressor (48).    
 
1.3.2.3 E2A – PBX1 t(1;19) 
The E2A – PBX1 translocation occurs in all B – cell lineage leukaemias, but most commonly 
in pre – B ALL (49).  The E2A gene is located on 19p13.3 and encodes 2 transcription factors, 
E12 and E47, which bind the IGK gene promoter and regulates downstream target genes. 
The homeodomain family gene PBX1 (1q23) encodes a transcription factor important in 
lymphoid haematopoiesis. The precise mechanism of leukaemogenesis is uncertain, but 
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transcriptional activation by the fusion oncoprotein of genes which are normally repressed 
in the lymphoid compartment may explain its action.   
 
1.3.2.4 Mixed Lineage Leukemia (MLL) gene rearrangements  
The MLL gene is located on chromosome 11q23 and mutations are involved in 2 –  5% 
paediatric (50, 51), 10% adult (52) and  65 – 70% infant  ALL (53).  In comparison with 
global incidence, a significantly higher frequency of MLL – rearranged leukaemias have 
been described in Mexico, up to 65% of childhood ALL, possibly related to the in utero 
exposure to toxins (54, 55).  
 
 MLL encodes for a transcriptional factor which regulates embryonic and haematopoietic 
development and differentiation; downstream targets include the homeobox family of 
genes and IKZF1. A significant number of translocation partners have been described most 
commonly chromosomes 4, 6, 9 and 19. These patients demonstrate a progenitor B (pro – B) 
CD10 negative immunophenotype with biphenotypic characteristics, co – expressing the 
myeloid marker myeloperoxidase.  
 
1.3.2.5 Intrachromosomal amplification of chromosome 21 (iAMP21) 
The MRC UK cytogenetic group described an intrachromosomal amplification of 
chromosome 21, in leukaemias which demonstrated increased RUNX1 signals but were 
negative for the ETV6/RUNX1 fusion using a FISH probe (56-58).  The abnormality has been 
associated with poor prognosis and is more commonly described in older children with low 
WCC at presentation (37, 56, 59-61). Intensification of therapy has diminished the 
unfavourable implication of this finding (62).  
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1.3.3 DNA context   
The number of chromosomes in the leukaemic blast can range from near haploid to over 65 
chromosomes and is an independent prognostic indicator (63, 64). Hyperdiploidy is 
associated with an improved survival (65), while survival diminishes with the decreasing 
number of chromosomes, with the poorest outcome seen in near haploid leukaemias (66, 
67).  
 
1.3.3.1 Hyperdiploidy 
The most commonly associated findings with hyperdiploid ALL are trisomies, especially 
chromosome 21 and the X chromosome (68). A number of structural rearrangements are 
also associated with hyperploidy, including translocations (5 – 10%), duplication of 1q and 
isochrome 17q (68-70).  
 
1.3.3.2 Hypodiploidy 
In leukaemias with a clonal loss of DNA, survival decreases once the total chromosome 
complement is less than 46 (71, 72). Particularly poor survival rates are present in patients 
with near haploid status (33). This abnormality is almost exclusive to children and may not 
be detected on standard cytogenetic testing. Near haploid leukaemias demonstrate a high 
frequency of RAS signalling pathway activating mutations (73). 
1.4 Response to treatment 
The most potent determinant of individual survival is the response to therapy (74). 
Refinement of assessment has progressed from simple morphological assessment by light 
microscopy to the detection of sub-microscopic minimal residual disease (MRD) by 
molecular and flow cytometric techniques.  
 
1.4.1 Assessment of early morphological response 
The early morphological response of leukaemia to therapy has historically been identified 
as a predictor of survival. The method of assessment and definition of response depends on 
the international co – operative. The cooperatives in the United States started to evaluate 
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day 7 or 14 bone marrow response to multi – agent therapy in 1970s, while the German 
BFM study group based response on the reduction of peripheral blasts after 7 days 
prednisone monotherapy (75). Early reductions in blast counts in both study groups 
positively correlated with improved outcomes (25, 76, 77).  
 
The benefit of treatment intensification based on the early assessment of in vivo response 
was demonstrated by Nachman et al. in the non – randomised CCG1882 trial (78, 79).  High 
risk patients (WCC>50 x 109/l and age >10yr) with  greater than 25% blasts at the day 7 
marrow assessment were treated with augmented therapy and achieved event free survival 
(EFS) similar to the rapid responders. This seminal work laid the basis for intensification of 
treatment based on in vivo response.  
 
1.4.2 Assessment of sub – microscopic disease 
Despite the incorporation of morphological assessment into treatment strategies, significant 
limitations existed, with a high degree of intra – and inter – observer variation and 
sensitivity limited to the detection of 2 – 3 blasts per 100 normal bone marrow cells. The 
sub-microscopic persistence of leukaemia in ‘remission’ marrow samples was recognised 
using a double marker immunofluorescence assay directed at antigens on leukaemic blasts 
(80, 81), and led to the development of two commonly used techniques to evaluate the 
presence of sub – microscopic minimal residual disease (MRD).   
 
1.4.3 Assessment of antigen – receptor gene rearrangements   
The rearrangement of gene segments encoding the immunoglobulin (Ig) or T – cell 
receptors (TCR) in normal B – and T – lymphocyte development generate unique 
combinations. Immunoglobulins are composed of heavy and light chains, both of which 
contain constant (C) and variable (V) regions. Random combination of genes encoding for 
the variable (V), diversity (D) and joining (J) segments of the V region allows for the wide 
scope of antigen recognition. Clonal rearrangements of VDJ segments are detectable in ALL 
as the oncogenic transformation arises from a single lymphoid progenitor. Using primers 
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directed at the VDJ junctions, the leukaemia – specific diagnostic clone is identified and 
sequenced by polymerase chain reaction (PCR). Rearrangements are identifiable in 
approximately 90% of patients to achieve sensitivity of 0.01% (82, 83). The presence of blast 
cells at greater than 0.01% at the end of induction therapy correlates with a higher rate of 
relapse (74, 84-87). A recent study from St Jude’s Children’s Research Hospital 
demonstrated the ability of molecular PCR to detect blasts at 0.001% normal marrow 
population (83). Recent studies have demonstrated that the presence of leukaemia blasts 
greater than 0.01% with current molecular techniques is the most important indicator of 
prognosis (74, 88). 
 
1.4.4 Flow cytometry assessment of MRD  
Leukaemia cells express aberrant phenotypic markers in comparison to their normal 
maturing counterparts (89). Normal haematopoietic B – cell precursors follow a regimented 
and predictable pattern of maturation and antigen expression. ALL blasts demonstrate 
alterations in antigen expression related to differing stages of maturation, with under – or 
overexpression of normal antigens and the co – expression of aberrant myeloid antigens.  
The leukaemia – associated immunophenotypes (LAIPs) are identified in more than 95% of 
cases (90) and can reliably be used to distinguish blast cells from normal haematopoietic 
tissue. The use of selected panels of fluorochrome – labelled antibodies has demonstrated 
sufficient robustness to detect low levels of LAIP during treatment and discriminate 
malignant from normal or regenerating haematopoietic tissue.  
 
Flow cytometric evaluation of leukaemia burden is generally reported one log degree less 
sensitive than the PCR – based technique. Recent studies have detected leukaemia cells at a  
sensitivity of 0.01%  by flow cytometric assessment and for patients treated on BFM – 
chemotherapy strategies low MRD levels correlate well with survival (74, 91). Borowitz et 
al. reported a 90% EFS in patients with MRD less than 0.01% assayed by flow cytometry on 
day 8 peripheral blood. In this study, as the level of detectable leukaemia rose the survival 
of patients reduced (74). Basso et al. demonstrated a direct correlation between the presence 
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of detectable leukaemia and relapse (87). Bone marrow samples assessed on day 15 of 
induction in which leukaemia was not detected at  less than 0.1%, correlated to a low 
relapse risk, 8% B – precursor ALL and 3% T – ALL (87). 
 
False negatives may arise in either technique as alterations in immunophenotype and 
Ig/TCR rearrangement profiles may occur during therapy (82, 88, 92, 93).  For this reason 2 
rearrangements are followed with PCR (94) and at least 2 LAIPs are utilised for flow 
cytometry (14). Concordance at sensitivity 0.01% is high between the 2 techniques at the 
end of induction and increases further into therapy (95, 96)  
 
1.5 Current treatment strategies  
The outlook for children with ALL has dramatically changed since Farber’s first 
monotherapy experiments with aminopterin in the 1940s (97). With modern strategies, 5 
year survival rate of over 80% are achieved in a previously universally fatal disease. The 
reasons for improved survival include the development of intensive multi – agent 
chemotherapy regimens, improved supportive care and more refined stratification of 
therapy.  
 
The basic structure of chemotherapy regimens worldwide is similar, evolving from the St 
Jude’s “Total Therapy” trials (98), consisting of 4 phases: remission induction, 
consolidation, intensification with CNS directed treatment and continuation therapy.   
 
The goal of induction is a haematological remission, i.e. bone marrow blast count of less 
than 5% with no evidence of abnormal haematopoiesis. Since the 1970s, the ability of a 
three-drug induction regimen (vincristine, steroid and asparaginase) has been recognised to 
induce remission in up to 95% of patients. Recently, with more intensive use of these drugs, 
remission is achieved in nearly 99% of ALL patients (99). The rate of tumour clearance 
appears to influence outcome, with rapid resolution associated with an improved relapse – 
free incidence (74, 85, 87, 100).  
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Once morphological clearance has been achieved, the need for an intensified phase to 
consolidate the depth of remission has long been recognised (98, 101). Assessment of 
leukaemia clearance is now governed predominantly by MRD status after induction, which 
alters the intensity of the subsequent treatment.  Numerous studies have shown that a 
significant number of patients require a consolidation/intensification block (102, 103), most 
of which are based on the BFM consolidation template, including cyclophosphamide, 
cytarabine and mercaptopurine. This combination does not induce a significant amount of 
myelosuppression and thus almost continuous treatment can occur.  
 
CNS relapse plagued early trials, with approximately 50% of relapses occurring in the 
neural axis (104, 105). Early trials used craniospinal irradiation as CNS – directed treatment 
and were associated with significant neuropsychological sequelae (106-109), problems with 
growth and puberty (109, 110) and secondary malignancies (111, 112). The safe replacement 
of irradiation with intrathecal (IT) and intensive systemic chemotherapy was initially 
reported by CCG (113) and later confirmed by UKALL XI (114) .     
 
A common chemotherapy backbone of the final phase of treatment, continuation therapy, 
consists of oral mercaptopurine and methotrexate. The duration of total therapy in UK 
trials is arbitrarily assigned as 2 years for girls and 3 years for boys (115). In BFM 
cooperative trials children of both sexes receive a total of 2 years therapy (116).  The precise 
mechanism of action of this phase is unknown. It has been proposed that the low dose 
chemotherapy modulates the immune system to suppress residual blasts.  
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Table 1.3 Summary of results from Co-operative Groups trials of ALL. Since the early 1990’s overall 
survival rates have generally been in excess of 80%.    
 
1.6 Relapsed/Refractory ALL 
Up to 20% of patients will relapse and treatment strategies depend on the duration of first 
remission, the site of relapse and immunophenotype of the leukaemia (123-125). Survival 
rates range from 0 – 60% (126-128) with catastrophic results for early (<18 months from 
diagnosis) bone marrow relapses.  
 
The emergence of resistant/relapsed leukaemia may arise from clones which have acquired 
a chemoresistant phenotype secondary to therapy or from the selection of an intrinsically 
resistant sub – clone which persists from diagnosis or the formation of a new sub – clone 
which arises from additional mutations. While alteration of clonal markers and 
immunophenotype at diagnosis and relapse are described, the relapsed clone or an 
ancestral clone has been demonstrated in the diagnostic sample (129, 130). A high 
quantitative level of this subpopulation at diagnosis has been correlated with early relapse 
(130, 131) and this subpopulation has been demonstrated to be chemoresistant (130, 132). 
 
 
 
Cooperative Trial  Dates Cohort  5yr Survival  Reference  
DCFI – 95 – 01 1996 – 2000  491 5yr EFS 82% 
5yr  OS 90%  
(117) 
AIEOP – BFM 2000 2000 – 2006  4016 EFS 80.4% (7yr) 
OS 91.8%  
(88) 
NOPHO ALL – 2000 2000 – 2007 1023 5yr EFS 79% 
5yr OS 89% 
(118) 
COALL-97 
 
1992 – 1997 667 5yr EFS 76 
5yr OS 85 
(119) 
CCG-1800  
 
1989 – 1995 5121 5yr EFS 75% 
5yr OS  73% 
(120) 
EORTC-58881  
 
1989 – 1998 2065 5yr EFS 70.9%  
5yr OS 82%  
(121) 
AIEOP-91  
 
1991 – 1995 1194 5yr EFS 71%  
5yr OS 80.3%  
(122) 
UKALL97/99 1997 – 2003 1725 EFS 78% 
OS 87%  
 (33) 
SJCH Total XV 2000 – 2007 498  EFS 85.6% 
OS 92.6%  
 (91) 
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1.7 Signal transduction pathways associated with chemoresistance: 
1.7.1 PI3K/Akt/mTOR Pathway  
The phosphatidyl – inositol 3 kinase (PI3K)/Akt-protein B/ mammalian target of rapamycin 
(mTOR) pathway is involved in cell survival, glucose metabolism, protein synthesis, 
motility and proliferation. PI3K is a membrane – bound serine/threonine kinase, activated 
by receptor tyrosine kinases (RTKs), cytokine receptors, integrins and B – cell receptors. 
Activation of PI3K induces phosphorylation of its target phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), which via phosphoinositide-dependent kinase-1 (PDK1) activates 
Akt.  Downstream targets of Akt include inhibition of pro – apoptotic proteins (Bim, Bax, 
Bad and FoxO1), cell cycle progression (inhibition of p27Kip1, p21Waf1/cip1 and Wee1) 
and induction of protein synthesis by inhibition of tumour suppressors, TSC 1/2, and 
induction of mTOR. mTOR is vital for normal homeostasis, acting as a sensor to ensure 
adequate energy supply to the cell. Activation is required for protein translation, protein 
synthesis, cell cycle progression and survival (133). Negative regulators of the PI3K/Akt 
pathway include the phosphatase PTEN, which dephosphorylates PIP3 to PIP2 preventing 
activation of Akt, and phosphatases which directly dephosphorylate Akt, including PP2A.    
Constitutive activation of the PI3K/Akt pathway occurs frequently in childhood T – ALL 
and can be mediated by overexpression of RTK, loss of PTEN phosphatase regulation, 
mutations of PI3K or gain – of – function mutations of mTOR itself or associated pathways 
(134, 135). Constitutive activation of Akt has recently been associated with poor response to 
induction therapy and shorter OS and EFS in pre – B ALL (136) and reduced in vitro 
sensitivity to induction agents, dexamethasone, doxorubicin and vincristine. mTOR 
inhibitors have demonstrated anti – leukaemic activity  in transgenic and xenograft murine 
models of pre – B ALL (137, 138) and sensitise ionising radiation – resistant cell lines to 
chemotherapy (134, 138-141). Upregulation of PI3K in response to chemotherapy may also 
contribute to chemoresistance (142). 
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1.7.2 Ras/Raf/MAPK Pathway  
The Mitogen – activated protein kinase (MAPK) pathway transmits growth signals from 
membrane – bound receptors to the nucleus of the cell. The canonical pathway relies on 
phosphorylation of the cytoplasmic domain of a RTK activating the docking protein GRB2 
and guanine nucleotide exchange factor, Son – of – Sevenless (SOS). The receptor signal is 
transmitted via activated GRB2 and SOS, thus activating the GTPase protein, Ras. The 
signal is cascaded via Ras, Raf kinase, Mitogen – activating protein kinase kinase (MAPKK) 
and the MAPK, Extracellular signal – regulated kinases (ERK1/2). Phosphorylated ERK is 
transported across the nuclear membrane and activated a significant number of 
transcription factors, including c-Fos, PAX5, ELK1 and Ets.     
 
Activation of the MAPK pathway has been demonstrated in T – cell and adult 
lymphoblastic leukaemias, with up to 30% of leukaemias possessing constitutively 
phosphorylated ERK (143, 144). In adult series, pathway activation has been associated 
with higher WCC and failure to achieve remission (143).  Recently, upregulation of MAPK 
and PI3K pathways in response to chemotherapy in T – cell ALL was demonstrated, 
leading to increased expression of the anti – apoptotic proteins, survivin and Bcl-2, and 
chemoresistance (142). In pre – B ALL, the relationship between mutations and 
chemoresistance is less well defined. Ras mutations are identified in 10 - 20% unselected 
ALL population (145-147), with an increased incidence in hyperdiploid (30%) (145, 148)  
and half the cases of MLL – rearranged ALL (149).  Activation of the MAPK pathway can 
arise from mutations in other genes, including RTKs, BRAF, the E3 – ligase CBL and the 
phosphatase PTPN11 (150-152). Lübbert et al. demonstrated a direct correlation between 
RAS mutations and higher rate of relapse and a non – significant lower rate of 
remission(153). These findings have not been able to be repeated (145, 146, 154). Increased 
activation of the MAPK pathway is demonstrated in relapsed leukaemias  and blasts with 
characteristic p-ERK activating RAS mutations at relapse have been cloned in the diagnostic 
sample (155). This finding may support the idea that sub-clone populations bearing RAS – 
mutations may contribute to chemoresistance and relapse (145). Pharmacological MAPK 
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pathway inhibitors are able to sensitise leukaemias resistant to conventional chemotherapy 
(156, 157). 
The Stankovic group (158) described microarray analysis of a cohort of primary ALL 
samples demonstrated to be resistant and sensitive to ionising radiation (IR) – induced 
apoptosis, as a proxy of response to chemotherapy. No single gene was found to 
discriminate between the two phenotypes at baseline or after exposure to IR. Microarray 
analysis of leukaemias which were resistant to IR – induced apoptosis identified 13 gene 
sets with pro – survival function on gene set enrichment analysis.  The pro – survival 
pathways included the intracellular kinase signalling modules, PI3K and MAPK, and 
upregulation of gene sets of the receptor tyrosine kinase (RTK) pathways, Epidermal 
growth factor (EGF), Platelet derived growth factor (PDGF) and Insulin growth factor 1 
(IGF – 1).   
1.8 Role of Receptor Tyrosine Kinases (RTK) in malignancies  
A total of 518 protein kinases have been identified by the Human Genome Project, of which 
90 are classified as tyrosine kinases (TK) (159). TKs play key roles in proliferation, 
migration, adhesion, metabolism, glucose utilisation, differentiation, cell survival, inter- 
and intracellular signalling (160).  
  
1.8.1 Classification and structure of Tyrosine Kinases 
TK are characterised by their relationship with the cell membrane, which defines their role. 
RTKs are single pass proteins which span the membrane, composed of an extracellular 
domain, transmembranous region and cytoplasmic component. RTKs transduce 
extracellular growth factor signals to the cytoplasm, as they contain both the ligand – 
binding ectodomain and the cytoplasmic kinase domain. RTKs have been grouped into 20 
classes, classified by the composition of the N – terminal external domain (161). The 
intracellular C – terminal displays the highest degree of conservation between the receptor 
classes. The intracellular component of RTKs consists of docking sites for intracellular 
proteins and the catalytic domain, which is responsible for the receptor’s kinase activity. 
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The catalytic domain induces autophosphorylation and phosphorylation of receptor 
substrates.     
                                                  
Figure 1.2 Schematic representation of Epidermal Growth Factor Receptor, the prototypical RTK 
(Reproduced from Pearson Education). The EGFR RTK was the first RTK characterised. The canonical RTK is 
composed of an extracellular ectodomain, transmembranous region and the cytoplasmic tail, which contains 
the kinase domain, carboxy –tail and the juxtamembranous region.   
 
Non-RTKs are cytoplasmic proteins which do not possess an extracellular or membrane – 
spanning domain. These TK depend on receptors from other families to transduce signals, 
e.g. JAK proteins are phosphorylated by interleukin receptors (162). TKs are predominantly 
involved in intracellular signalling. 
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Figure 1.3 Schematic representation of structure of extracellular domains used to classify the 20 families of 
RTK (Reproduced from Lemmon and Schlessinger (163). RTKs are classified predominantly by the 
extracellular ectodomain. The intracellular cytoplasmic region is usually conserved.   
 
1.8.2 Activation of RTK  
Phosphorylation is the most common post-translational modification and is utilised to 
modulate specific functions of the affected protein. Kinases catalyse the phosphorylation of 
proteins by transferring a terminal gamma phosphate from adenine tri-phosphate (ATP) to 
the free hydroxyl group of an amino acid residue. The original model of RTK activation 
described the binding of 2 inactive RTK monomers to a bivalent cognate ligand, which 
  Introduction 
19 
 
induced receptor dimerization, autophosphorylation of the kinase domain and subsequent 
phosphorylation of the c – terminal tyrosine residues.  This model has proven too crude as 
the inactive state and binding partners of RTKs exhibit a high degree of complexity. Some 
RTKs, for example insulin and IGF – 1R (164), can exist as oligomers in their inactive state 
and ligand – induced oligomerisation occurs at a higher order of interaction. 
   
                                  
Figure 1.4 Representation of activation of EGFR monomers by binding of EGF – ligand to extracellular 
domain.  The cognate ligand induces dimerisation of the individual receptors. Alteration in the structure 
induces kinase domain activity leading to autophosphorylation of the cytoplasmic domain tyrosine 
substrates. (Reproduced from Pearson Education).   
 
While physiological activation of a RTK is a ligand – mediated event, RTKs display 
significant promiscuity with respect to binding partner. RTKs may bind to the same type of 
receptor, e.g. VEGFR1/VEGFR1 (homodimerisation) (165), partners within the same class, 
e.g. EGFR/HER2 (heterodimerisation) (166) or dimerise across classes, e.g. EGFR/Met 
(cross-talk/heterotypic dimerization) (167).  
Different mechanisms of activation have been described (163), based on the type of 
interaction between ligand and extracellular domain of the RTK.    
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The first mode of binding involves a dimeric ligand binding to the  extracellular domains of 
2 RTKs, with no contact between the extracellular components of the 2 RTKs molecules 
themselves, as exhibited by the Axl (168) and VEGF receptors (165).  
 
A second mechanism has been described in the Kit receptor, where the cognate bivalent 
ligand, Stem Cell Factor (SCF), mediates cross – linking of the ligand – binding site and 
brings the extracellular domains of the RTK into intimate contact. The ligand – receptor 
complex induces an allosteric change proximal to the ligand – binding site, which orientates 
the Kit molecules for activation (169).  
 
The third mechanism of activation is utilised by the fibroblast growth factor receptor 
(FGFR) family, where a dimeric ligand induces direct contact between the extracellular 
components of 2 receptors, but requires an accessory molecule to establish the active 
conformation.  FGFR requires the binding of heparin to stabilise the ligand and receptors 
for activation (170).  
 
The fourth mechanism of activation, is “receptor – mediated” and employed by EGFR, 
where the dimerization interface is composed only the receptors. The ligand does not cross 
– link the 2 receptors, but 2 separate domains of the extracellular component within the 
same receptor binds to alter the structure and reveal the dimerisation site (171).  
 
In general, dimerisation of the receptors induces trans – phosphorylation of the kinase 
domain, exposing the catalytic active site allowing for transfer of a phosphate group from 
ATP to the amino acid residue. The catalytic region is composed of the amino – terminal (N 
–) lobe, the carboxy – terminal (C –) lobe and an activating – loop. The 2 lobes form a cleft, 
which acts as the ATP – binding site while the C – lobes form the substrate binding site 
which accepts the peptide with the tyrosine residue (172). The unstimulated receptor is 
kept quiescent by auto-inhibitory mechanisms which may be mediated by the activation 
loop, juxtamembranous region or c – terminal.  
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The first mechanism of cis – inhibition is mediated by the activation – loop. In the 
unphosphorylated ‘inactive’ form the activation – loop blocks the ATP – and substrate – 
binding sites, preventing access and inhibiting the catalytic ability of the RTK. Dimerisation 
induces trans – phosphorylation of key tyrosine residues on the activation loop, altering its 
conformation into an ‘active’ position, allowing access to the ATP/binding site and 
exponentially increasing the catalytic ability of the domain.  The insulin activation loop 
occludes the ATP binding site (173), while FGFR1 prevents access to the substrate site  
(174).  
 
The second mechanism of autoregulation involves juxtamembranous inhibition of the 
catalytic domain of RTKs, which is seen in the FLT3 and Kit receptors. The intracytoplasmic 
region projects into the catalytic domain preventing it from adopting an active form and 
blocking access to the active site. An example of this is the FLT3 RTK which possesses the 
key juxtamembranous tyrosine residues, Tyr589 and Tyr591. When these residues are 
transphosphorylated they alter the inhibitory structure of the region, allowing access to the 
catalytic domain (175). 
 
A third mechanism of occluding the catalytic domain in the inactive form is present in the 
Tie -2 RTK. The activation loop of this receptor is positioned in an active conformation even 
when not phosphorylated (176), however residues in the c – terminal protrude into the 
catalytic domain and prevent access. Phosphorylation of c – terminal tyrosine residues 
alters its conformation and allows access to the active site (177).          
 
Once the auto – inhibition is released the efficacy of the catalytic domain is exponentially 
increased, allowing for further phosphorylation of tyrosine residues in the cytoplasmic 
region of the receptor. The c – terminal phosphorylated sites recruit a variety of molecules 
important in intracellular signal transduction. These phosphorylated residues act as 
binding sites for proteins which contain phosphotyrosine binding (PTB) or Src homology – 
2 (SH2) domains. PTB – and SH2 – containing proteins, such as Grb2 or IRS1, bind to the 
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RTK platform, and mediate interactions with downstream signalling pathways, such as the 
recruitment of the guanine nucleotide releasing factor Sos which in turn activates the 
Ras/MAPK pathway (178) or IRS – 1 recruits and activates the catalytic component of PI3K 
(179). 
  
1.9 Negative regulation of the RTK 
The proliferative and pro – survival functions of RTKs need to be tightly controlled and the 
attenuation of RTK signalling is regulated by receptor dephosphorylation and 
ubiquitination.  
 
1.9.1 Protein tyrosine Phosphatases 
RTK dephosphorylation, and thus inactivation, is mediated via the “classical” protein-
tyrosine phosphatases (PTP). These enzymes dephosphorylate tyrosine substrates through 
a conserved active catalytic domain, which contains an oxidation – sensitive active – site 
cysteine residue, thus attenuating RTK signalling (180, 181).  For example, the PTP DEP – 1 
has revealed an important antagonistic role in PDGFR (182), VEGFR (183) and Met (184) 
signalling via a direct dephosphorylation of RTKs. DEP – 1 deletion induced 
hyperphosphorylation of FLT3 in AML cell lines with associated ERK pathway signalling 
and cellular proliferation; whereas activated FLT3 signalling was attenuated by DEPI 
overexpression (185), thus PTP loss of function mutations have been implicated in more 
aggressive tumours.  
 
1.9.2 Ubiquitination 
Negative regulation of the RTK is also mediated by the multidomain E3 ubiquitin ligase, 
Casitas B – lineage Lymphoma (Cbl), which plays an important role in modulating the 
EGFR (186), CSF – 1R (187), PDGFR (188), VEGFR (189), Met (190) pathways. Cbl is 
recruited to specific phosphorylated tyrosine residues on activated receptors and binds by a 
highly conserved N – terminal phosphotyrosine binding domain. Cbl conjugates ubiquitin 
to the receptor’s cytoplasmic domains, targeting it for degradation. Signal attenuation is 
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also induced by ubiquitination of adaptor molecules, for example Gab1 in Met pathway 
(191). Dysfunction of Cbl results in aberrant RTK signalling (152) and malignant 
transformation of fibroblasts has been reported as a result of RTKs unable to recruit and 
bind Cbl (192).  
 
1.10 Role of TK in B – cell physiology   
1.10.1 Tyrosine kinases in normal B – cell development  
The non – receptor TKs, Btk, Syk and the Src family, are involved in pre – B and B – cell 
receptor signalling and in the development of normal B – cells.  
 
Murine knockout models of these TKs have demonstrated their importance in the 
development and maturation of normal B – lymphocytes. Homozygous Syk-/- are 
embryonically lethal (193), while individual knockdowns of Lyn and Btk demonstrate 
arrest after the pre – B stage of differentiation. In these models, normal development is 
present in the bone marrow of cells up to the pre – B stage but then a reduction of 
peripheral mature lymphocytes (194-197). Triple knockdowns of the Src family kinases, 
Blk/Fyn/Lyn induced severe lymphopaenia with an arrest at pro – to pre – B development 
(198). Lyn up/up also lead to a reduction of peripheral B – cells, most likely related to the 
development of autoantibodies (199). 
 
1.10.2 RTKs in B – cell development 
The role of RTKs in normal lymphocyte development is less certain. While a significant 
number of RTKs are expressed in normal haematopoietic tissue, limited functional 
assessment has been performed. The protein expression of PDGFR (200), VEGFR 1 – 3 (201), 
Trk family (202, 203) and Tie – 1 and Tie – 2 (201) have all been reported in CD34+ cells and 
myeloid precursors. The expression and function of Kit and FLT3 in normal lymphoid 
progenitors is better defined. Despite the expression of RTKs on haematopoietic cells, 
normal haematopoiesis does not depend on ALK, FGFR or PDGFR (204-206) . 
 
  Introduction 
24 
 
FLT3 is preferentially expressed in CD34+, pro – B cells and CD4-CD8- thymocytes. FLT3-/- 
knockdown mice demonstrate a reduction in the precursor - B cell in the bone marrow, 
however apart from a reduction in peripheral dendritic cells the composition of the 
peripheral blood is indistinguishable from FLT3wt mice  (207, 208). Kit is expressed on early 
haematopoietic stem cells and extensively on myeloid, dendritic and B– and T – lymphoid 
progenitors (209). While no haematological abnormalities are present in single Kit-/- the 
complimentary nature of these 2 RTKs in signalling was confirmed when double Kit/FLT3 
knockdowns demonstrated a more severe phenotype (207). These findings suggest that 
neither RTK is individually central to the development of lymphocytes.  
 
1.11 RTK deregulation in cancer  
RTKs are intimately involved in the proliferation and survival of normal cells and 
deregulation has been implicated in a wide variety of tumours. The mechanisms of 
deregulation as summarised in table 1.5. 
 
Mechanism of Dysregulation Wild type receptor Receptor Gene alterations 
Ligand – dependent 1. Autocrine 
2. Paracrine 
 
 
Ligand – independent 1. Overexpression 
2. Abnormal receptor 
processing 
3. Defects in negative 
regulation 
 
1. Overexpression due to 
gene amplification 
2. Gene rearrangement 
3. Mutations 
4. Truncation 
 
Table 1.4 Mechanisms of RTK dysregulation in malignancies. Aberrant RTK signalling can be classified on 
the presence of ligand biding to the receptor domain, or the kinase activating itself alone. 
 
1.11.1 Epidermal Growth Factor (EGFR)  
The constitutive activation of EGFR is described in a wide range of adult tumours, 
including breast, gastric, colon and lung cancer. Dysregulation occurs by receptor 
overexpression or mutation. Overexpression promotes spontaneous dimerisation and 
ligand – independent activation and is present in higher stage non – small cell lung cancer 
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and correlates with poor prognosis (210). Mutations, such as the truncated EGFRvIII, resist 
endosomal degradation and signal downregulation, are detected in up to 42% head and 
neck squamous cell carcinoma (211) and may contribute to EGFR – monoclonal and 
tyrosine kinase inhibitor (TKI) resistance.  
 
1.11.2 Insulin Growth Factor – 1 receptor (IGF-1R) 
Increased IGF – 1R activity has been reported in paediatric tumours, including 
rhabdomyosarcoma (RMS), Ewing’s sarcoma, osteosarcoma, Wilms tumour and 
neuroblastoma. Mutations of the RTK are not described in malignancies, thus increased 
activity is due to ligand – dependent activation, receptor overexpression or aberrant 
regulation of the gene promoter. Increased autocrine secretion of IGF – II has been reported 
in primary RMS tumours, as a result of maternal loss of imprinting or biallelic expression of 
the IGF – II .  The IGF-1R gene is regulated by the tumour suppressor Wilms tumour gene 1 
(WT1), the product represses the promoter of IGF – 1R (212). The loss of WT1 results in 
derepression of IGF – 1R and increased activity in Wilms and aggressive solid tumours 
(213, 214).  
 
1.11.3 Anaplastic lymphoma kinase (ALK) 
Gain – of – function mutations of the ALK receptor are associated with several tumours, 
including anaplastic thyroid carcinoma, lung carcinoma and neuroblastoma (215). The 
predominant mutations cluster around the kinase domain and result in increased 
PI3K/AKT (216) and MAPK signalling (217).  Constitutively active chimeric oncoproteins 
are found in anaplastic large cell lymphoma (NPM – ALK) (218) and lung cancer (EML4 – 
ALK) (219).  
 
1.12 Review of involvement of Tyrosine Kinases in ALL  
A limited number of RTKs have been demonstrated in childhood ALL. Global gene 
expression analysis has identified the overexpression of MER in t(1;19) (220) and FLT3 in 
MLL – rearranged  leukaemias (221). Recent gene expression array studies have implicated 
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the non – RTK JAK family in chemoresistant ALL(222). Gene expression profiling of adult 
ALL confirmed similar gene expression profiles to childhood ALL, including similar 
profiles for MLL – rearranged, Bcr/Abl and t(1;19) leukaemias (223). The study identified 
overexpression of the RTKs FLT3, NTRK3, AXL, MER and DDR1. Unlike childhood ALL, 
the increased expression of FLT3 was not limited to MLL – rearranged profiles. 
    
1.12.1 Philadelphia positive ALL 
In Ph+ ALL the resultant oncoprotein encodes a constitutively activated tyrosine kinase 
which is proliferative in cellular models, however requires additional genetic mutations to 
achieve full malignant transformation. Murine models of transplantation of cells 
transfected with Bcr/Abl demonstrate the p190Bcr-abl isoform is more potently leukaemogenic 
and aggressive in comparison to the p210Bcr-abl (224-226). Transgenic models have 
demonstrated a wide variety of phenotype but p190Bcr-abl mice with metallothionen 
promoter exclusively develop B – ALL (227).  
 
Chemoresistance in Ph+ ALL is mediated by aberrant activation of intracellular pathways, 
including JAK/STAT, Ras/Raf/MEK, PI3K/Akt  (228-230), as well as  resistance to DNA – 
damage dependent apoptosis by modulating DNA repair checkpoints (231).  Constitutively 
activated STAT signalling is reported to increase expression of anti – apoptotic Bcl - XL 
(232).  
 
1.12.2 CRLF2/JAK in Down Syndrome and High Risk ALL  
The non – receptor tyrosine kinase JAK family (JAK1 – 3, Tyk2) is implicated in the 
aetiology of haematological malignancies, predominantly myelodysplastic disorders and 
AML (233). The most common mutation, V617F valine – to – phenylalanine substitution in 
JAK2, results in constitutive activation as the auto-inhibitory JH2 pseudokinase region is 
defective. This mutation has not been found in childhood ALL (234). Constitutively 
activated JAK was initially described in relapsed ALL (235) , but more recently activating 
mutations in the JAK pathway have been associated with overexpression of the cytokine 
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receptor – like factor 2 (CRLF2) in Down Syndrome – associated ALL (236-239) and high 
risk leukaemias with a Bcr/Abl – like gene expression profile (222, 240, 241). These high risk 
leukaemias demonstrated a strong association between CLRF2 overexpression, JAK2 
mutations and deletions of PAX5, IKZF and CDKN2A (222). JAK mutations are reported in 
up to 20% of DS – ALL (236, 239, 242), 10% high risk and 3% in the unselected ALL 
population (222). Murine modelling demonstrated co – expression of both JAK mutation 
and CRLF2 overexpression is required for constitutive STAT5 signalling and cytokine 
independence (237, 238, 243).  Mutations of JAK1 are uncommon in childhood B – cell ALL 
(222), but have been reported in 3% childhood T – ALL and up to 18% in adult T – ALL 
(244-246).  
 
1.12.3 Fms – like tyrosine kinase 3 (FLT3) in childhood ALL 
The FLT3 receptor is encoded by a gene on chromosome 13q12 and is structurally related to 
the Kit, Platelet Derived Growth Factor (PDGFR), and Colony stimulating factor – 1 (CSF-
1R) receptors, all of which possess two split catalytic kinase domains. Physiological 
expression is relatively restricted to primitive lymphoid and myeloid precursors, natural 
killer and dendritic cells, in addition to placenta, brain and gonads.  FLT3 – ligand (FLT3L) 
is the cognate ligand (encoded by 19q1.3) and expressed on the membranes of most tissue 
and stimulates FLT3 in a paracrine manner. Dimerisation of FLT3 releases the 
juxtamembranous cis – inhibition and exposes the kinase domain, which allows for 
initiation of intracellular signalling via PI3K, Ras/MAPK, PLCγ and NFκB (247-249)  
 
In the unselected paediatric ALL population the frequency of FLT3 mutations is low (3 – 
5%), however aberrant activation is more common in MLL – rearranged and hyperdiploid 
leukaemias (250). Mutations of the JM regions, FLT3 – internal tandem duplication (FLT3 – 
ITD) are the most common mutation in AML however these are rare in paediatric ALL 
(250). FLT3 – ITD results from segmental duplication of the autoinhibitory JM domain, 
encoded by exons 14 and 15 (251). This allosteric alteration abolishes the structural 
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autoinhibition of the inactive RTK, inducing autophosphorylation and ligand – 
independent signalling.   
The more common gain – of – function mutations in childhood ALL are missense point 
mutations, deletions or insertions in the activating loop of the second kinase domain, 
including D835Y (215).  Constitutive activation of FLT3 has been reported in MLL – 
rearranged infant ALL via overexpression of wild type receptor (221, 252)  
 
1.12.4 Mer in childhood ALL  
Mer, encoded by a gene located at chromosome 2q14.1 (253), was initially cloned from a B – 
cell lymphoblastoid library (254) and is part of the TAM receptor family, which includes 
Axl and Dtk/Tyro – 3. Mer is not required for normal B/T-lymphocyte development (255, 
256). The common ligand for all 3 TAM receptors is growth arrest specific gene (Gas) 6, 
while protein S is a second ligand for Mer and Dtk. Ligand – binding mediates downstream 
signalling via PLCγ, PI3K/Akt, MAPK and vav1 (257, 258).  
 
No mutations of the Mer receptor have been described, but several human cancers 
demonstrate overexpression, including rhabdomyosarcoma (259) and gastric cancer (260). 
Ectopic expression of Mer at mRNA and protein level has been demonstrated in both T-cell 
(255, 256) and t(1;19) pre – B ALL (261) cell lines and primary samples. Keating et al. 
confirmed Mer’s leukaemogenic potential  in transgenic mice, (MerTg) which displayed 
circulating lymphoblasts consistent with T – cell lymphoma/leukaemia (262). The blasts 
exhibited increased Akt and ERK1/2 signalling and relative resistance to dexamethasone 
when compared to wild type lymphocytes.  
 
Ectopic overexpression of Mer is observed in the gene expression profile of t(1;19) pre – B 
leukaemias (220) and differentially increased expression of transcript and protein has been 
confirmed  in this cytogenetic subtype (261). While Mer is often expressed in pre – B ALL 
cell lines irrespective of translocation status, Linger et al. demonstrated protein expression 
was weighted towards primary t(1;19) leukaemias (261). The same group proposed a pro – 
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survival function for Mer as knockdown models demonstrated increased apoptosis to 
serum starvation and potentiated the apoptotic response when combined with cytotoxic 
agents. This has been supported by siRNA screens performed by Tyner et al. (263).   
 
1.12.5 Tropomyosin – receptor kinase (Trk) in ALL 
The high affinity neurotrophic tyrosine kinase receptor family which include Trk A (1q21 – 
22), B (9q22.1) and C (15q25), were first identified as a colon – derived oncogene (264). 
These receptors are important in normal neurological development, as knockout mice have 
demonstrated neurodevelopmental abnormalities specific to the ablated receptor (265).   
Five different neurotrophins are the cognate ligands, all of which display preferential 
binding for specific receptors. Nerve growth factor (NGF) preferentially binds Trk A, while 
Trk B binds brain – derived neurotrophic factor, neurotrophin – 4 and – 5 (NT – 4/5) and 
Trk C binds NT – 3.  All receptors are expressed predominantly on neuronal tissue, but Trk 
A and B are detected in normal B – lymphocytes.  
 
Meyer et al. described the induction of lymphoblastic leukaemogenesis in mice serially 
transplanted with cells with the oncogenic truncated Trk A (ΔTrkA) receptor (266). The 
blasts demonstrated constitutively active PI3K signalling and demonstrated sensitivity to 
mTOR inhibition (267). The same group investigated the expression of Trk in adult primary 
leukaemias and observed myeloid (52%) and lymphoblastic leukaemias (73%) expressed at 
least 1 Trk receptor (268). Co – expression of Trk A/B/C was present on myeloid blasts, 
whereas lymphoblastic leukaemias were restricted to TrkB. A strong correlation existed 
between the myeloid cytogenetic subgroup and the expression of specific Trk, however the 
molecular findings of the ALL samples was not reported. Furthermore, activation of Trk A 
and B in transfected murine myeloid cells reduced radiation – induced apoptosis and co – 
expression of the Trk A/B receptor and ligand induced myeloid leukaemia (268). 
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1.12.6 c – Met/Hepatocyte Growth Factor Receptor in leukaemia  
The Met receptor, encoded by the gene located at chromosome 7q31, was first isolated from 
a chemically induced human osteosarcoma cell line (HOS) (269) and is part of the Met 
family of receptors. The cognate ligand is hepatocyte growth factor (HGF), and receptor 
and ligand are widely expressed. Both Met and HGF are required for normal 
embryogenesis, and dysregulation of either gene results in lethality (270-272) Physiological 
activity of the Met receptor includes angiogenesis, tissue repair and wound healing. 
Subversion of these properties explains the increased invasion, metastasis and anti – 
apoptotic properties in cells with deregulated Met (273, 274). Dysregulation of the Met 
pathway can occur by overexpression of Met/HGF, MET amplification and germline or 
somatic Met mutations. While functional Met is expressed in Adult T – cell Leukaemia 
(ATL) and pre – B ALL, the biological effect of activation appears different.  In ATL, a Met 
autocrine loop was shown to drive proliferation (275) while paradoxically activation of Met 
in the t(12;21) leukaemia sensitised cells to doxorubicin (276).  The role of Met in 
leukaemogenesis and chemoresistance is uncertain.  
 
1.12.7 Novel chimeric tyrosine kinase – containing oncogenes  
Approximately half of leukaemias with Bcr/Abl – like gene expression profiles do not 
possess CRLF2 or JAK lesions. More detailed sequencing of this group has identified a   
subset of leukaemias with diverse kinase rearrangements, including NUP214 – ABL1, 
previously described in T – cell ALL, BCR – JAK2, STRN3 – JAK2 and EBF1 – PDFGRB (277, 
278) (279). Each of these lesions is thought to result in aberrant activation of the chimeric 
tyrosine kinase domain and constitutive signalling. A small study has demonstrated that 
the leukaemias with ABL and PDGFRB mutations were inhibited by TKIs, which resulted in 
reduced tyrosine phosphorylation (280). 
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1.13 Discovery of targets and novel agents for the treatment in cancer   
1.13.1 Rationale for molecular targeted therapy   
Although cancer is the culmination of numerous complex events (281) the rationale for 
molecularly targeted therapy relies on the restricted repertoire of pathways required by 
malignant cells for proliferation and survival. Weinstein et al. coined the term “oncogene 
addiction” to describe the absolute dependence of tumour survival on the activity of a 
single pathway (282, 283).  
 
Moody et al. demonstrated the conditional activation of HER2 in a transgenic mouse model 
of inducible invasive mammary tumours (284). Regression of both the primary and 
metastatic tumours was seen when the HER2 gene was deactivated. The clinical application 
of this concept was demonstrated with the successful use of the monoclonal antibody, 
trastuzumab, in HER2 – expressing tumours (285). In the murine model, the tumours 
recurred as they developed HER2 – independent survival pathways (286) and this 
development is mirrored in clinical practice. 
 
1.13.2 Small molecule tyrosine kinase inhibitors 
RTKs are important targets for cancer not only because they are deregulated in many 
malignancies, but the catalytic domain clefts possessed by tyrosine kinases make them a 
particularly ‘druggable’ target. Small molecules can bind in the active sites of the kinase 
domain interfering with the transfer of the phosphate group to substrate, thus disrupting 
signal transduction.  
 
Three classes of TKI are described on the basis of interaction between the inhibitor and the 
kinase and on the mechanism of interference (287):  
 Type I inhibitors, e.g. sunitinib, bind the active form of the kinase in the ATP – 
binding site and are direct ATP competitors (288).  
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 Type II inhibitors, for example imatinib, sorafenib and nilotinib, bind to the inactive 
form of the kinase and indirectly compete with ATP by occupying the hydrophobic 
pocket, preventing the catalytic transfer of phosphate (289).  
 Type III inhibitors, e.g. the aniline – quinazoline family of inhibitors, block the ATP – 
binding site by forming irreversible covalent bond with the cysteine residues in the 
catalytic domain, preventing the binding of ATP for phosphotransfer (290) .  
 
The first 2 classes of TKIs are ATP competitors, which block the ATP – or substrate – 
binding site of the receptor and prevent the transfer of the phosphate. These inhibitors are 
relatively non – specific as these kinase regions are conserved throughout the tyrosine 
kinase family. 
 
The biological effect of a tyrosine kinase inhibitor depends not only on the presence of a 
target, but also the binding affinity of the molecule for the kinase, the expression or 
activation status of  targets and the presence of resistance mechanisms, including efflux 
pumps, kinase mutations or the co – opting of  redundant/alternative pro – survival  
pathways. Resistance to imatinib was quickly identified (291), mutations in the activation 
loop altering the accessibility of the compound to hydrophobic pocket adjacent to ATP – 
binding pocket, with  little or no change in kinase activity. The most potent Bcr/Abl 
mutation, T315I, completely abrogates the ability of imatinib to bind to the receptor (292).  
 
The accrual of further mutations in other signalling pathways can circumvent the targeting 
of an oncogene addiction, by leading to the activation of intracellular pathways despite 
inhibition of the original oncogenic mutation. For example, mutation of the downstream K 
– RAS oncogene negates the activity of the EGFR monoclonal antibody cetuximab, in EGFR 
– expressing colorectal and lung tumours (293). The activating mutation bypasses the 
inhibitory effect of the antibody as the tumour persistently signals via the MAPK pathway, 
independent of the RTK. Resistance to TKI and monoclonal antibodies can also occur with 
the co – operative activation of numerous RTK in tumours (294, 295). Simultaneous 
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activation of two or more RTKs allows for robust and continuous intracellular signalling if 
one the RTKs were to be inhibited. This phenomenon of “coactivation” was first 
demonstrated by Stommel et al.. in glioblastoma multiforme, where activation of the PI3K 
pathway is induced by both EGFR and Met (294). Individual inhibition of either of these 
pathways did not alter cell survival, and the phenotype was only altered when multi-
targeted therapy directed against PGDFR, EGFR and Met occurred. Co – activation and 
cross talk of RTK networks in breast and lung cancers has driven the rational design of dual 
RTK inhibitors (296, 297). 
 
1.14 Role of TKI in paediatric ALL 
At present the role of TKI in paediatric ALL is limited to clinical trials for the treatment of 
Ph+ ALL, FLT3 inhibitors for myeloid and infant ALL and more recently the development 
of early phase trials for JAK inhibition in leukaemia. The most robust evidence for the 
successful use of TKI was recently demonstrated when the 3yr EFS for Ph+ ALL was 
dramatically increased to 80%, for patients treated with imatinib and intensive 
chemotherapy  in comparison with historical controls (35%±4) (298). A recent European 
study, utilising imatinib in combination with an intensive chemotherapy backbone has 
corroborated the increased EFS (299). 
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1.15 Aims of study  
There has been limited exploration into the use of TKIs outside of Ph+ ALL and the 
literature reviewed above. This area warrants further investigation if a targeted therapy 
approach has a wider application for childhood ALL. For this reason the research in this 
thesis was undertaken.  
 
The specific aims of this thesis are to: 
 
1. Undertake an assessment of baseline RTK activation in primary ALL samples to 
determine whether a distinct kinase signature may account for increased 
chemoresistance  
 
2. The identification of “kinase – associated signatures” and the elucidation of the 
induction of RTK pathways in high risk ALL 
 
3. To screen a kinase inhibitor library, identify candidate compounds and by inference 
the putative kinases central to cell viability   
 
4. Evaluate the candidate inhibitors in in vitro and in vivo models of childhood ALL
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2 Materials and Methods 
2.1. Cell culture  
2.1.1. ALL primary samples  
Primary leukaemia cells were collected from patients enrolled on the UKALL2003/R3 trial 
with precursor – B ALL at initial diagnosis or relapse at Birmingham Children’s Hospital. 
Samples were collected after written informed consent, in accordance with the Declaration 
of Helsinki and stored in compliance with the Human Tissue Act. Samples are provided in 
an anonymised manner but linked to clinical data. Local Research Ethics Committee 
approval was granted for all experiments (LREC 09/H1202/101).  
 
2.1.2. Separation of mononuclear cells from bone marrow   
Mononuclear cells were isolated from bone marrow on a Ficoll – Paque gradient. Bone 
marrow samples were diluted to 15ml RPMI (Gibco®, Invitrogen) supplemented with heat 
inactivated foetal calf serum (FCS) 10%v/v (PAA, The Cell Culture Company) and 
penicillin/streptomycin 1% v/v (Gibco®, Invitrogen) and layered on 35ml Lymphoprep 
(Axis Shield). The cells were centrifuged for 30 minutes at 1600rpm with no brake. The 
mononuclear layer was harvested into a universal container (Sterilin, UK) and washed in 
10ml media. The cells were re – centrifuged at 1600rpm and the pellets resuspended in 
10ml media. Cells were counted and cryopreserved in aliquots of 1x107 cells in 1ml freezing 
media, 10% dimethyl sulfoxamide (DMSO) (Sigma) and 90% FCS, in cryovials (Nunc, 
Denmark). Cells were gradually frozen overnight in -800 C freezer in a freezing box.  The 
next day, samples were transferred to liquid nitrogen for long term preservation.   
 
2.1.3. Maintenance of cell lines 
Suspension leukaemia cell lines (table 2.1) were maintained in RPMI, FCS 10%v/v, 
penicillin/streptomycin 1%v/v, in 25cm2 flasks (Iwaki, UK) incubated at 37oC in 5% CO2 
and 95% air (incubator make). Cells were grown at a density of 2x106/ml and divided 1:3 
twice weekly.  
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Cell line  
 
Growth 
Characteristics 
Cytogenetic/Molecular features Response to IR  - 
induced 
apoptosis 
Reference:  
Nalm 6 Suspension  Pre – B ALL translocation (5;12)  Intermediate (300) 
Nalm 17  Suspension Pre – B ALL normal karyotype  Proficient  (301) 
REH Suspension Pre – B ALL t(12;21)  Defective (302) 
SD – 1 Suspension Pre – B lymphoblastoid t(9;22)  Defective (303) 
SupB15 Suspension Pre- B ALL t(9;22) Proficient  (304) 
TOM -1 Suspension Pre – B ALL t(9;22) Defective (305) 
CEMC-1 Suspension T – cell ALL Not assessed  (306) 
Kasumi -1  Suspension AML t(8;21) Kit mutant  Not assessed  (307) 
HL60 Suspension AML Not assessed  (308) 
K562  Suspension CML t(9;22) Not assessed  (309) 
KM-H2 Suspension Hodgkin Lymphoma Not assessed  (310) 
L428 Suspension Hodgkin Lymphoma  Not assessed  (311) 
MCF-7 Adherent  Breast adenocarcinoma  Not assessed  (312) 
HB2 Adherent  Human mammary luminal epithelial 
cell line 
Not assessed (313) 
SY – 5Y Adherent  Neuroblastoma ALK positive  Not assessed  (314) 
    
Table 2.1 Summary of cell lines used in experiments 
 
The adherent cell lines, HB2, MCF7 and SY-5Y, were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma), supplemented with FCS 8%v/v and penicillin/streptomycin 1% 
v/v, in 10mm plastic dishes (Corning, USA). Cells were passaged when the dishes were 
80% confluent. Cells were washed with 10ml warm phosphate – buffered saline (PBS) and 
incubated with 1ml trypsin substitute (TrypLETM Express, Gibco®, Invitrogen) for 5 minutes 
at 37oC in an incubator. The detached cells were resuspended in 10ml FCS – containing 
media to inactivate the trypsin substitute, centrifuged at 1600rpm for 5 minutes and 
resuspended in DMEM and plated at 1:10 dilution.   For all cell lines, fresh cultures were 
replenished from cryopreserved stock every 2 months. 
 
2.1.4. Recovery of cryopreserved cells 
Vials of frozen cells were rapidly defrosted in 370C water bath to reduce DMSO contact. 
10ml media was applied in drop – wise manner to acclimatise cells and to dilute the DMSO. 
Cells were centrifuged 1600 rpm for 5 minutes, the supernatant discarded and pellets re-
suspended in 10ml media. The cells were counted and utilised for experiments or to re – 
establish fresh cultures in the case of cell lines. 
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2.1.5. Cell counting 
Cells were suspended in 10ml media and counted using a haemocytometer, Glasstic® slide 
(Hycor Biomedical Ltd, Edinburgh). 10µl of cell suspension was added to an equal volume 
of 0.2% trypan blue (Sigma, UK) and loaded onto the counting chamber. A light microscope 
was used to visualise all viable bright, non – stained cells and 9 squares were counted. The 
cell concentration was determined by multiplying the counted cells by 2 x 104 to equate to 
number of cells per ml. For all primary leukaemia experiments 80% viability was the 
minimum accepted. 
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2.1.6. Characteristics of primary ALL samples  
Biological and clinical characteristics of the primary ALL samples used in this study are 
displayed in tables 2.2 and 2.3. The minimal residual disease (MRD) status of leukaemias 
was determined by the Regional National Health Service molecular genetics laboratory in 
the case of molecular MRD status and by the Birmingham Children’s Hospital 
Haematology Department in the case of flow cytometric MRD status.     
 
Sample 
code 
Age  
(yrs) 
Sex WCC  
(x109/L) 
Outcome Cytogenetics Response 
at  D8/15 
Flow 
MRD 
Molecular 
MRD 
Apoptosis 
phenotype 
ALL-1 1 M 62 CR Hyperdiploid (52) GER HR HR Defective 
ALL-2 2 M 391 CR 45XY, dic(9;20)+8, -13 GER SR HR Defective 
ALL-3 15 M 117 CR Hyperdiploid PER SR HR Defective 
ALL-4 4 M 2.4 CR Normal GER HR NK Defective 
ALL-5 14 M 11 CR 46XY, add 7q, add 12p GER HR HR Defective 
ALL-6 8 M 22 CR t(12;21) GER SR NK Defective 
ALL-7 4.1 M 51 CR t(12;21) N/K HR SR Defective 
ALL-8 10.1 F 1.1 D Normal PER HR HR Defective 
ALL-9 14 M 150 D Normal PER HR HR Defective 
ALL-10 7.1 M 82 CR None GER SR SR Proficient 
ALL-11 2.2 F 88 CR t(3;22) PER HR HR Proficient 
ALL-12 3 F 5 CR t(12;21) GER SR SR Proficient 
ALL-13 2.75 F 5.2 CR t(12;21) GER SR SR Proficient 
ALL-14 8.9 F 74 CR t(12;21) GER SR SR Proficient 
ALL-15 11.1 M 10 CR t(12;21) PER SR SR Proficient 
ALL-16 3.5 M 3.4 CR t(12;21) GER HR HR Proficient 
ALL-17 2.1 M 26 CR Normal GER NK SR Proficient 
ALL-18 7.8 M 9 CR 53XY GER NK SR Proficient 
ALL-19 5 M 10 CR t(12;21) GER SR SR Proficient 
ALL-20 12 F 109 CR 46XX, t(3;10) t(9;16) +8 
biallelic del p16 
GER Ind SR Proficient 
  
 Key:  
 CR:    Complete Remission  
 D:    Died of disease  
 GER:    Good early response (Blasts < 25% on day 8/15)  
 PER:    Poor early response (Blasts ≥ 25% on day 8/15)  
 MRD:    Minimal residual disease  
 HR:    High Risk  leukaemia cells detectable >0.01% 
 SR:    Standard Risk   leukaemia cell not detectable <0.01% 
 NK   Not known 
 Ind    Indeterminate   
  
 Highlight grey:  Leukaemia samples with defective phenotype in response to IR – induced 
    apoptosis  
Table 2.2 Clinical features of primary paediatric B – precursor ALL used in the phospho – RTK array 
experiments. Eighteen of the 20 samples were interrogated with the R&D array and 6 samples interrogated 
with the Raybiotech array. The samples highlighted in grey were demonstrated to have defective apoptotic 
phenotypes in response to IR – induced apoptosis.  
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Sample 
code 
Age 
(yrs)  
Sex WCC  
(x109/L) 
Outcome Cytogenetics Response at 
day 8/15 
Flow 
MRD 
Molecular 
MRD 
ALL-16 3.5 M 3.4 CR t(12;21) GER HR HR 
ALL-20 12 F 109 CR 46XX, t(3;10) t(9;16) +8 
biallelic del p16 
GER Ind SR 
ALL-21 12 F 8 CR t(12;21) GER SR NK 
ALL-22 2 F 20 CR Normal GER SR SR 
ALL-23 9.5 M 24 CR 45XY, der19, t(1;19) GER HR SR 
ALL-24 10.92 M 59.7 CR 46XY, del9p21p21, 
monoallelic CDKN2A 
loss,13q14 loss 
PER HR HR 
ALL-25 3 M 12.7 CR No report GER HR HR 
ALL-26 0.5 M 109.9 CR t(9;11) GPR NK SR 
ALL-27 9.5 M 26 CR 46XY GER HR HR 
ALL-28 8.5 M 4 CR Hyperdiploid GER HR SR 
ALL-29 3 F 5 CR t(12;21) GER SR SR 
ALL-30 10.5 F 83 CR 47XX, t(12;21) GER SR SR 
ALL-31 11 F 73 CR 46XX, der 19 , t(1;19) GER SR SR 
ALL-32 0.5 F 44.7 CR t(4;11) GPR NK SR 
ALL-33 3 M 43 CR Hyperdiploid GER SR SR 
ALL-34 9.92 M 15.8 awaiting 
transplant 
t(12;21) GER HR NK 
ALL-35 2 F 41 CR Hyperdiploid GER HR HR 
ALL-36 16 F 60 Died 46XX, t(2;12), 
p1p13(8) 
GER HR HR 
ALL-37 2 F 45 CR Hyperdiploid GER HR HR 
ALL-38 5 F 15 CR Normal GER HR SR 
AML- 2 15 M 63 Died FLT3 – ITD n/a n/a n/a 
 Key:  
 CR:    Complete Remission  
 D:    Died  
 GER:    Good early response (Blasts < 25% on day 8/15 bone marrow) 
GPR: Good Prednisolone response (Peripheral Blasts <1x109/L after 7 days 
prednisolone monotherapy)  
 PER:    Poor early response (Blasts ≥ 25% on day 8/15 bone marrow)  
 MRD:    Minimal residual disease  
 HR:    High Risk, leukaemia cells detectable >0.01% 
 SR:    Standard Risk, leukaemia cells not detectable < 0.01%  
 NK   Not known  
 n/a:   not applicable  
 
Table 2.3 Clinical and biological features of the primary Acute Leukaemia samples used in the tyrosine 
kinase inhibitor screening experiments of this study. The myeloid primary leukaemia sample, AML – 2, was 
demonstrated to the FLT3 – internal tandem duplication (FLT3 – ITD) when sequenced by the regional 
National Health Service molecular genetics laboratory.    
 
2.2. Cell lysis and protein extraction  
Cells in suspension were transferred to a universal container and harvested by centrifuging 
at 1600rpm for 5 minutes at 4OC. The supernatant was aspirated and the pellet was washed 
in 10ml ice cold PBS to remove media and serum. The centrifuge was repeated and the PBS 
aspirated.  The cells were kept on ice until lysed. Adherent cells were harvested when 80% 
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confluent. After aspiration of the media the cells were washed twice in 10ml ice cold PBS 
and kept on ice.  For immunoblotting, cells were lysed in ice cold Radio – Immuno – 
Precipitation Assay (RIPA) lysis buffer, unless otherwise stated. 50 ml of stock solution was 
made of Tris – HCl pH8 (Calbiochem, USA), 1% Triton X – 100 (Sigma), 0.1% SDS (Sigma), 
0.1% Sodium deoxycholate (Sigma) and 150mM NaCl (Severn Biotech, UK) and kept for a 
week. For each experiment 10ml of stock was utilised, to which 1 Protease inhibitor tablet 
(Roche) and 100µl 10x PhosSTOP (Roche) solution was added.  
 
For suspension cells, 40 - 80µl of chilled RIPA buffer was added to 1 – 5x106 cells, mixed 
and sonicated. For adherent cells 500µl of cold buffer was added directly to plate, the cells 
harvested with scraper, thoroughly mixed and transferred to 1.5 ml tube for sonication. 
Cells were sonicated for 7 sec at level 4. Post – sonication, cells were lysed on ice for 30 
minutes. Thereafter the cells were transferred to 1.5ml tubes, centrifuged at 13000rpm at 
4OC to clear cellular and nuclear debris. The supernatant was aspirated and transferred to 
clean 1.5ml tubes and kept on ice or snap frozen and transferred to -80OC freezer.   
 
2.3. Protein quantification  
Bovine serum albumin (BSA) (Sigma, USA) 1mg/ml stock was diluted to 0.1µg/ml, 
0.2µg/ml, 0.3µg/ml, 0.4µg/ml and 0.5µg/ml for protein standards and 10µl pipetted in 
triplicate into 96-well plate (Iwaki).  For each sample, whole cell lysate was diluted 1:10 in 
distilled water and 10µl of diluted sample pipetted into a 96 well plate (Iwaki) in triplicate. 
200µl of 1x Bradford Protein Assay (Bio-Rad Laboratories) was added to protein standards 
and samples then absorbance analysed on Bio-Rad 680 microplate reader at 595nM. The 
absorbance readings of the BSA standards were utilised to generate a standard curve to 
determine the protein concentrations of each sample.    
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2.4. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS – PAGE) 
Proteins were resolved on single phase SDS – PAGE gels, with the final acrylamide 
concentration determined by the size of the proteins of interest, 6 – 12%. Resolving gels 
consisted of 30% Acrylamide (Severn Biotech, UK), 0.1% SDS, 390mM Tris-HCL pH8, 0.06% 
N,N,N,N – tetramethylethylenediamine (Temed, Sigma) and 0.1% Ammonium Persulphate 
(Sigma) prepared with each gel. The apparatus plates were cleaned with distilled water and 
70% ethanol prior to mixing the gel. The gel was mixed and poured into the gel apparatus, 
a comb was inserted and the gel was left to polymerise. Once set, the comb was removed 
and the wells washed with distilled water and running buffer, 0.1M Tris/Bicine, 0.1% SDS 
made to 1000ml distilled water . 
 
30 - 50µg of protein was transferred to 1.5ml tube and diluted 1:1 with 2x Laemmli buffer, 
consisting of 10%  β – mercaptoethanol (Sigma), 125mM Tris – HCl (pH 6.8), 0.004% 
bromophenol blue (Sigma), 20% glycerol (Sigma) and 4% SDS. The protein was denatured 
by boiling at 95OC for 5 minutes and then returned to ice. The first lane of the gel was 
loaded with 10µl of Laemmli buffer and the second lane was loaded with full range protein 
marker (Rainbow Marker GE Healthcare or SpectraTM Multicolour Broad Range Ladder, 
Fermentas). The samples were centrifuged at 13 000 rpm for 10 seconds and transferred 
with a Hamilton syringe to the wells.   Gels were run at 30mA for 5 – 8 hours to resolve 
proteins.  
 
2.5. Protein transfer 
Transfer buffer, 40.6 g Tris (Calbiochem), 203g Glycine (Fisher Scientific), 1400ml methanol 
(Sigma) and distilled water to a total volume of 7000ml, was prepared and added to the 
transfer tank (Geneflow, EBM 20) and a plastic tray to soak the nitrocellulose membrane 
(Biotrace NT, Pall Life Sciences), Whatman® paper (Sigma - Aldrich) and sponges required 
for transfer. SDS-PAGE gels were layered onto nitrocellulose membranes and placed 
between two layers of blotting paper and encased in sponge in cassettes and placed into the 
transfer tank for overnight transfer at 200mA at 4OC.  
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2.6. Western Blotting with antibodies  
The protein loading was assessed with Poncaeau Red (Sigma) then washed with Tris – 
buffered saline – Tween (TBST), consisting of 1.21g Tris and 8.77g NaCl (Sigma) in 1 litre 
ionised water with 0.5ml Tween20 (Fisher Scientific), titrated to pH7.6 with HCl (Sigma). 
Non – specific protein binding was blocked by incubating nitrocellulose blots for 2 hours in 
5% non – fat milk/TBST when blotting for total protein and in 5% BSA/TBST when blotting 
for phospho – proteins. Membranes were incubated with primary antibodies (table 2.4) 
overnight at 40C in 5% milk or 5%BSA/TBST. The membranes were washed 3 times for 10 
minutes in TBST, incubated with the corresponding secondary antibody (table 2.4) for 2 
hours at room temperature and rinsed three times in TBST.   
 
The presence of protein – bound antibody was detected with Immobilon Western 
Chemiluminescence kit (Millipore). A 1:1 dilution of luminol and peroxide was mixed for 1 
minute and the membrane was incubated for a further minute. Excess solution was 
removed, the membrane inverted onto Sarran wrap and transferred to an autoradiography 
cassette. In a dark room, radiographic film (Kodak, UK) was exposed to the membrane for 
between 5sec and 10min. The film was developed in a Kodak X – OMAT 1000 processor.  
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Table 2.4 List of antibodies used for immunoblotting and immunofluorescence 
 
 
2.7. Model for assessing apoptosis response to IR – induced damage  
Weston et al. (315) reported the stratification of ALL in response to ionising radiation. 
Leukaemia cells with a proficient intrinsic apoptosis pathway demonstrated p53 
accumulation in response to 5Gy ionising irradiation, with cleavage of PARP – 1 and 
procaspase 7; beginning by 4 – 8 hours and completed by 24 hours. Normal accumulation 
of p53 was present in cells which were apoptosis defective, however no cleavage of PARP – 
1 and procaspase 7 was evident. 
 
Primary antibodies  
Antibody Species Dilution Company 
PARP – 1 Rabbit 1:400 Cell signaling 
Caspase – 7 Mouse 1:1000 Cell signaling 
p53 Mouse 1:20 Dr R Grand (serum) 
p21Waf1/Cip1 Mouse 1:1000 Cell signaling 
β-Actin Mouse 1:10 000 Sigma 
Tubulin – α Rabbit 1:1000 Cell signaling 
Cyclin B1 Mouse 1:1000 Santa Cruz 
Total IGF – 1R Rabbit 1:1000 Cell signaling 
Phospho – IGF – 1R (Y1131) Rabbit 1:1000 Cell signaling 
ERK Rabbit 1:1000 Cell signalling 
Phospho– p44/42 MAPK (ERK1/2) Rabbit 1:1000 Cell signaling #9106 
AKT Rabbit 1:1000 Cell signaling 
Phospho-AKT  (ser473) Mouse 1:1000 Cell signalling #4051 
EGFR Mouse 1:100 Thermo – Scientific 
Phospho – EGFR (Y992) Rabbit 1:100 Cell signaling 
Pan – phosphotyrosine  (pTyr – 100) Mouse 1:1000 – 1:2000 Cell signaling #9411S 
Phospho - γH2AX Mouse 1:500 Upstate 
Secondary antibodies  
Antibody  Species Dilution Company 
Polyclonal anti – Rabbit (Horse radish 
peroxidase conjugated) 
Swine 1:3000 Dako, Denmark 
Polyclonal anti – Mouse (Horse radish 
peroxidase conjugated)   
Goat 1:2000 Dako, Denmark 
Polyclonal anti – Mouse Alexa Flour 594  
(Fluorochrome conjugated)  
Rabbit 1:1000 Invitrogen  
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Primary cells and cell lines were defrosted, harvested, counted and suspended in media. 
For cell lines 5x106 cells per time point were and for primary cells 2x106 cells per time point. 
Cells were subjected to 5Gy ionising radiation from a Cobalt60 source, transferred to an 
incubator and harvested onto ice at 4, 8, 24 hours and protein prepared as described.  30µg 
of protein was loaded onto 8% SDS – PAGE gel and blotted for actin, cleavage of PARP – 1 
and procaspases 7 and p53 accumulation to assess apoptosis phenotype.  
 
2.8. Assessment of phospho – tyrosine kinase status by array systems   
2.8.1. Principle of phospho – tyrosine kinase array kits  
The simultaneous assessment of phosphorylated tyrosine kinases was assessed using 2 
array systems, the Raybio® Human RTK Phosphorylation Antibody Array 1 (Raybiotech, 
Inc. Norcross, USA) and the R&D Proteome Profiler TM Array Human Phospho-RTK Array 
kit (R&D, Minneapolis). Each array system has antibodies directed against the total tyrosine 
kinase spotted in duplicate on a nitrocellulose membrane. Positive and negative internal 
controls are also spotted on the membranes.  
 
 
Figure 2.1 Map of outlay of phospho – tyrosine kinase antibodies embedded on the RayBio® Human RTK 
Phosphorylation Antibody Array. The Raybiotech array system can identify up to 71 tyrosine kinases. Each 
point represents an embedded antibody (in duplicate) directed against a specific phosphorylated tyrosine 
kinase.  
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Figure 2.2 Map of outlay of antibodies directed against phosphorylated RTKs on the R&D Human 
Phospho – RTK array.  The R&D array can simultaneously assess the phosphorylation status of 42 RTKs. 
Each circle represents an embedded antibody (in duplicate) directed against a specific phosphorylated 
tyrosine kinase. 
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Similarities Differences 
Both arrays used an embedded antibody to 
capture the tyrosine kinase 
 
Difference in the RTKs investigated in 
each array system: 
- Raybiotech array included 
antibodies for non – receptor 
tyrosine kinases 
 
- No FLT3 on Raybio® Human RTK 
Phosphorylation Antibody Array 
 
Arrays utilised a pan – phosphotyrosine 
secondary antibody to detect activated 
tyrosine kinases 
The R&D anti – phosphotyrosine 
antibody is conjugated HRP 
 
Table 2.5 Summary of similarities and differences noted between the 2 array systems.  
 
2.8.2. Protocol for preparation of phospho – array membranes  
All primary cells were retrieved from cryopreservation and suspended in media. Cell lines 
were maintained as per section 2.1.3. For the Raybiotech array the cell lysis buffer, protease 
inhibitor and phosphatase inhibitor cocktails are provided with the kit with no details 
about the constituent components. Cells were prepared and hybridised to the arrays 
according to manufacturer’s protocol, with all buffers were kept on ice.  For the R&D Array 
system, cells were lysed according to manufacturer’s suggested buffer: 1% NP – 40 (Sigma), 
20mM Tris – HCl (pH8), 137mM NaCl, 10% glycerol, 2mM EDTA (Sigma), PhosSTOP 
Phosphatase inhibitor 10%v/v, cOmplete ULTRA Protease Inhibitor Tablet 1 per 10ml 
buffer.   
 
For both array systems, protein determination was performed and 50µg of whole cell lysate 
incubated with each array overnight at 4OC, hybridising to the arrays via the membrane – 
bound antibody. The membranes were washed 6 times in TBST for 5 minutes each wash to 
remove excess lysate. A secondary pan – phosphotyrosine antibody was applied for 4 hours 
which bound to the phosphorylated tyrosine residues. The membranes were washed 6 
times in TBST for 5 minutes each wash to remove antibody.   
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Signals were detected by chemiluminescence provided by each kit and developed on 
radiograph film (Kodak). The pixel density of each array spot was measured and expressed 
as optical density (OD)/mm2. To account for variation in exposure, 6 blank readings and 
readings over the negative control markers were performed. All signal readings were 
exported to Microsoft Excel. The mean signal for the pair of duplicate spots representing 
each TK was determined and the median blank and negative reading was subtracted to 
give the final reading.  
 
2.9. Treatment of cells with Tyrosine Kinase Inhibitors (TKIs) and cytotoxics  
A library of 33 tyrosine kinase inhibitors (table 2.6) was purchased from Selleck® Chemicals, 
USA.  CEP – 701 (lestaurtinib) and dovitinib were purchased from LC Laboratories 
(Woburn, MA, USA) and AMG – Tie – 2 – 1 inhibitor from SYN|thesis med chem Ltd. 
Vatalinib and PF – 04217903 were dissolved in distilled sterile water, while the remaining 
31 inhibitors were dissolved in DMSO, to produce 10mM stock aliquots, stored at -200C.   
 
The chemotherapeutic agents, cytarabine, dexamethasone, doxorubicin, fludarabine, 
methotrexate, mitoxantrone and vincristine were kindly provided by the Birmingham 
Children’s Hospital Pharmacy department. All cytotoxics were provided in normal saline 
and 2x serial dilutions in media were prepared, 0.02 - 20µM.   
 
For initial screening of cell lines and primary cells, 10mM stock solution was serially 
diluted to prepare 2x concentration, 2µM and 20µM. For more detailed investigation 
aliquots were serially diluted to desired concentrations. For cell lines, the TKI was diluted 
in RPMI/10%FCS/PS and for primary leukaemia cells RPMI/10%FCS/1%PS with additional 
100µM β – mercaptoethanol (2x dilution).  
 
The 2x dilution of TKI/drug was to ensure a final concentration between 0.001 - 10µM after 
the addition of an equal volume of media containing cells.  
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TKI Putative primary targets References 
JAK inhibitors  
AG490  JAK 2 – 3, EGFR  (316) 
CP690550 JAK 1 – 3  (317) 
IGF-1R/Insulin inhibitors  
GSK1904529A IGF – 1R/Insulin  (318) 
NVPAEW541 IGF – 1R/Insulin (319) 
Irreversible EGFR/HER2  
BIBW-2992 EGFR/HER2 (320) 
CI – 1033 EGFR/HER2/HER4 (321) 
Restricted spectrum inhibitors  
AZD0530 Abl/Src/EGFR (322) 
Bosutinib Abl/Src/Axl/EGFR/Trk (323) 
Dasatinib Abl/Src/CSF-1R/Kit/PDGFRα/β (324) 
Imatinib Abl/CSF-1R/Kit/PDGFRα/β (325) 
Masitinib Kit/PDGFRα/β (326) 
Nilotinib Abl/Kit/PDGFRα/β (325) 
PF-04217903 Met (327). 
PF-2341066 Met/ALK (328) 
PHA739358 Aurora kinase A – C/Abl/Src/RET  (329) 
AMG – TIE-2 
– 1  
Tie – 2  (330) 
Multikinase inhibitors (VEGFR/PDGFR)  
Axitinib VEGFR 1 – 3/PDGFRα/β/CSF – 1R/Kit/FGFR 1  (331) 
Brivanib VEGFR 1 -3/FGFR 1 – 3  (332) 
Cediranib VEGFR 1 – 3/PDGFRα/β/CSF – 1R/Kit/FGFR 1  (333) 
Motesanib VEGFR 1 – 3/PDGFRα/Kit/RET  (334) 
Pazopanib VEGFR 1 – 3/PDGFRα/β/CSF – 1R/Kit/FGFR 1, 3 and 4 (335) 
Vandetanib VEGFR 1 -3/EGFR/RET (336) 
Vatalinib VEGFR 1 – 3/PDGFRβ/Kit (337) 
Multikinase inhibitors with FLT3 activity   
ABT-869 FLT3/VEGFR 1 – 3/PDGFRβ/CSF – 1R/Kit (338) 
BIBF1120 FLT3/VEGFR 1 – 3/PDGFRα/β/FGFR 1 – 4/Src  (339) 
CEP-701 FLT3/VEGFR 1 – 2/PDGFRβ/RET/TrkA (340, 341) 
Dovitinib FLT3/VEGFR 1 – 3/PDGFRα/β/CSF – 1R/Kit/FGFR 1 and 3 (342) 
Foretinib FLT3/Axl/ CSF –1R/ FGFR1/ PDGFRα/β/ Kit/ Ron/ Tie-2 
/VEGFR1–3 
(297) 
NVPTAE684 FLT3/Met/ALK (343) 
Sorafenib FLT3/VEGFR 2 -3/PDGFRβ/Kit/B – raf  (344) 
Sunitinib FLT3/VEGFR 1 – 3/PDGFRα/β/CSF – 1R/Kit/RET/FGFR1 (345) 
Tandutinib FLT3/PDGFRα/β/Kit (346) 
VX-680 FLT3/Aurora kinase A – C/Abl  (347) 
 
Table 2.6 List of tyrosine kinase inhibitors with primary putative targets (348).TKIs were chosen to cover 
the kinome. The inhibitors have been grouped together by principle activity: (i) Jak inhibitors, (ii) IR/IGF – 1R, 
(iii) EGFR/HER2 inhibitors, (iv) restricted inhibitors with no FLT3 activity, (v) multikinase inhibitors with no 
FLT3 activity and (vi) multikinase inhibitors with FLT3 activity.   
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2.10. Cell viability assays 
2.10.1. Promega CellTiter-Glo® luminescence ATP – based cell viability assay   
Cell viability was assessed with the Promega CellTiter – Glo® Luminescent Cell Viability 
Assay (Promega, UK) which is a luciferase – based assay measuring intracellular ATP, as a 
proxy of cell viability and proliferation. The reagent lyses the cells and complexes 
thermostable luciferase with ATP to generate a luminescent signal. CellTiter – Glo® 
demonstrates excellent signal to noise and background ratios (349). In addition, there have 
been recent concerns about the reliability of alternative cell viability assays using 
tetrazolium (MTT) salt – based assays for TKI assessment, as doses above 1µM can interfere 
with the reduction of MTT to formazan (350). However, the Promega assay which measures 
intracellular ATP by luminescence is not dependent on compound reduction and so 
provides a more robust method for cell viability following TKI treatment.   
 
2.10.2. Assessment of activity of TKIs, cytotoxics and combination therapy   
Fifty microlitres of 2x serial dilutions of inhibitor/cytotoxic were pipetted, in triplicate, into 
the wells of opaque – walled 96 well plates (Corning Costar®). For screening, each 
experiment investigated 33 TKIs and a DMSO/distilled water control to account for the 
effect of the vehicle on cell growth.  To account for background luminescent wells 
containing 100µl media but no cells/inhibitor, were assayed. For detailed dose response 
curves, 50 µl of serial log concentration dilutions (0.001µM – 10µM) of 2x concentrations 
were plated in triplicate.   
Cell lines were harvested, counted and suspended in media at 2x105/ml and 50µl added to 
each well. Primary cells were defrosted, counted and viability assessed. Only primary 
samples with viability >80% were used, suspended in media and seeded at 2000 – 22 000 
cells per well. The plates were incubated with TKI at 37OC, 5% CO2 for 72 hours for cell 
lines and 48 hours for primary cells. One hour prior to assessing the luminescence of the 
cells, the plates were removed from the incubator and allowed to equilibrate to room 
temperature. One hundred microlitres of CellTiter-Glo® reagent was added to the wells and 
the plates were placed on a rotary shaker for 2 minutes, to lyse the cells and aid mixing. The 
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plates were left for at least 10 minutes to ensure mixing and luminescence assessed with 
Wallac Viktor2 1420 Multilabel Counter (Perkin – Elmer, Boston, USA). The change in cell 
viability was calculated by reflecting the mean luminescence reading of the treated cells as 
a percentage of the mean untreated cell wells. The untreated cells were designated 100%.  
The readings were normalised to the control luminescence readings of DMSO/water to 
account for their effect on cell growth. Dose response curves were analysed by Graphpad 
Prism® vers5.01 for Windows (GraphPad Sotware Inc., La Jolla, CA, USA) and IC50 
generated. 
 
2.10.3. Interaction of TKI and conventional cytotoxic combination therapy   
To assess the interaction of specified TKIs with conventional cytotoxics, dose response 
curves were initially generated for the TKI and chemotherapy in cell lines. To assess drug 
interactions cell lines were incubated with serial dilutions of TKI and chemotherapy, log 
concentration dose ranges 0.0001 – 10µM, and in combination with a fixed sub – IC50 dose of 
TKI with serial dilutions of chemotherapy, log concentration dose ranges 0.0001µM – 
10µM. Cell lines and primary cells were prepared as above and 50µl added to untreated 
well in triplicate with a multichannel pipette. 2x dilution of TKI was added to the cells just 
prior to plating into chemotherapies in triplicate.  
 
Calcusyn (Biosoft, Cambridge UK) was used to analyse the effect of drug – combination 
studies, using the Cho – Talalay median effect method. Interactions were expressed as 
combination indices (CI), synergy expressed by CI<1, antagonism CI>1 and an additive 
effect CI=1 (351, 352) (table 2.7).  
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Range of CI Symbol Description 
<0.1 +++++ Very strong synergism 
0.1 – 0.3 ++++ Strong synergism 
0.3 – 0.7 +++ Synergism 
0.7 – 0.85 ++ Moderate synergism 
0.85 – 0.90 + Slight Synergism 
0.90 – 1.10 ± Nearly additive 
1.10 – 1.20 - Slight antagonism 
1.20 – 1.45 -- Moderate Antagonism 
1.45 – 3.3 --- Antagonism 
3.3 – 10 ---- Strong antagonism 
>10 ----- Very strong antagonism 
 
Table 2.7 Recommended symbols for describing synergism or antagonism in drug Combination Studies 
analysed with the Combination Index (CI) Method. 
 
2.11. Cell cycle profiling with Propidium Iodide (PI) 
Cell lines were harvested, counted and resuspended in media at concentration of 
5x105cells/ml. 2ml was added to 24 well plates (Iwaki) and 1x dilution of the TKI added to 
prepare 0.15, 0.5 or 1µM concentration. Controls were treated with 0.1% DMSO. Cells were 
harvested at 24, 48 and 72 hours and washed in ice cold PBS, centrifuged at 1600rpm for 5 
minutes and permeabilised in 1ml 80% ice cold ethanol for at least 1 hour. Samples which 
were not analysed on the same day were stored at -20OC, up to 1 week. Post – 
permeabilisation, cells were washed twice in ice cold PBS, resuspended in 0.25mg/ml 
Propidium Iodide (Fluka), 0.02mg/ml Concert TM RNAse A (Invitrogen) and incubated in 
the dark for 30 minutes. 500µl of PBS was added and samples analysis performed on a 
Coulter EPICS® XL-MCL flow cytometer.  Cell cycle profiles were analysed with 
WinMDI2.9 freeware (Phoenix, USA). 
   
2.12. Assessment of apoptosis  
2.12.1. Assessment of Apoptosis by DNA fragmentation   
To assess the mechanism of cell death, assessment of apoptosis by DNA fragmentation was 
performed (353, 354). The cell lines were harvested, counted and resuspended at 1x106 
cells/ml in 5ml media in 6 well plates (Iwaki). For TKI treated cells 0.5µl of 10mM stock was 
added to prepare final concentration of 1µM, DMSO controls had 0.5µl added. Control and 
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treated cells were harvested at 24, 48 and 72 hours. The cells were harvested and 
centrifuged at 2000rpm for 5 minutes and the supernatant was discarded. The pellet was 
rinsed to remove the cytoplasmic fraction in 1ml 10mM Tris-HCL pH 8.7, 3mM MgCl2 
(Sigma) and transferred to 1.5ml Eppendorf. The samples were centrifuged at 13 000rpm 
for 5 minutes and the supernatant discarded. The pellets were dissolved in 100µl 10mM 
EDTA, 50mM Tris – HCl pH 7.8, 0.5% SDS and RNAse A and incubated at 50OC for 15 
minutes. Proteinase K (ThermoScientific) was added at a concentration of 1mg/ml and 
lysates were incubated for a further 30 minutes at 50OC. The samples were diluted 1:1 with 
1x Tris, Borate, EDTA (TBE) buffer (Sigma Aldrich), 20% glycerol, and 0.01% v/v 
bromophenol blue and 20 µl loaded onto a 1.8% agarose gel in 1x TBE. Samples were run 
alongside 5µl 100bp DNA ladder (Invitrogen) at 100V for 2 hours and incubated in SYBR® 
Safe (Invitrogen) for visualisation. Images were taken using UV GeneFlash imager 
(Syngene Bio Imaging, UK).  
 
2.12.2. Assessment of Annexin V – PI staining by flow cytometry   
Cell membrane changes occur early in apoptosis with externalisation of the phospholipid, 
phosphatidylserine (PS), from the inner membrane to the outer leaflet. The calcium – 
dependent phospholipid – binding protein Annexin V binds strongly to PS on the external 
membrane. Detection of fluorochrome – labelled Annexin V by flow cytometry has been 
exploited as a marker of early apoptosis (355). This assay was used assess the mechanism of 
cell death and to quantify the induction of apoptosis in cells treated with TKI alone, 
chemotherapy alone or a combination of TKI and chemotherapy. 
 
5x106 cells were harvested, washed, resuspended in 5ml media and seeded in 6 – well 
plates. The cells were treated with DMSO, TKI, dexamethasone or combination of TKI and 
dexamethasone and harvested at 24h intervals. Cells were harvested, washed twice in cold 
PBS, centrifuged at 4OC 1600rpm and resuspended in 100µl 1X Binding Buffer (Invitrogen). 
Each sample had 2µl FITC – labelled Annexin V (Invitrogen) and 4µl PI (Invitrogen) added 
and was incubated in the dark for 15 minutes at room temperature. 400µl of binding buffer 
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was added to each sample, which were analysed by Coulter XL – MCL flow cytometer. 
Control samples for compensation were made of untreated, Annexin – and PI – only 
stained cells.      
 
2.13. Immunofluorescence staining  
To assess whether the TKIs induced DNA damage, γH2AX foci were assessed as a proxy of 
DNA DSB. Nalm17 cell line was exposed to 2Gy ionising radiation to induce DSB as a 
positive control. 
 
The day prior to the experiment, slides were washed with 70% ethanol/1% HCl on a rotary 
– shaker for 1 hour and rinsed 4 times in distilled water for 20 minutes. The slides were 
dried in 37OC incubator overnight. On the day of the experiment poly – L – lysine (Sigma) 
was placed on each well and left for 20 minutes at room temperature. Excess poly – L – 
lysine was aspirated and distilled water placed on each well and aspirated off. The slides 
were placed in 37OC incubator for at least 30 minutes to dry. Cells were harvested, counted 
and resuspended at concentration 5x105 cells/ml in 5ml media. The cells were incubated 
under 3 conditions: (i) untreated, (ii) 2Gy IR or (iii) inhibitor 1µM. The irradiated cells were 
harvested at 2 hours and cells treated with inhibitor at 24 hours. Cells were centrifuged at 
1200rpm for 3 minutes and the supernatant removed. The pellet was resuspended in the 
remaining media and placed on a well in triplicate and left to adhere for at least 30 minutes.     
The slides were fixed by being placed upright in a coplin jar in ice cold methanol (Sigma) 
for 15 minutes. The slides were washed in PBS for 5 minutes, 3 times, at room temperature.  
Once fixed, the cells were blocked with 10% FCS in PBS and left overnight in a moist box at 
4OC. After blocking, the slides were washed for 5 minutes in PBS, 3 times. The excess PBS 
was wiped off with a cotton bud and 30µl of 1:500 mouse phospho - γH2AX (Upstate) 
1%FCS/PBS antibody added to each well. The primary antibody was incubated in moist 
dark box for 1 hour. Thereafter the slides were washed for 5 minutes in PBS for 3 times. The 
slides were dried with a cotton bud and 10µl of 1:1000 dilution of Alexa Fluor 594 
(Invitrogen) secondary antibody was applied to each well and incubated in a moist box at 
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room temperature for 1 hour. The slides were washed 3 times for 5 minutes in PBS in a foil 
– covered coplin jar. Excess PBS was dried in between wells and DAPI (Vector 
Laboratories) placed between each well with a cut 20µl pipette tip. Ethanol – cleaned cover 
slips were placed over the well and all bubbles removed. Cells were visualised with high – 
power oil immersion Nikon microscope at 100X and the number of γH2AX foci in 100 cells 
counted. DNA damage was present in the irradiated cell line, Nalm 17, with increase in the 
number of γH2AX foci. Ten foci per nucleus appeared discriminatory between normal cell 
cycling and DNA damage. Cells with greater than 10 foci per nucleus were considered to 
have DNA damage.  
 
2.14. Confirmation of polypoidy by DAPI staining  
To assess the nuclear changes induced by TKIs, cell lines were harvested, counted and 
resuspended at 5x105cells/ml and treated with 1µM TKI. Cells were harvested and 
centrifuged at 1500rpm for 5 minutes and the supernatant discarded. The cells were rinsed 
in PBS, recentrifuged at 1500rpm for 5 minutes and the supernatant was discarded. The 
cells were resuspended in the remaining PBS and pipette onto slide wells in triplicate. 10µL 
of VECTASHIELD (Vector Laboratories) was pipetted onto each well and mounted with an 
ethanol cleaned coverslip. The nuclei were visualised with high – power oil immersion 
Nikon microscope at 100X. Size and shape of nuclei were assessed to demonstrate 
polyploidy.  
 
2.15. Nucleic acid work  
2.15.1. Primer design for Real Time Quantitative Polymerase Chain Reaction  
Polymerase chain reaction (PCR) primers were designed on Invitrogen® website 
(www.invitrogen.com) and synthesised by Invitrogen. Desirable characteristics of the 
primer sequence were an annealing temperature approximately 70OC with product length 
of approximately 100bp. The specificity of the primers was assessed with the basic local 
alignment search tool (BLAST) (www.ncbi.nlm.nih.gov/BLAST). Primers were 
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reconstituted in sterile RNA free water (Sigma) to a concentration of 200µM and stored at    
-20OC.   
 
2.15.2. Purification of RNA 
RNA was typically purified from 5x106 cells with the RNeasy Miniprep kit (Qiagen) 
according to manufacturer’s protocol. RNA was  eluted with 40µl RNA – free sterile water 
(Qiagen) and DNA degraded with addition of 1µl DNAse (Qiagen), incubated for 20 
minutes at 37OC and the DNAse degraded thereafter for 10minutes at 80OC. RNA content 
was quantified with a nanodrop spectrophotometer.    
  
2.15.3. Synthesis of complementary DNA (cDNA) 
cDNA was synthesised in a 2 stage process. Initially a mastermix consisting of 1µg RNA, 
sterile water, 10mM mixed dNTPs (Promega) and 1µl random hexamers (Promega) to a 
total volume of 12µl was denatured for 5 minutes at 65OC then placed on ice for 2minutes. 
To each sample 4µl first strand (FS) buffer, 2µl 100mM dithiothretiol (DTT) and 1µl 
SuperscriptTM II Reverse Transcriptase (Invitrogen) was added for 5 minutes at room 
temperature. Each sample was incubated at 42OC for 50minutes in an Eppendorf Thermal 
Cycler, followed by inactivation at 80OC 15minutes. cDNA was used for amplification or 
stored at -20OC. 
 
2.15.4. FAST SYBR® Green Real time quantitative PCR of cDNA 
For each gene, a mastermix was prepared in a sterile 1.5ml tube for each of the genes of 
interest. For each gene of interest 16µl of the mastermix, consisting of 0.25µl of 20µM 
forward and reverse primers (table 2.8), 10µl FAST SYBR® Green 2x and 5.5 µl of sterile 
RNA – free water, and 4µl cDNA was added to each well in triplicate on the PCR plate.  For 
each reaction -actin was utilised as an endogenous control. PCR amplification was 
performed with Applied Biosystems 7500 Fast Real-Time PCR System for 35 cycles, 
commencing with denaturing for 3sec at 95OC, annealing/extension step for 30sec at 60OC. 
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2.15.5. Agarose gel electrophoresis 
10x TBE was diluted to 500ml (1x) and 100ml transferred into a 250ml glass container. 1.8g 
agarose (ThermoScientific) was added to 100ml TBE1x, boiled in a microwave and allowed 
to cool. 4µl SYBR® Safe DNA gel stain (Life Technologies, UK) was added, the gel poured 
and combs inserted. 5µl of 100bp DNA ladder (Invitrogen) was pipette into the first lane of 
the submerged gel and samples, 20µl DNA or RNA transcript, added to the subsequent 
lanes. The gel was run at 100V for up to 2 hours. Images were taken using UV GeneFlash 
imager (Syngene Bio Imaging, UK).      
 
2.15.6. Gel extraction and purification  
PCR products were visualised with a UV light and individual bands excised with a scalpel 
blade. The gel was transferred to a clean eppendorf and extraction of product was 
performed according to the manufacturer’s guidelines of the Qiagen QIAquick® Gel 
extraction kit.  
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Primer Sequence  Tm (OC) Length (bp)  Control  
Βeta actin Forward CACCATTGGCAATGAGCGGTTC 
Reverse  AGGTCTTTGCGGATGTCCACGT 
68 
72 
22 
22 
REH 
ALK Forward TTGTTGGTGATTCCAAGGAG 
Reverse   GCAGAGAGGGAAGGCTGTC 
67 
72 
21 
19 
SY-5Y 
AXL Forward  TGGCTGTGAAGACGATGAAG 
Reverse     TCGTTCAGAACCCTGGAAAC 
68 
68 
20 
20 
MCF7 
CSF -1R Forward GTGGCTGTGAAGATGCTGAA 
Reverse   CCCAGAAGGTTGACGATGTT 
70 
68 
20 
20 
HL60 
EGFR Forward  AACTGTGAGGTGGTCCTTGG 
Reverse    GTTGAGGGCAATGAGGACAT 
70 
68 
20 
20 
MCF7 
HER2 
 
Forward   ACCAAGCTCTGCTCCACACT 
Reverse    ACTGGCTGCAGTTGACACAC 
70 
70 
20 
20 
MCF7 
HER3 Forward   CAGGGGTGTAAAGGACCAGA 
Reverse     CCCACGCCAGTAGAGAAAAG 
70 
70 
20 
20 
MCF7 
HER4 Forward   ACCCCCAGTGTGAGAAGATG 
Reverse     GAAACTGTTTGCCCCCTGTA 
70 
68 
20 
20 
MCF7 
FGFR1 Forward ATGCTAGCAGGGGTCTCTGA 
Reverse   ATAGCCTCTGCCAACACCAC 
70 
70 
20 
20 
HL60 
FGFR2 Forward CGCAGCCACGTACACTTCT 
Reverse    CGGCCCTCCTTCAGTTTAGT 
70 
70 
19 
20 
MCF7 
FGFR3 Forward  GACGTGCACAACCTCGACTA 
Reverse    CCAAAGGACCAGACGTCACT 
70 
70 
20 
20 
REH 
FGFR4 Forward GTGCTGGTGACTGAGGACAA 
Reverse   GTACACCCGGTCAAACAAGG 
70 
70 
20 
20 
MCF7 
FLT3 Forward GGACGGACATAAGGTGCTGT 
Reverse   GGCAATGTGGTCTGAGGAGT 
70 
70 
20 
20 
SupB15 
Kit  Forward TGACTTACGACAGGCTCGTG 
Reverse   CCACTGGCAGTACAGAAGCA 
70 
70 
20 
20 
Kasumi 
Met Forward TTGGACAATGATGGCAAGAA 
Reverse   GATGATTCCCTCGGTCAGAA 
64 
68 
20 
20 
L428 
PDGFRα Forward GCTCAGCCCTGTGAGAAGAC 
Reverse   ATTGCGGAATAACATCGGAG 
72 
66 
20 
20 
KMH2 
PDGFRβ Forward  GACAGGGAGGTGGATTCTGA 
Reverse    AGGTGTAGGTCCCCGAGTCT 
70 
72 
20 
20 
Nalm 17 
Ron Forward GTGACTTGATGGCACATTGG 
Reverse   GTCACCCACAGTGACCGAGT 
68 
72 
20 
20 
KMH2 
RET Forward  ACAGGGGATGCAGTATCTGG 
Reverse    AAGCCGAAATCCGAAATCTT 
70 
64 
20 
20 
HL60 
Tie – 2 Forward  AGGCAATGCAGGTGAGAGAT 
Reverse    GGAGTCAGCTTGCTCCTTTC 
68 
70 
20 
20 
MCF7 
Trk A Forward GTGAGGTTTCTCAGCTCCCC 
Reverse   GCGCAGAGAACCTGACTGA 
72 
70 
20 
19 
SY – 5Y 
VEGFR1 Forward TCC CTT CCT TCA GTC ATG TGT 
Reverse   AAGAAGGAAACAGAATCTGCAA  
69 
66 
21 
22 
MCF7 
VEGFR2 Forward TGATCGGAAATGACACTGGA 
Reverse  CACGACTCCATGTTGGTCAC 
66 
70 
20 
20 
MCF7 
VEGFR3  Forward TCGGAGCTCAAGATCCTCAT 
Reverse   CTTGCAGAACTCCACGATCA 
68 
68 
20 
20 
MCF7 
VDJ Primers    
Fr3A 3'- ACACGGCYSTGTATTACTGT-5’ 57 100 
J1H 3'-ACCTGAGGAGACGGTGACCAGGGT -5' 57 100 
 
Table 2.8 Primers for sequencing nucleic acid work in this study. Transcript for putative RTK targets were 
assessed with FAST SYBR® Green Reverse Transcriptase quantitative polymerase chain reactions (RT qPCR).  
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2.15.7. Sequencing of primer products to confirm target   
DNA was sequenced using the Big Dye® sequencing kit (Applied Biosystems, UK). For each 
extracted DNA sample, a final volume of 20µl was added to a 0.2ml PCR tube, which 
included 4µl 5x buffer, 1µl Big Dye®, 1µl forward/reverse primer and 14µl of DNA. 
Applied Biosystems 7500 Fast Real-Time PCR System, was used to initially denature the 
sample for 10 seconds followed by 25 cycles of denaturing for 10 seconds at 95 OC, 
annealing at 50OC for 5 seconds and 60 OC extension for 4 minutes. The final extension was 
at 60OC for 10 seconds, followed by 25OC indefinitely. After amplification, each sample was 
resuspended in 2µl sodium acetate and 50µl ethanol and transferred to 1.5ml tube, 
vortexed and left at room temperature for 20 minutes to precipitate. Each sample was 
centrifuged at 13000rpm and the supernatant aspirated. Samples were washed in 250µl 
100% ethanol, vortexed, centrifuged at 13000rpm and aspirated dry. After 20 minutes at 
room temperature, 12µl of Hi – DiTM Formamide (Invitrogen) was added and boiled at 95OC 
for 5 minutes. Samples were sequenced on 3100 DNA Sequencer 3130xl Genetic Analyzer, 
Applied Biosystems, Hitachi.  
 
2.16. Xenograft model methods 
All murine experiments were conducted according to Home Office Guidelines (Licence 
30/2904). Non – obese diabetic/severe combined immunodeficient (NOD/Scid) or Non – 
obese/severe combined immunodeficient/IL-2 receptor gamma chain deficiency (NOG) 
mice were used for experiments (Jackson lab, Maine, USA). Both strains of mice lack 
mature functional B - and T – lymphocytes which enable efficient engraftment of human 
cells, NOG mice demonstrate additional Natural Killer cell deficiency.  
 
2.16.1. Analysis of engraftment patterns of  leukaemic populations 
B – cells follow a reproducible pattern of maturity from stem cells to mature plasma B – 
cells. ALL mirrors the development of normal B – cells, with maturational arrest leading to 
clonal expansion of B – cell progenitor (pro – B), B – cell precursor (pre – B) or common 
components. Expression of the surface antigens can be used to identify human leukaemias 
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(CD45) in murine xenografts and define the subtype of B – cell precursor ALL. To quantify 
the degree of leukaemia engraftment and the TKI activity on the engrafted leukaemic cells, 
flow cytometric assessment of human leukaemia cells was performed using fluorochrome – 
conjugated antibodies (table 2.9).      
 
2.16.2. Primagraft model 
Primary leukaemia cells were rapidly thawed, centrifuged, resuspended in media and 
viability assessed as previously described. Cells were centrifuged and resuspended 1x106 
cells/ 100µl ice – cold PBS and stored on ice until injected. For the initial engraftment kinetic 
experiments 1x106 cells were injected into 8 NOG mice via the lateral tail vein. For TKI 
experiments, 1x106 cells were injected into NOD/Scid mice. 
 
Mice were examined daily for well – being and a maximum of 80µl peripheral murine 
blood was sampled in a week. Red cells were lysed with 1ml 1x red cell lysis concentrate 
(BD Pharm) for 5 minutes at room temperature, centrifuged at 1600rpm for 5 minutes and 
the supernatant aspirated. The cells were resuspended in 2ml PBS, transferred to 2 clean 
5ml Falcon tubes (one for isotype control and the other for antibody stained cells), 
centrifuged at 1600rpm, the supernatant aspirated and 14.5µl of antibody mastermix (table 
2.9) was added to each sample tube and incubated in the fridge for 30 minutes. Cells were 
washed in ice cold PBS, centrifuged at 1600rpm and the supernatant aspirated. The cells 
were resuspended in 500µl 1% formaldehyde/PBS and assessed with BDTM LSRII Flow 
Cytometer (BD Biosciences, San Jose, USA).  Cell viability was assessed by plotting forward 
vs. side scatter and the live cells gated for further analysis. Engraftment was established 
when the human CD45 (hCD45) >1% of total viable cells in murine peripheral blood.  
At the end of experiments, mice were killed by cervical dislocation (schedule 1) and the 
liver, spleen and BM harvested. Single cell suspensions were made by macerating the liver, 
spleen through a tea-strainer and passed through a 40µm cell – strainer (BD Biosciences) 
into 50ml Falcon tube. Blasts were harvested from femoral bone marrow by flushing femurs 
with RPMI.  
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Cells harvested from the liver and spleen were resuspended in 15ml media, layered on 
35ml lymphoprep and centrifuged 1600rpm for 30minutes with the brake off. The 
mononuclear cells were aspirated and washed twice in 10ml media. An aliquot of cells was 
transferred for analysis and the remaining cells counted and aliquots frozen in 10% 
DMSO/FCS for storage at -80OC.   
 
Bone marrow cells were washed twice in media and transferred to FACS Falcon tube for 
staining. Cells were stained with the antibody mastermix (table 2.9) and analysed on BDTM 
LSRII Flow Cytometer (BD Biosciences, San Jose, USA). 
 
 
Table 2.9 List of fluorochrome – conjugated antibodies for xenograft experiments 
 
2.16.3. Preparation and treatment protocols of TKIs for primagraft experiments 
Dovitinib and foretinib were prepared in sterile conditions, dissolved in DMSO and 
aliquots transferred into sterile tubes. Doses which were not used on the first day were kept 
at -20OC until required. Drugs were administered via oral gavage. 
  
Mice were randomised to receive treatment or an equal volume of DMSO. For the foretinib 
experiment, 5 mice were treated with foretinib 30mg/kg/day 5 days on and 9 days off for 2 
cycles. Five mice received an equal volume of DMSO as the control cohort. Six mice were 
treated with dovitinib 65mg/kg/day for 5 days on, 2 days off for 3 cycles, while the control 
cohort consisted of 5 mice treated with equal volumes of DMSO.  
 
 
Antibody Fluorochrome Volume per sample (µl) Company 
CD10 APC 5 eBioscience  
CD19  PerCP cy 5.5 2 eBioscience 
CD34  PE Cy7 3 eBioscience 
Human CD45 (hCD45)  Pacific Blue 4 eBioscience 
Murine CD45 (mCD45)  Alexa Fluor 700 0.5 eBioscience 
Total volume of mastermix   14.5  
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2.16.4. Taqman Molecular analysis of VDJ rearrangement Taq polymerase  
To confirm the clonal stability of the murine xenograft model, VDJ rearrangements of 
transplanted lymphoblasts were assessed by Taq polymerase PCR. 5x106 cells of the ALL – 
20 pre – injected primary sample and bone marrow, liver and spleen harvested from mice 
after engraftment were counted, suspended in 10ml media and centrifuged at 1600rpm for 
5 minutes at 4OC to pellet the cells. The supernatant was aspirated, the cells washed in 
chilled PBS and transferred to 1.5ml tubes and kept on ice. Genomic DNA was extracted 
with Qiagen DNA QIAamp mini-kit according to the manufacturer’s protocol. Each 
reaction was set up to total volume 50µl, consisting of 100 – 500ng DNA, 250ng each primer 
(table 2.7), 5µl 5x buffer, 20mM each dNTP, DNA/RNA free sterile water (Sigma), a drop of 
mineral oil and 2Units Taq polymerase. Using an Eppendorf Thermal cycler, hot start 
amplification was commenced initially denaturing for 94OC for 3 minutes, after which the 
Taq polymerase was added, then elongation at 80OC for 2 minutes. The reaction was halted 
and 2 Units Taq polymerase added. The samples were subjected to 38 cycles of denaturing 
at 94OC for 30 seconds, annealing at 57 OC for 30 seconds and extension at 68 OC for 30 
seconds. A final extension of 5 minutes at 80OC. DNA was run on a TBE/agarose gel and 
sequenced as described 2.15.7. 
 
2.17. Statistical analysis 
2.17.1. Analysis of groups  
Graphpad Prism® version 5.01 for Windows (GraphPad Sotware Inc., La Jolla, CA, USA) was 
used for statistical analysis. Student’s t – test as used to measure statistical significance 
between 2 groups and multiple comparisons were performed with one – way ANOVA. 
Comparison of 2x2 contingency tables was performed with Chi square or Fisher’s exact test.   
Differences were considered statistically significant when p <0.05 (two – tailed).  
 
2.17.2. Survival comparison  
For in vivo studies, Kaplan – Meier survival curves were generated by Graphpad Prism 
vers5 and comparison of vehicle and treatment groups performed by log rank test. 
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3    Baseline phosphorylation tyrosine kinase profiles of childhood ALL   
3.1 Introduction  
Recent work by the Stankovic group identified a group of high risk leukaemias which fail 
to undergo apoptosis by using a robust in vitro model for evaluating the mechanisms of 
resistance to DNA damage induced by ionising radiation (158, 315). Failure to undergo 
apoptosis after IR – induced DNA damage correlated with poor clinical responses to 
induction therapy (158). In response to IR, these high risk leukaemias revealed aberrant 
activation of NF-κB (315) as well as heterogeneous enrichment of gene sets with anti – 
apoptotic and proliferative functions which included overrepresentation of gene sets 
involved in EGF, IGF and PDGF signalling (158). Gene expression array analysis did not 
reveal significant differences in basal gene expression between apoptotic sensitive and 
apoptotic resistant tumours, however aberrant activation of (R)TKs by phosphorylation 
may account for these responses to DNA damage and could provide useful novel 
biomarkers as well as therapeutic targets.  
 
To address the possible role of aberrant constitutive phosphorylation of RTKs in primary 
ALL with impaired apoptotic responses to DNA damage, 2 commercially available 
phospho – RTK array systems were used to detect the phosphorylation status of up to 71 
tyrosine kinases in 20 primary ALLs and their relationship with biological and clinical 
features was investigated. The first tyrosine kinase phosphorylation array is produced by 
RaybioInc. (Norcross, GA, USA) and enables simultaneous detection of 71 receptor and non 
– receptor tyrosine kinases. The second array from R&D Systems (Minneapolis, MN, USA) 
assesses the activation status of 42 RTKs in parallel. Both array systems capture non – 
phosphorylated and phosphorylated proteins on the membrane – embedded antibodies.  
Antibodies to the specific (R)TK were spotted in duplicate on the membrane.  Only the 
phosphorylated form is visualised with the binding of a secondary pan – tyrosine antibody.  
 
The main difference between the array systems is the Raybiotech array possesses antibodies 
for 26 cytoplasmic TKs, while the R&D array only binds RTKs. Table 3.1 demonstrates the 
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spectrum of RTKs bound by each array with differences between the 2 systems highlighted. 
Of particular note, the Raybiotech array does not bind FLT3, Mer, Ron or VEGFR – 1 while 
R&D does not bind ALK, DDR2, EphA5, EphB3, LTK, ROS and RYK. The full spectrum of 
each array is presented in section 2.8. Neither company has published information about 
the primary antibodies which are impregnated on the membranes.     
 
The objectives of the work presented in this chapter were to establish baseline 
phosphorylation profiles of leukaemias stratified by previously identified patterns of 
apoptotic response to IR – induced DNA damage. Subsequently, current ALL risk criteria 
were correlated with phosphorylation signals of individual RTK to identify any 
associations.  
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Tyrosine kinase Raybio® Human RTK array R&D Systems® Proteome ProfilerTM Human Phospho-
RTK array 
ALK + - 
Axl + + 
Dtk + + 
EGFR + + 
ERBB2/HER2 + + 
ERBB3/HER3 + + 
ERBB4/HER4 + + 
EphA1 + + 
EphA2 + + 
EphA3 + + 
EphA4 + + 
EphA5 + - 
EphA6 + + 
EphA7 + + 
EphA8 + + 
EphB1 + + 
EphB2 + + 
EphB3 + - 
EphB4 + + 
EphB6 + + 
FGFR1 + + 
FGFR2 + + 
FGFR3 + + 
FGFR4 + + 
FLT3 - + 
IGF1 – R + + 
Insulin + + 
Kit + + 
LTK + - 
CSF-1R/MCSFR + + 
Mer - + 
Met/HGFR + + 
MuSK + + 
NGFR/TrkA + + 
PDGFRα + + 
PDGFRβ + + 
RET + + 
Ron - + 
ROR1 + + 
ROR2 + + 
ROS + - 
RYK + - 
Tie – 1 + + 
Tie – 2 + + 
TrkB + + 
Tyro10/DDR2 + - 
VEGFR1 - + 
VEGFR2 + + 
VEGFR3 + + 
Table3.1. Summary of RTK antibodies imprinted on the membrane arrays for each system. Kinases 
highlighted in grey were imprinted on only 1 of the 2 arrays systems.   
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3.2 Stratification of primary ALL samples by clinical, genetic features and response to 
apoptotic induction by IR – induced apoptosis   
The 20 childhood B – precursor ALL samples evaluated for RTK phosphorylation profiling 
were characterised for treatment response based on the biological evaluation of early bone 
marrow morphology, for the presence or absence of blasts, and the MRD status on day 29 
of induction therapy. MRD assessment was performed by identification of a persistent 
aberrant immunophenotype by flow cytometry (flow MRD) or distinguishing 
immunoglobulin or T – cell receptor gene rearrangements by polymerase chain reaction 
techniques (molecular MRD). The patterns of apoptotic response following IR – induced 
DNA damage were established as a predictive marker for treatment response, according to 
the methodology previously described  (315).  
 
Following the induction of DNA double stranded breaks (DSBs) by 5Gy IR, cells were 
harvested at 4, 8 and 24 hours. Proficiency of apoptosis was assessed by detecting cleaved 
products of procaspase 3 and 7 and PARP – 1 proteins at these time points. Normal 
accumulation of the tumour suppressor p53 protein was also assessed to exclude potential 
involvement in apoptosis resistance.  
 
Eleven of the 20 ALLs (samples ALL 10 – 20) displayed a proficient apoptotic response after 
IR – damage with accumulation of p53, cleavage of PARP – 1 and procaspase 3 and 7 by 24 
hours (fig 3.1a).  The remaining 9 ALLs (samples ALL 1 – 9) displayed an apoptosis 
defective phenotype, normal accumulation of p53 with no concomitant cleavage of PARP-1 
or the procaspases (fig 3.1b). Table 3.2 shows the clinical features, genetic characterisation 
and apoptotic responses of leukaemias analysed using the R& D and Raybiotech phospho – 
RTK arrays.  
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Figure 3.1 Western Blots of representative responses in cell lines to IR – induced apoptosis by 5Gy IR. (a) 
Ionising radiation induced apoptosis the apoptosis proficient cell line (SupB15). Exposure to 5Gy ionising 
radiation induces the activation of p53 and leads to apoptosis, demonstrated by the cleavage of PARP – 1 and 
procaspase 7 (b) Ionising radiation did not induce PARP – 1 cleavage in the apoptosis defective cell line      
(SD – 1). Exposure to 5Gy IR induces the accumulation of p53 but does not lead to apoptosis.    
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Sample 
code 
Age Sex WCC Cytogenetics Response Flow 
MRD 
Mol 
MRD 
Apoptosis 
Phenotype 
R&D Raybiotech 
ALL-1 1 M 62 Hyperdiploid GER HR HR Defective + + 
ALL-2 2 M 391 Non – contributory GER SR HR Defective + + 
ALL-3 15 M 117 Hyperdiploid PER SR HR Defective + + 
ALL-4 4 M 2.4 Non – contributory GER HR NK Defective + + 
ALL-5 14 M 11 Non – contributory GER HR HR Defective + - 
ALL-6 8 M 22 t(12;21) GER SR NK Defective + - 
ALL-7 4.1 M 51 t(12;21) N/K HR SR Defective + - 
ALL-8 10.1 F 1.1 Non – contributory PER HR HR Defective + - 
ALL-9 14 M 150 Non – contributory PER HR HR Defective + - 
ALL-10 7.1 M 82 Non – contributory GER SR SR Proficient + - 
ALL-11 2.2 F 88 Non – contributory PER HR HR Proficient + - 
ALL-12 3 F 5 t(12;21) GER SR SR Proficient + - 
ALL-13 2.75 F 5.2 t(12;21) GER SR SR Proficient + - 
ALL-14 8.9 F 74 t(12;21) GER SR SR Proficient + - 
ALL-15 11.1 M 10 t(12;21) PER SR SR Proficient + - 
ALL-16 3.5 M 3.4 t(12;21) GER HR HR Proficient + - 
ALL-17 2.1 M 26 Non – contributory GER NK SR Proficient + + 
ALL-18 7.8 M 9 Hyperdiploid GER NK SR Proficient + + 
ALL-19 5 M 10 t(12;21) GER SR SR Proficient - + 
ALL-20 12 F 109 Non – contributory GER Ind SR Proficient - + 
  
Key:  
 CR:    Complete Remission  
 D:    Died of disease  
 GER:    Good early response (Blasts < 25% on day 8/15)  
 PER:    Poor early response (Blasts ≥ 25% on day 8/15)  
 MRD:    Minimal residual disease  
 Mol MRD:  Molecular MRD  
 Flow MRD:    Flow cytometric MRD  
 HR:    High Risk leukaemia cells detectable > 0.01% 
 SR:    Standard Risk leukaemia cell not detectable < 0.01% 
 NK   Not known 
 Ind    Indeterminate   
 
Table 3.2 Clinical features of primary paediatric B – precursor ALL used in this study. Eighteen of the 20 
samples were interrogated with the R&D array and 6 samples interrogated with the Raybiotech array. 
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3.3 Evaluation of Phospho – RTK arrays with human cell lines  
Prior to screening the primary leukaemias, the two array systems were evaluated using 
haematological and non – haematological human cell lines.  
 
3.3.1 Evaluation of Raybio® Human RTK array 
The pre – B ALL cell lines Nalm 17 and REH were used for evaluation of the Raybio® 
Human RTK array. These cells display model patterns of response as described by the in 
vitro model of IR – induced apoptosis (158, 315); Nalm 17 was apoptosis proficient and REH 
apoptosis defective. Whole cell lysates were prepared from the cell lines and hybridised to 
the arrays at 40C overnight. Signal intensities of the RTKs were quantified by optical 
densitometry, expressed as pixel density and compared (fig 3.2a - c). A clear differential in 
the phosphorylation of kinases was evident in the 2 cell lines tested (fig 3.2a and b). Nalm 
17 demonstrated phosphorylation of specific members of the Eph family (EphA3, EphA5, 
EphA6, EphA8, EphB1-2), platelet – derived growth factor receptor β (PDGFRβ) and 
vascular endothelial growth factor receptor – 2 (VEGFR2), while REH expressed signal 
from the non – receptor kinases JAK3, Lck and ZAP-70. Of the RTK signals common to both 
cell lines IGF-1R demonstrated a marked reduction in intensity in the Nalm17 cell line 
compared with REH. IGF – 1R was selected as the candidate protein for validation using 
Western Blotting as an independent technique for comparing RTK phosphorylation.  
Subsequently, immunoblotting revealed the presence of IGF-1R beta subunit at 95kDa in 
both Nalm17 and REH lysates, while phosphorylation of IGF-1R Tyr1131 was detectable only 
in the REH and not Nalm 17 lysates (fig 3.3). The tyrosine residue Tyr1131 is located in the 
intrinsic kinase domain. These data independently validate the array data indicating that 
the arrays can be used to differentiate between phospho – RTK profiles in haematological 
cells. 
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Figure 3.2c   
 
Figure 3.2 Phosphorylation signal of (R)TKs in pre – B ALL cell lines (Nalm 17 and REH) using Raybiotech 
arrays. Both cell lines demonstrated phosphorylation of Axl, EphA1, EphA7, EphB3, FGFR2, FGFR2α, IGF – 
1R, LTK and Tie – 2. Differential phosphorylation of numerous (R) TKs was identifed using the Raybiotech 
array in: (a) Nalm 17 and (b) REH cell lines.Phosphorylated tyrosine kinases common to both cell lines are 
numbered in the key. The positive controls are contained in the yellow boxes. (c) Optical densitometry was 
performed on the duplicate signals and phosphorylation profiles established for each ALL cell line.   
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Figure 3.2a            Figure 3.2b 
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Figure 3.3 Western Blot analysis demonstrates differential phosphorylation signal of IGF – 1R in REH and 
Nalm 17 B – cell precursor ALL cell lines. The difference in phosphorylation intensity observed on the 
Raybio® Human Proteome RTK Arrays was confirmed on Western Blot. Total expression of IGF – 1R was 
equal in both cell lines.    
 
3.3.2 R&D Systems® Proteome ProfilerTM Human Phospho-RTK array  
To evaluate the sensitivity of the second phospho – RTK array (R&D), the HB2 human 
mammary luminal epithelial cell line was used, which overexpresses EGFR (356). To assess 
the sensitivity and specificity of the arrays HB2 cells were subjected to three pre-treatment 
conditions in DMEM media with 10% FCS; (i) no pretreatment, (ii) 20 ng/ml EGF for 10 
minutes and (iii) 0.5 µM gefitinib (EGFR/HER2 inhibitor) for 5 hours followed by 20ng/ml 
EGF for 10 minutes. Whole cell lysates were hybridised to the arrays and visualised by 
chemiluminescence. Fig 3.4a (i-iii) shows the arrays hybridised with HB2 lysates from each 
of the corresponding conditions described. As expected, the EGFR phosphorylation signal 
increased following the addition of EGF and with concomitant activation of receptors, Mer 
and Tie-2 and pre – incubation with an EGFR inhibitor reduced EGFR phosphorylation 
corresponding to a decrease in signal intensity. Quantification by optical densitometry of 
pixel density (OD/mm2) confirmed more than a four-fold increase in EGFR phosphorylation 
by EGF treatment which reduced to below the basal level following gefitinib treatment (fig 
3.4b).  
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Figure 3.4a       Figure 3.4b  
 
 
Figure 3.4 R&D phospho – RTK arrays hybridised with lysates from HB2 mammary epithelial cells. (a) 
Arrays reveal EGFR expression (red box) in untreated cells (i) which increases following EGF pre-treatment 
concomitantly with Mer (green box) and Tie 2 (yellow box) (ii), and which are inhibited following gefitinib 
treatment (iii). Blue boxes show duplicate positive controls in all conditions, (B) Graph of densitometry value 
of phosphorylated EGFR from arrays from each condition. 
 
 
Western Blot analysis was used to validate these array data (fig 3.5). EGFR protein levels 
were consistent between the three conditions whereas phosphorylated EGFR Tyr992 
increased following EGF treatment and reduced profoundly following gefitinib – mediated 
inhibition. These data show that the R&D phospho – arrays can provide quantifiable and 
reproducible data regarding phosphorylation status of RTKs. 
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Fig 3.4a (ii) 
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Figure 3.5 Western Blot showing stimulation and inhibition of EGFR phosphorylation in HB2 cell line, 
validating the phospho – RTK array findings. The phosphorylation site Tyr992 was blotted for following 
addition of 20ng/ml EGF (lane 2) and incubation with 0.5µM gefitinib (lane 3) treatment compared with no 
treatment (lane 1) confirming previous array data. Total EGFR and Actin serve as loading controls 
 
3.4 Screening of primary ALL cells for baseline phosphorylation profiles with Phospho – 
RTK arrays
Subsequent to the successful evaluation of the arrays, screening for baseline RTK 
phosphorylation profiles in 20 primary ALL was initiated. Of the 20 samples, 18 leukaemias 
were profiled with the R&D array system, while 8 were hybridised to the Raybiotech array 
and 6 samples were investigated with both arrays (table 3.2).  Cells were thawed in RPMI 
media with 10% serum and then washed twice in warm PBS and prepared for the arrays 
according to the manufacturer’s instructions. Multiple RTK signals were detected on both 
arrays in all primary cells tested by both arrays, over a range of intensities. Optical 
densitometric readings were performed on all visible phosphorylation signals to develop a 
profile of parallel kinase activation for each ALL. 
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3.4.1  Baseline phosphorylation profiles of 8 leukaemias with Raybiotech array 
In the 8 leukaemia samples investigated with the Raybiotech array, a restricted and 
relatively homogeneous population of phosphorylated kinases was detected. Signals were 
present for only 4 tyrosine kinases in total (fig 3.6). Two non – receptor tyrosine kinases Txk 
and JAK2 were detected, with Txk present in all 8 samples and JAK2 in 7/8. The RTKs, Axl 
and FGFR2, were present in 4 and 7 of the 8 samples respectively. Signal intensity ranged 
from 0.0078 – 0.1462 OD/mm2.  
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 Figure 3.6a 
 
             
 Figure 3.6b 
 
Figure 3.6 The Raybiotech array system identified a restricted repertoire of (R) TKs in the 8 primary 
leukaemia samples investigated (a) The presented array is representative of the 8 ALL samples as it reveals 
the 4 phosphorylated tyrosine kinases, namely 2 non – receptor tyrosine kinases (JAK and Txk) and 2 RTKs 
(Axl, FGFR2). (b) The bar graph demonstrates the mean phosphorylation signals measured by pixel 
densitometry (optical density per millimetre squared) of each of the (R)TKs reported of the 8 primary ALL 
samples; error bars are expression of standard deviation. The most intense mean phosphorylation signal was 
JAK2.  
 
 
 
 
 
Key: 
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2 – FGFR2 
3 – JAK2 
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3.4.2 Baseline phosphorylation profiles of 18 leukaemias with R&D array  
Subsequently the baseline phosphorylation profiles of 18 samples were assessed with the 
R&D arrays (representative blot displayed in fig 3.7a). Unlike the Raybiotech array, marked 
heterogeneity was observed in the leukaemia phosphorylation patterns assessed by the 
R&D array. Signals were derived from an average of 33 RTKs per sample, with a wide 
variation in intensity after accounting for background, from 0.0007 to 3.71 OD/mm2. 
 
Fig 3.7b shows the mean phosphorylation of each individual RTK for the 18 leukaemias. 
Dtk, which exhibited the most activation, was followed in order by EGFR, EphB2, Ron, Tie 
– 2, Tie – 1, Mer, ErbB2/HER2, ErbB4/HER4 and FGFR3.  
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 Figure 3.7a 
 
         
 Figure 3.7b 
 
Figure 3.7 An heterogeneous repertoire of RTKs was identified with the R&D array system in 18 primary 
leukaemia samples. (a) Representative array of a primary ALL sample using the R&D array system. Positive 
controls are boxed in yellow. Signals from 7 of the 10 most intense signals are demonstrated, namely EGFR, 
HER4, Dtk, Ron, TIE – 2 and EphB2, (b) Mean phosphorylation signals for the individual RTKs of the 18 
primary leukaemia samples assessed with the R&D array. Error bars are standard deviations.  
Key: 
1 – EGFR 
2 – HER4  
3 – Dtk 
4 – Ron 
5 – Tie – 2 
6 – EphB2  
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3.4.3  Baseline phosphorylation of 6 samples analysed on both arrays   
Six samples were analysed using both arrays, ALL 1 – 4, ALL 17 and ALL – 18.  Axl and 
FGFR2 were the only 2 RTKs detected on both arrays. Phosphorylation of Axl was 
detectable in 2/6 samples assessed with the Raybiotech array and 4/6 leukaemias on the 
R&D array system (fig 3.8a and b). Phosphorylation of FGFR2 was present in all 6 samples 
analysed with both arrays, but there was no direct correlation between the signal intensity 
derived from each array. 
                    
  Figure 3.8a       Figure 3.8b 
 
Figure 3.8 Dot plots comparing the Axl and FGFR2 signals derived from the 2 array systems. Mean intensity 
of phosphorylation signals of the RTKS (a) Axl and (b) FGFR2 were higher in R&D arrays. No obvious 
relationship was observed between the signal intensities investigated by the 2 arrays.   
 
Table 3.3 shows the level of phosphorylation observed on the Raybiotech did not correlate 
with signals derived from the R&D array.  The lack of concordance may be due to the 
avidity of antibodies used in the different array systems.   
 
Leukaemia Sample Raybio Axl R&D Axl Raybio FGFR2 R&D FGFR2 
ALL – 1 0 0.008 0.01 0.23 
ALL – 2 0 0.11 0.0056 0.085 
ALL – 3 0 0 0.015 0.186 
ALL – 4 0 0.086 0.008 0.079 
ALL – 17 0.034 0 0.056 0.074 
ALL – 18 0.036 0.022 0.08 0.035 
 
Table 3.3 Comparison of the phosphorylation signals for Axl and FGFR2 derived from the 2 array systems. 
No direct relationship was present between the phosphorylation signals in the 2 systems used to investigate 
the 6 primary ALL samples. Data presented is the mean optical densitometry reading for each (R)TK derived 
for the primary ALLs. 
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3.5 Association of apoptotic phenotype with baseline phosphorylation signal  
RTK phosphorylation profiles were investigated for an association with apoptotic 
phenotypes, clinical, biological or genetic features. Eight samples (n=4 apoptosis proficient 
and n=4 apoptosis deficient) were investigated with the Raybiotech array, while 18 
leukaemias were assayed for the R&D experiments (9 samples in each apoptotic 
phenotype).  
 
The RTK phosphorylation profile from the 8 ALLs analysed using the Raybiotech array 
showed an association with apoptotic phenotype (fig 3.9a and b).  JAK2, Txk, Axl and 
FGFR2 were all phosphorylated in the apoptosis proficient leukaemias, whereas the JAK2, 
FGFR2 and Txk signal intensities were reduced and Axl virtually absent in the apoptosis 
defective samples.  
 
The tyrosine kinase with the most intense mean phosphorylation signal was JAK2, with 
mean intensity of 0.09 (SD±0.06) OD/mm2 in the apoptotic sensitive leukaemias, compared 
with 0.02 (SD±0.01) OD/mm2 in the apoptotic defective samples (fig 3.10). Comparison of 
signal intensities by t – test, identified a significant difference in level of phosphorylation 
between the 2 groups (apoptotic proficient and apoptotic defective) for the (R)TKs Axl 
(p<0.0001) and Txk (p<0.005). Comparison of FGFR2 and JAK2 signals exhibited a 
statistically non – significant difference (p=0.07), with a higher phosphorylation signals 
present in the apoptotic proficient leukaemias. 
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Figure 3.9a  
 
 
   
Figure 3.9b    
 
Figure 3.9 Representative Raybiotech arrays of samples stratified by apoptotic phenotype. Phosphorylation 
signals were present for Txk in all 8 samples. The tyrosine kinases JAK2 and FGFR2 were expressed in (a) 3/4 
apoptosis proficient leukaemias and (b) all the apoptosis defective samples. 4/4 apoptotic senstive samples 
demostrated an additional low level signal at Axl. The mean intensity of all signals were greater in cells with 
proficient apoptotic response. The TKs are numbered 1 – 4.  
                 
Key for both figures: 
1 – Axl  
2 – FGFR2 
3 – JAK2 
4 – Txk  
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Figure 3.10 Increased phosphorylation signals of the kinases Axl and Txk correlate with the apoptosis 
proficent leukaemias.  The mean intensity of phosphorylation signals for all kinases identified in the 8 
primary ALL samples investigated with Raybiotech arrays was higher in the apoptotic proficient samples. 
Significantly more intense signals were identified in the Axl (p<0.0001) and Txk (p<0.005) kinases of the 
apoptotic proficient leukaemia samples. Error bars are standard error of mean.    
 
The baseline phosphorylation profiles of 18 samples derived from the R&D arrays were 
correlated with the defined apoptotic phenotypes, 9 apoptosis proficient and the 9 
apoptosis defective.  
 
Fig 3.11 shows the distribution of the most intense signals in the cohort with normal 
apoptotic responses to IR (shown in blue) included Dtk which exhibited the most 
activation, followed in order by EphB2, EGFR, Tie-2, RON, FGFR3 and Mer. Similarly, in 
the cohort with defective apoptotic responses (shown in red), the RTK with the highest 
mean phosphorylation signal was Dtk, followed in order by EGFR, EphB2, RON, Tie-1, 
ErbB2/HER2, ErbB4/HER4 and Mer.  
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Figure 3.11 Comparison of signal intensity of ALL samples stratified by apoptotic phenotype using R&D 
array system. The strongest signals were derived from 5 RTK families: TAM, EGFR, Met and Tie.  Mean 
phosphorylation signals were calculated for each cohort (n=9) and plotted, error bars are the standard 
deviation for each mean RTK signal. 
 
 
To identify RTKs which were significantly differentially phosphorylated, a direct 
comparison of signal intensity was performed using the parametric unpaired t-test (table 
3.4). No significant difference was identified in mean phosphorylation of any of the RTKs 
between the 2 groups categorised by apoptotic phenotype.  
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 Apoptosis 
proficient 
(n=9) 
Apoptosis 
defective 
(n=9) 
  Apoptosis 
proficient 
(n=9) 
Apoptosis 
defective 
(n=9) 
 
RTK  Mean 
(SD) 
Mean 
(SD) 
p –
value 
RTK Mean  
(SD) 
Mean 
(SD) 
p – 
value 
Axl 0.05 (0.06) 0.06 (0.05) 0.64 IGF-1R 0.08(0.07) 0.08(0.07) 0.99 
Dtk 0.94 (0.86) 1.00(0.53) 0.86 Insulin 0.13(0.09) 0.17(0.12) 0.45 
EGFR 0.47(0.21) 0.96(1.12) 0.21 Kit 0.02(0.02) 0.02(0.04) 0.88 
EphA1 0.07(0.09) 0.07(0.07) 0.93 M-CSF 0.03(0.04) 0.06(0.08) 0.37 
EphA2 0.03 (0.06) 0.03(0.06) 0.95 Mer 0.22(0.21) 0.32(0.35) 0.46 
EphA3 0.02 (0.02) 0.06(0.15) 0.39 Met 0.01(0.03) 0.08(0.22) 0.35 
EphA4 0.09(0.12) 0.23(0.18) 0.07 Ron 0.41(0.46) 0.45(0.42) 0.86 
EphA6 0.22(0.18) 0.12(0.13) 0.19 MuSK 0.09(0.13) 0.06(0.12) 0.60 
EphA7 0.19(0.18) 0.18(0.12) 0.89 PDGFRα 0.01(0.04) 0.06(0.13) 0.35 
EphB1 0.08(0.10) 0.18(0.25) 0.29 PDGFRβ 0.03(0.05) 0.05(0.06) 0.35 
EphB2 0.51(0.26) 0.55(0.35) 0.78 Ret 0.05(0.06) 0.08(0.12) 0.43 
EphB4 0.07(0.09) 0.16(0.23) 0.30 ROR1 0.19(0.11) 0.22(0.25) 0.75 
EphB6 0.07(0.08) 0.07(0.10) 1.00 ROR2 0.12(0.12) 0.22(0.23) 0.31 
ErbB2/HER2 0.16(0.19) 0.34(0.79) 0.52 Tie-1 0.21(0.14) 0.38(0.27) 0.11 
ErbB3/HER3 0.03(0.08) 0.12(0.31) 0.39 Tie-2 0.41(0.35) 0.29(0.26) 0.42 
ErbB4/HER4 0.15(0.15) 0.34(0.32) 0.11 Trk A 0.10(0.13) 0.12(0.12) 0.73 
FGFR1 0.01(0.01) 0.05(0.12) 0.27 Trk B 0.06(0.05) 0.09(0.13) 0.44 
FGFR2α 0.08(0.09) 0.15(0.10) 0.16 Trk C 0.01(0.02) 0.06(0.11) 0.18 
FGFR3 0.23(0.30) 0.19(0.15) 0.68 VEGFR1 0.00(0.01) 0.03(0.04) 0.07 
FGFR4 0.00(0.00) 0.01(0.02) 0.22 VEGFR2 0.01(0.02) 0.01(0.01) 0.97 
FLT3 0.06(0.08) 0.19(0.24) 0.15 VEGFR3 0.10(0.09) 0.10(0.08) 0.94 
 Key  
 SD     Standard deviation  
 Statistical analysis  t – test  
 
Table 3.4 Mean RTK phosphorylation signal intensities derived by R&D array in apoptosis proficient and 
apoptosis defective ALL groups and statistical comparisons. No statistically signficant difference in 
phosphorylation was identified, but differences in EphA4 and VEGFR1 phosphorylation approached 
significance. Data presented is the mean optical densitometry reading for each RTK derived for the primary 
ALLs, standard deviation is presented in parentheses. 
 
In summary, significant differential TK signals were identified on the Raybiotech array 
when the primary leukaemias were stratified by apoptotic phenotype, but not significantly 
with the R&D array. The phosphorylation signals with the higher intensity were derived 
from the apoptotic proficient leukaemias on the Raybiotech arrays. 
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3.6 Association of cytogenetic groups with RTK phosphorylation profiles  
To determine whether a relationship could be established between particular cytogenetic 
abnormalities and RTK phosphorylation profiles, the samples were categorised according 
to cytogenetic subtype. Of the 20 samples investigated, 8 had t(12;21), 3 were hyperdiploid 
and the remaining 9 possessed either normal (n=5) or cytogenetic findings which at present 
are not recognised to influence outcome in current UK treatment protocols and thus do not 
alter treatment schedules (n=4). The cytogenetic findings for these 4 samples included 
t(3;22), 46XY +7q+12p, 46XX t(3;10) t(9;16) +8 biallelic del p16 and 45XY dic(9;20)+8-13. For 
the purpose of this study, the cytogenetic profile for these 9 samples has been designated 
‘non – contributory’ in the text and figures (table 3.2). 
 
The cytogenetic subtypes of the 8 leukaemias used in the Raybiotech experiments, consisted 
of 1 t(12;21), 3 hyperdiploid and 4 non – contributory samples. There were no differences in 
the mean phosphorylation signals for JAK2 and Txk across all 3 cytogenetic subtypes (fig 
3.12a and b). FGFR2 signals were detected in the hyperdiploid (n=3) and ‘non – 
contributory’ (n=4) groups, but not in the t(12;21) sample (fig 3.12c). Phosphorylation of Axl 
was detected in 1/3 hyperdiploid, 2/4 ‘non –contributory’ samples and the t(12;21) 
leukaemia (fig 3.12d). The sample size for each cytogenetic group was not sufficient to 
analyse by column statistics.  
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          Figure 3.12a                            Figure 3.12b 
               
        Figure 3.12c        Figure 3.12d 
 
Figure 3.12 a – d Dot plots of phosphorylation signals of primary ALL samples grouped by cytogenetics 
assayed by Raybiotech arrays.  No statistically significant correlations were identified in the cytogenetic 
subgroups between the phosphorylation signals of (a) JAK2, (b) Txk, (c) FGFR2 and (d) Axl.  
 
 
The phosphorylation signal intensity observed in the 3 hyperdiploid samples was not 
significantly different from the other cytogenetic subgroups both when analysed against 
non – contributory group alone (n=4) or against all other leukaemia samples in the 
Raybiotech panel (table 3.5).   
 
 
 
 
 
                                                                                                  Baseline phosphorylation profiles  
85 
 
 
 
 
 
 
 
 
 
Table 3.5 Comparison of cytogenetics groupings in the 8 ALL samples investigated with the Raybiotech 
array system. No statistically significant differences were identified in the comparison of (a) hyperdiploid 
samples and (b) non – contributory samples with the remaining samples. Data presented is the mean optical 
densitometry reading for each RTK derived for the primary ALLs, standard deviation is presented in 
parentheses. 
 
The cytogenetic profiles of the 18 leukaemias investigated with the R&D array were 3 
hyperdiploid, 8 non – contributory and 7 t(12;21) ALLs. Mean RTK phosphorylation signal 
intensity was determined for each of these subgroups.   
 
In all 3 cytogenetic groups Dtk demonstrated the highest mean signal; however the pattern 
of highest phosphorylated RTKs were notably different between the cytogenetic groups (fig 
3.13). The pattern of phosphorylation was different in the hyperdiploid group, with Mer 
and FLT3 demonstrating the next highest signals after Dtk. These were followed by Ron, 
EGFR and EphB2.   When the RTK phosphorylation profiles of these three cytogenetic 
groups were analysed using one way ANOVA (see table 3.6), no statistically significant 
differences were observed, the phosphorylation signals of 2 RTKs, EphA2 and FLT3, 
approached significance (p=0.07 and p=0.09, respectively).  
 
 
 
 Hyperdiploid 
(n = 3) 
Rest 
(n = 5)  
t-test  
(p – value) 
Non – contributory  
(n = 4) 
Rest 
(n = 4) 
t-test 
(p – value) 
Axl 0.01(0.02) 0.03(0.02) 0.46 0.02 (0.02) 0.02(0.03) 0.86 
FGFR2 0.04(0.04) 0.02 (0.03) 0.66 0.03(0.03) 0.03 (0.04) 0.86 
JAK2 0.06(0.07) 0.05 (0.06) 0.89 0.05(0.06) 0.07 (0.06) 0.64 
Txk 0.02 (0.02) 0.03(0.03) 0.44 0.03(0.03) 0.02(0.02) 0.46 
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Figure 3.13 Comparison of phosphorylation signals divided into 3 cytogenetic subgroups (TEL/AML 
hyperdiploid and non – contributory). No significant differences in signal intensity were present between the 
3 cytogenetic subgroups of the 18 primary ALLs investigated. The plots are the mean phosphorylation signal 
for each cytogenetic subgroup, with error bars the standard deviation.   
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Table 3.6 Comparison of mean RTK phosphorylation signals in the 3 cytogenetic subgroups by one – way 
ANOVA (R&D arrays). No statistically significant differences were identified between the 3 cytogenetic 
subgroups, but EphA2 and FLT3 approached significance (highlighted in grey). Data presented is the mean 
optical densitometry reading for each RTK derived for the primary ALLs, standard deviation is presented in 
parentheses.  
 
 
 t(12;21) 
(n=8) 
Non – contributory 
(n=9) 
Hyperdiploid 
(n=3) 
ANOVA 
(p value) 
Axl  0.07 (0.06) 0.07 (0.04) 0.01 (0.01) 0.21 
Dtk  1.17 (0.83) 0.84 (0.63) 0.87 (0.66) 0.66 
EGFR 0.98 (1.21) 0.65 (0.47) 0.26 (0.26) 0.45 
EphA1  0.08 (0.10) 0.08 (0.07) 0.03 (0.02) 0.63 
EphA2  0.00 (0.00) 0.06 (0.07) 0.00 (0.00) 0.07 
EphA3  0.02 (0.01) 0.07 (0.16) 0.00 (0.00) 0.53 
EphA4  0.16 (0.16) 0.16 (0.17) 0.19 (0.24) 0.96 
EphA6  0.16 (0.01) 0.20 (0.22) 0.09 (0.08) 0.59 
EphA7  0.22 (0.21) 0.16 (0.12) 0.14 (0.1) 0.73 
EphB1  0.14 (0.15) 0.15 (0.25) 0.05 (0.09) 0.76 
EphB2  0.53 (0.25) 0.65 (0.32) 0.22 (0.09) 0.11 
EphB4  0.11 (0.09) 0.15 (0.24) 0.02 (0.03) 0.58 
EphB6  0.06 (0.08) 0.09 (0.09) 0.02 (0.02) 0.46 
ErbB2/HER2  0.53 (0.86) 0.09 (0.10) 0.04 (0.03) 0.27 
ErbB3/HER3  0.14 (0.36) 0.05 (0.09) 0.01 (0.01) 0.67 
ErbB4/HER4  0.33 (0.32) 0.19 (0.23) 0.20 (0.20) 0.59 
FGFR1  0.05 (0.13) 0.01 (0.01) 0.04 (0.03) 0.58 
FGFR2α 0.13 (0.11) 0.09 (1.73) 0.15 (0.10) 0.70 
FGFR3  0.32 (0.33) 0.14 (0.10) 0.14 (0.12) 0.27 
FGFR4  0.00 (0.00) 0.01 (0.03) 0.00 (0.00) 0.57 
FLT3 0.10 (0.12) 0.07 (0.07) 0.33 (0.37) 0.09 
IGF-1R 0.11 (0.06) 0.07 (0.07) 0.04 (0.02) 0.29 
Insulin  0.19 (0.08) 0.14 (0.13) 0.07 (0.01) 0.26 
KIT 0.03 (0.05) 0.01 (0.02) 0.00 (0.00) 0.57 
M-CSF 0.02 (0.03) 0.07 (0.08) 0.04 (0.02) 0.24 
Mer  0.33 (0.28) 0.15 (0.14) 0.47 (0.49) 0.20 
Met  0.10 (0.25) 0.02 (0.03) 0.00 (0.00) 0.55 
Ron  0.63 (0.47) 0.31 (0.40) 0.30 (0.30) 0.30 
MuSK  0.13 (0.17) 0.05 (0.09) 0.01 (0.01) 0.31 
PDGFRα 0.06 (0.15) 0.02 (0.04) 0.00 (0.00) 0.59 
PDGFRβ 0.03 (0.08) 0.05 (0.04) 0.05 (0.02) 0.85 
Ret 0.10 (0.14) 0.05 (0.05) 0.04 (0.03) 0.59 
ROR1  0.16 (0.13) 0.27 (0.25) 0.10 (0.06) 0.33 
ROR2  0.17 (0.13) 0.22 (0.24) 0.05 (0.02) 0.41 
Tie-1 0.37 (0.32) 0.27 (0.14) 0.20 (0.13) 0.55 
Tie-2 0.41 (0.35) 0.40 (0.30) 0.12 (0.06) 0.37 
Trk A  0.14 (0.16) 0.10 (0.09) 0.07 (0.09) 0.75 
Trk B  0.10 (0.14) 0.07 (0.06) 0.04 (0.03) 0.68 
Trk C  0.05 (0.12) 0.03 (0.03) 0.01 (0.01) 0.70 
VEGFR1  0.02 (0.04) 0.01 (0.02) 0.01 (0.02) 0.99 
VEGFR2  0.01 (0.02) 0.01 (0.01) 0.00 (0.00) 0.60 
VEGFR3  0.12 (0.01) 0.07 (0.06) 0.11 (0.09) 0.45 
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 Unpaired t – test  (p – value) 
 Hyperdiploid vs. Rest t(12;21) vs. Rest Non-Contributory vs. Rest 
Axl 0.07 0.58 0.46 
Dtk  0.79 0.35 0.48 
EGFR 0.31 0.28 0.77 
EphA1 0.33 0.64 0.79 
EphA2 0.38 0.12 0.02 
EphA3 0.51 0.52 0.26 
EphA4 0.78 0.95 0.89 
EphA6 0.36 0.88 0.41 
EphA7 0.65 0.43 0.67 
EphB1 0.45 0.83 0.73 
EphB2 0.04 0.98 0.15 
EphB4 0.33 0.99 0.46 
EphB6 0.27 0.87 0.32 
FGFR1 0.88 0.35 0.30 
FGFR2α 0.54 0.74 0.43 
FGFR3 0.60 0.10 0.24 
FGFR4 0.65 0.46 0.28 
FLT3 0.03 0.68 0.25 
HER2 0.49 0.10 0.30 
HER3 0.57 0.38 0.67 
HER4 0.77 0.30 0.43 
IGF-I R 0.27 0.15 0.57 
Insulin 0.15 0.20 0.85 
Kit 0.46 0.32 0.68 
M-CSF 0.88 0.13 0.11 
Mer 0.19 0.51 0.10 
Met/HGFR 0.57 0.27 0.53 
RON 0.58 0.11 0.27 
MuSK 0.32 0.14 0.51 
PDGFRα 0.50 0.32 0.65 
PDGFRβ 0.73 0.57 0.77 
Ret 0.63 0.30 0.52 
ROR1 0.32 0.51 0.16 
ROR2 0.21 0.96 0.33 
Tie – 1 0.43 0.31 0.70 
Tie – 2 0.15 0.58 0.61 
Trk A 0.61 0.46 0.74 
Trk B 0.48 0.45 0.83 
Trk C 0.59 0.42 0.70 
VEGFR1 0.96 0.91 0.95 
VEGFR2 0.35 0.46 0.97 
VEGFR3 0.86 0.26 0.21 
 
Table 3.7 Summary of analysis comparing individual cytogenetic groups to the remaining leukaemias 
(R&D arrays). Statistically significant differences were identified in the phosphorylation signals at EphA2, 
EphB2 and FLT3. The EphA2 signal for samples with non – contributory cytogenetics was more intense than 
the other 2 cytogenetic groups. EphB2 phosphorylation was significantly lower in the hyperdiploid leukaemia 
samples, while FLT3 phosphorylation was significantly more intense in the same hyperdiploid cohort.    
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Although no significant differences were detected for individual RTK phosphorylation 
signals, potential patterns of RTK phosphorylation relating to cytogenetics were explored. 
Each cytogenetic subgroup was compared with the rest of genetically unrelated samples. 
Table 3.7 displays the summary of the p – values of this comparative approach. Statistically 
significant differences of phosphorylation signals were identified for the samples with non 
– contributory cytogenetics vs. rest EphA2 (p=0.02) and hyperdiploid samples vs. rest 
EphB2 (p=0.04) and FLT3 (p = 0.03). A non – significant difference in signal was identified 
in hyperdiploid samples for Axl which was approaching statistical significance (p=0.07). 
 
Of the 8 samples with non – contributory cytogenetics, 5/8 had striking higher EphA2 
phosphorylation compared to the remaining 3 with non – contributory cytogenetics and 
with the other cytogenetic groups (fig 3.14b). EphA2 phosphorylation signal appears to 
correlate with the presenting WCC, a known predictor of clinical outcome. The mean 
presentation WCC was 133.2 x109/l (SD 154.5) in the 5 strongly EphA2 positive samples 
compared to 34.3 x109/l (SD 38.8) in the remaining 13 samples (p = 0.04 t – test, table 3.8). In 
contrast, no relationship was observed between EphA2 phosphorylation and blast 
clearance (p=0.67), molecular (p=0.16) or flow (p=0.41) MRD status and apoptotic 
phenotype (p=1).  
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  Figure 3.14a       Figure 3.14b                                                              
 
Figure 13.14 Comparison of phosphorylation signals for EphA2 by cytogenetic subgroup. (a) Comparison 
of mean phosphorylation signals in the 3 cytogenetic subgroups did not reveal a statistically significant 
difference (One – way ANOVA). (b) Comparison of samples with non – contributory cytogenetics (n = 8) with 
remaining cytogenetic samples (n = 10) demonstrated a significantly higher phosphorylation signal (p = 0.02).   
 
 
 
 High EphA2 Low EphA2 Statistical analysis 
 (n=5) (n=13)  
Mean WCC (SD) 133.16 (154.47) 34.3 (38.8) p = 0.04 (t – test) 
Age (SD) 6.9 (6.6) 6.66 (4) p = 0.92 (t – test) 
Molecular MRD   p = 0.16 (Chi square) 
High Risk 4 4  
Standard Risk 1 7  
Not known 0 2  
Flow MRD   p = 0.4 (Chi square) 
High risk 3 5  
Standard risk 1 7  
Not known 1 1  
Blast clearance   p = 0.67 (Chi square ) 
Poor early response 2 3  
Good early response 3 9  
Not known 0 1  
  SD = standard deviation  
 
Table 3.8 Comparison of the 5 leukaemias with phosphorylated EphA2 with 13 samples with low 
phosphorylation signals. A positive correlation was identified between the 5 leukaemias with increased 
EphA2 signal and the adverse NCI/Rome WCC risk factor. The 5 samples with increase EphA2 all had normal 
cytogenetics.      
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The other differentially phosphorylated RTKs, EphB2 and FLT3, demonstrated a significant 
difference in activation between the hyperdiploid and remaining 15 leukaemia samples. 
The FLT3 phosphorylation status was statistically higher in the 3 hyperdiploid samples (fig 
3.15a and b), when compared with the remaining 15 samples (p = 0.03 Student’s t – test).  
       
 Figure 3.15a        Figure 3.15b 
 
Figure 3.15 Comparison phosphorylation signals for FLT3 in cytogenetic subtypes. (a) Comparison of mean 
phosphorylation signals in the 3 cytogenetic subgroups did not reveal a statistically significant difference 
(One – way ANOVA). (b) Comparison of samples with non – contributory cytogenetics (n = 3) with remaining 
cytogenetic samples (n = 15) demonstrated a significantly higher phosphorylation signal (p = 0.03).   
 
 
 
Conversely, EphB2 demonstrated a lower level of expression in the hyperdiploid group  
(p = 0.04, fig 3.16a).   
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 Figure 3.16a       Figure 3.16b   
 
Figure 3.16 Comparison phosphorylation signals for EphB2 by cytogenetic subgroup. (a) Comparison of 
mean phosphorylation signals in the 3 cytogenetic subgroups did not reveal a statistically significant 
difference (One – way ANOVA). (b) Comparison of samples with hyperdiploid cytogenetics (n = 3) with 
remaining cytogenetic samples (n = 15) demonstrated a significantly higher phosphorylation signal (p = 0.04).  
 
In summary, differential expression between cytogenetic subgroups was observed for 3 
RTKs when using the R&D array only. Of the RTKs exhibiting differential activation, 
EphB2 demonstrated significantly lower phosphorylation in the favourable hyperdiploid 
cytogenetic group, while Axl revealed a trend to lower expression in this group. In contrast, 
the hyperdiploid leukaemias demonstrated a significantly higher phosphorylation 
signature for FLT3. The increased phosphorylation of EphA2 in the leukaemias with non – 
contributory cytogenetics and high WCC may identify a new risk group.   
 
3.7 Association of NCI/Rome risk criteria with RTK phosphorylation profiles  
To address the possibility that clinical features could correlate with particular RTK 
activation, the relationships with NCI/Rome white cell and age risk classification criteria 
were explored.  
 
The presentation WCC was compared with the phosphorylation signal of (R)TKs from the 
Raybiotech array in all 8 samples. While both risk categories were associated with 
phosphorylation signal detection of 4 TKs Axl, FGFR2, JAK2 and TXK, the mean intensity 
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of all four kinases was higher in the favourable risk category (fig 3.17). This inverse 
relationship between phosphorylation and adverse WCC was only statistically significant 
for JAK2 (p=0.02 t - test) (fig 3.17). 
 
 
Figure 3.17 Phosphorylation signal of JAK2 detected by the Raybiotech array inversely correlated with the 
WCC at presentation.  The phosphorylation signal for the non – receptor tyrosine kinase JAK2 was 
statistically significantly higher in the ALL samples with an adverse WCC risk factor (p – value = 0.02).  
 
The association of WCC risk criteria and RTK phosphorylation in 18 leukaemias assessed 
by the R&D arrays was analysed (fig 3.18). Elevated phosphorylation of FGFR2α (p < 0.01 t 
– test) and Mer (p = 0.04 t – test) positively correlated with an adverse WCC (>50x109/l) and 
were statistically significant (figs 3.19a and b).  In addition, a trend towards differentially 
increased phosphorylation of EphB2 (p = 0.08) and Trk A (p = 0.08) in those tumours with 
adverse WCC (>50x109/l) compared with those with standard risk (<50x109/l) was also 
observed.  
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Figure 3.18 Representation of mean phosphorylation signals of individual RTKs in ALL samples grouped 
by NCI/Rome WCC risk classification. Statistically significant differences were observed in the 
phosphorylation signals of FGFR2 and Mer between the 2 NCI/Rome risk groups. The plots are the mean 
phosphorylation signal for each risk category, error bars are standard deviation.   
             
          
      
       Figure 3.19a       Figure 3.19b 
 
Figure 3.19 Differential RTK phosphorylation expression of FGFR2 and Mer in adverse compared with 
standard risk WCC. Both (a) FGFR2 and (b) Mer RTKs demonstrated higher phosphorylation signal in ALL 
samples with adverse NCI/Rome risk criteria. Error bars are standard error of mean (SEM).   
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Subsequently the age criteria were correlated with the phosphorylation signals derived 
from both arrays. Due to the limited sample size, it was not possible to assess whether 
correlations were present between the age and TK signals in the Raybiotech arrays, as only 
2 leukaemias were >10years and 6 leukaemias <10years. While signals from all TK were 
detectable in both groups, the mean JAK2 signal was higher in the favourable age group 
(0.07 vs. 0.01 OD/mm2).  
 
In the 18 R&D array samples, both age groups (≤10y and >10y), exhibited the highest mean 
RTK phosphorylation signal in Dtk, followed by EGFR and EphB2 (fig 3.20). However, 
statistical analysis failed to reveal any statistically significant differences in individual RTK 
phosphorylation between the two groups. 
 
   
 
Figure 3.20 Mean phosphorylation signals of RTK in ALLs grouped by age according to NCI/Rome criteria. 
No statistically significant differences were observed between the risk groups. The plots are the mean 
phosphorylation signal for each risk category, error bars are standard deviation.   
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3.8 Association of blast clearance and MRD status with RTK phosphorylation profiles  
The question whether RTK phosphorylation patterns could be a predictor of 
chemosensitivity, as determined by assessment of bone marrow at D8/15 and minimal 
residual disease at D29 of induction therapy was subsequently addressed.  
 
For the 8 leukaemias investigated using the Raybiotech array, analysis could not be 
performed for blast clearance and flow MRD, because 7/8 leukaemias demonstrated good 
early blast clearance and flow MRD data was not available for 3/8 samples. Nevertheless, 
molecular MRD data was available for 7/8, and analysis of these samples revealed a strong 
relationship between the molecular MRD negative status and the phosphorylation signal of 
Axl and Txk, p = 0.0002 and p = 0.006 respectively (fig.3.21).   
 
                             
 
Figure 3.21 Increased Axl and JAK2 phosphorylation signals were evident in the leukaemia samples with 
detectable molecular MRD assessed by the Raybiotech arrays. Statistically significantly increased signal was 
evident in the Molecular MRD negative leukaemia samples, Axl (p=0.002) and JAK2 (p = 0.006). Error bars are 
SEM. 
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Data for blast clearance and MRD (PCR and flow) was available for 17/18 and 16/18 of the 
ALL cohort investigated with R&D array, respectively. When analysed (table 3.9), no 
association was observed between the individual phosphorylation signals and rate of blast 
clearance (fig3.22). Furthermore, no association was identified between RTK 
phosphorylation signals and day 29 molecular MRD status (fig 3.23).  
 
             
       
 
 
 
Figure 3.22 Association of blast clearance with individual RTK phosphorylation signals (R&D Array). No 
statistically significant differences were observed between the risk groups. The plots are the mean 
phosphorylation signal for each risk category, error bars are standard deviation.   
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Figure 3.23 Association of molecular MRD status with individual RTK phosphorylation signals identified 
with R&D array. No statistically significant differences were observed between the risk groups. The plots are 
the mean phosphorylation signal for each risk category, error bars are standard deviation.   
 
 
Analysis of 16/18 samples for which flow MRD data was available identified a significantly 
higher level of phosphorylation of the PDGFRβ kinase in cells from patients positive for 
MRD by flow cytometry at D28 (p=0.02 by t-test, table 3.10).    
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 Blast clearance  Molecular MRD status  
 GER 
(n=12) 
Std  
dev 
PER 
(n=5) 
Std 
Dev 
t-test Mol neg 
(n=8) 
Std 
dev 
Mol pos 
(n=9) 
Std 
Dev 
t-test 
Axl  0.06 0.05 0.06 0.06 0.97 0.05 0.06 0.06 0.05 0.49 
Dtk  0.99 0.78 1.09 0.37 0.79 0.88 0.95 1.04 0.47 0.66 
EGFR 0.46 0.19 0.74 0.59 0.15 0.87 1.17 0.61 0.45 0.54 
EphA1  0.09 0.09 0.05 0.06 0.50 0.07 0.10 0.07 0.06 0.95 
EphA2  0.02 0.05 0.04 0.07 0.57 0.01 0.02 0.05 0.07 0.19 
EphA3  0.05 0.13 0.01 0.01 0.54 0.01 0.02 0.06 0.15 0.37 
EphA4  0.17 0.17 0.17 0.20 0.99 0.10 0.13 0.20 0.18 0.21 
EphA6  0.17 0.18 0.13 0.14 0.64 0.21 0.18 0.14 0.15 0.35 
EphA7  0.17 0.17 0.17 0.10 0.92 0.21 0.19 0.17 0.11 0.58 
EphB1  0.13 0.22 0.08 0.06 0.63 0.13 0.14 0.13 0.25 0.99 
EphB2  0.53 0.29 0.50 0.39 0.83 0.58 0.24 0.50 0.37 0.61 
EphB4  0.15 0.20 0.03 0.03 0.22 0.08 0.09 0.13 0.23 0.56 
EphB6  0.09 0.09 0.02 0.02 0.11 0.08 0.08 0.07 0.10 0.83 
ErbB2  0.14 0.16 0.10 0.13 0.66 0.44 0.83 0.10 0.10 0.23 
ErbB3  0.01 0.03 0.05 0.11 0.32 0.12 0.33 0.04 0.08 0.52 
ErbB4  0.23 0.26 0.18 0.18 0.67 0.20 0.25 0.22 0.23 0.86 
FGFR1  0.01 0.02 0.00 0.01 0.46 0.05 0.13 0.01 0.02 0.37 
FGFR2α 0.11 0.10 0.13 0.13 0.75 0.09 0.10 0.12 0.10 0.56 
FGFR3  0.24 0.27 0.17 0.12 0.62 0.23 0.32 0.16 0.10 0.52 
FGFR4  0.00 0.00 0.02 0.03 0.18 0.00 0.00 0.01 0.02 0.33 
Flt-3 0.11 0.11 0.17 0.32 0.58 0.06 0.08 0.16 0.23 0.24 
IGF-1R 0.07 0.06 0.10 0.08 0.35 0.08 0.07 0.08 0.07 0.89 
Insulin  0.12 0.08 0.21 0.15 0.11 0.15 0.10 0.16 0.12 0.87 
KIT 0.01 0.01 0.01 0.02 0.71 0.02 0.05 0.01 0.02 0.42 
M-CSF 0.05 0.05 0.05 0.09 0.84 0.03 0.04 0.06 0.07 0.27 
Mer  0.26 0.29 0.20 0.21 0.67 0.28 0.29 0.28 0.31 0.97 
Met 0.01 0.01 0.02 0.04 0.58 0.09 0.23 0.02 0.03 0.39 
MuSK  0.09 0.14 0.05 0.11 0.53 0.07 0.13 0.05 0.09 0.64 
PDGFRα 0.01 0.02 0.02 0.05 0.46 0.05 0.14 0.02 0.04 0.54 
PDGFRβ 0.03 0.03 0.05 0.06 0.29 0.04 0.07 0.05 0.04 0.69 
Ret 0.08 0.11 0.05 0.05 0.64 0.04 0.06 0.06 0.05 0.59 
Ron 0.45 0.45 0.34 0.43 0.66 0.42 0.40 0.35 0.38 0.74 
ROR1  0.20 0.12 0.22 0.33 0.84 0.18 0.13 0.23 0.25 0.62 
ROR2  0.18 0.17 0.18 0.24 0.98 0.12 0.13 0.20 0.23 0.43 
Tie-1 0.33 0.27 0.23 0.10 0.46 0.21 0.15 0.29 0.13 0.27 
Tie-2 0.35 0.29 0.42 0.37 0.68 0.36 0.35 0.36 0.30 0.98 
Trk A  0.11 0.11 0.06 0.10 0.42 0.13 0.16 0.10 0.09 0.65 
Trk B  0.06 0.06 0.05 0.05 0.88 0.10 0.13 0.06 0.06 0.48 
Trk C  0.02 0.03 0.01 0.01 0.66 0.05 0.11 0.02 0.03 0.52 
VEGFR1  0.01 0.02 0.01 0.02 0.90 0.02 0.04 0.01 0.02 0.92 
VEGFR2  0.01 0.02 0.00 0.00 0.25 0.01 0.02 0.01 0.01 0.41 
VEGFR3  0.11 0.09 0.09 0.06 0.64 0.09 0.09 0.09 0.07 0.88 
 Key: 
 GER:   Good early response (Blasts <25% day8/15)  
 PER:   Poor early response (Blasts >25% day 8/15)   
 Mol neg:  Molecular MRD <0.01% 
 Mol pos:  Molecular MRD >0.01%  
Table 3.9 Association of blast clearance and MRD status with individual RTK phosphorylation profiles. 
No difference in phosphorylation signals were identified when phosphorylation intensity was correlated to 
rate of blast clearance and MRD status.  Data presented is the mean optical densitometry reading for each 
RTK derived for the primary ALLs. 
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 Flow MRD 
positive 
D29 (n=8) 
Std dev Flow MRD 
negative D29 
(n=8) 
Std dev p-value (t-test) 
 
Axl  0.06 0.04 0.07 0.06 0.86 
Dtk  0.85 0.58 1.31 0.67 0.16 
EGFR 1.06 1.16 0.47 0.21 0.17 
EphA1  0.05 0.05 0.10 0.11 0.29 
EphA2  0.03 0.06 0.02 0.06 0.84 
EphA3  0.01 0.01 0.07 0.16 0.33 
EphA4  0.11 0.11 0.25 0.20 0.11 
EphA6  0.16 0.16 0.12 0.10 0.59 
EphA7  0.17 0.12 0.21 0.19 0.58 
EphB1  0.08 0.12 0.20 0.25 0.25 
EphB2  0.47 0.33 0.61 0.28 0.38 
EphB4  0.07 0.13 0.18 0.21 0.21 
EphB6  0.03 0.05 0.10 0.11 0.12 
ErbB2  0.39 0.83 0.17 0.18 0.49 
ErbB3  0.15 0.33 0.01 0.04 0.26 
ErbB4  0.25 0.28 0.29 0.27 0.79 
FGFR1  0.06 0.13 0.01 0.01 0.27 
FGFR2α 0.13 0.11 0.12 0.11 0.90 
FGFR3  0.15 0.12 0.31 0.31 0.20 
FGFR4  0.01 0.02 0.00 0.00 0.14 
Flt-3 0.09 0.10 0.18 0.25 0.35 
IGF-1R 0.08 0.07 0.09 0.06 0.68 
Insulin  0.19 0.12 0.13 0.09 0.23 
KIT 0.03 0.04 0.00 0.00 0.13 
M-CSF 0.07 0.08 0.02 0.03 0.09 
Mer  0.34 0.38 0.26 0.19 0.61 
Met  0.10 0.23 0.01 0.01 0.30 
MuSK  0.04 0.09 0.13 0.15 0.15 
PDGFRα 0.07 0.14 0.01 0.02 0.31 
PDGFRβ 0.07 0.07 0.01 0.02 0.03 
Ret 0.03 0.04 0.11 0.12 0.12 
Ron  0.35 0.40 0.61 0.45 0.24 
ROR1  0.21 0.25 0.20 0.16 0.92 
ROR2  0.15 0.19 0.22 0.20 0.48 
Tie-1 0.28 0.12 0.37 0.30 0.42 
Tie-2 0.32 0.32 0.43 0.32 0.53 
Trk A  0.14 0.13 0.09 0.12 0.44 
Trk B  0.10 0.13 0.06 0.05 0.40 
Trk C  0.05 0.11 0.02 0.03 0.43 
VEGFR1  0.02 0.04 0.01 0.01 0.28 
VEGFR2  0.01 0.01 0.01 0.02 0.81 
VEGFR3  0.08 0.08 0.14 0.08 0.16 
 
Table3.10 Association of flow MRD status with individual RTK phosphorylation profiles.  
PDGFRβ phosphorylation status was significantly more intense in the leukaemia samples which 
demonstrated positive flow MRD (>0.01%) at the end of induction (p=0.03).  Data presented is the mean 
optical densitometry reading for each RTK derived for the primary ALLs. 
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Figure 3.24 Increased PDGFRβ signal is associated with presence of MRD detected by flow cytometry. The 
phosphorylation signal for PDGFRβ was significantly more intense for the 8 ALL samples with leukaemia 
detectable >0.01% when assayed by flow cytometry. Error bars are standard error of the mean (SEM).  
 
 
Comparison of clinical and biological features of the flow MRD positive and negative 
groups did not demonstrate a difference in the 2 populations age (p= 0.82 t – test), WCC (p= 
0.41 t – test), cytogenetics (p=0.42 Chi square), molecular MRD status (p=0.09 Chi square) or 
apoptotic phenotype (p = 0.31 Fisher’s exact). The dot plot revealed a split in signal 
intensity in the 16 samples correlated to flow MRD (fig 3.24), with no signal in 6 
leukaemias, while there significant expression in the remaining 10.  
 
 In summary, whilst the Raybiotech array suggested molecular MRD negative status 
correlated with a high phosphorylation signal of Axl and Txk, the R&D array identified 
PDGFRβ expression positively correlated with the persistence of MRD when assessed by 
flow cytometry and cytogenetic subtype.  
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3.9 Discussion 
The aim of this chapter was to investigate whether aberrant activation of specific receptor 
tyrosine kinases in childhood ALL could be correlated with clinical features and predictive 
markers of chemosensitivity, including early response to treatment, MRD and apoptotic 
patterns to IR – induced DNA damage. To this end, the baseline tyrosine kinase 
phosphorylation signatures from 20 primary ALLs were investigated using 2 types of 
antibody – based protein arrays.  The hypothesis that differential constitutive 
phosphorylation of individual RTKs upregulate pro – survival pathways in ALL cells that 
are resistant to IR – induced apoptosis is not supported by the results from both the array 
experiments. 
 
Multiple phosphorylated RTKs were detected with the R&D array, with a wide range of 
intensity. A large number of the kinases demonstrated low levels of phosphorylation when 
using 50µg of primary leukaemia whole cell lysate for hybridisation.  In previous studies, 
up to 2mg of cell line and primary lysate was used (294). The hybridisation of larger 
amounts of protein would probably improve the detection rate of RTK activation, but this 
goal was unachievable in this study because of the limited amount of primary material 
available. In the initial array validation studies, 50µg of cell lysate from cell lines was 
sufficient to demonstrate a phosphorylation signal, which could be confirmed by Western 
Blot.  An equal amount of primary tumour protein did not elicit as intense signals. An 
explanation for this finding may be the more homogenous nature of cell lines and the sub – 
clonal evolution present in ALL (357, 358).  The bone marrow samples used for this study 
were prepared by gradient density centrifuge and collection of the mononuclear fraction, 
with no cell sorting. While the total leukaemic yield may still be high an activated RTK may 
only be expressed in a minor sub – population and thus yield a low level of signal.  
 
Results derived from both the R&D and Raybiotech arrays have been published in peer – 
reviewed journals, investigating a wide variety of solid tumours, including glioblastoma 
multiforme, chordoma and mesothelioma (294, 359-361). Phosphorylation profiles derived 
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from these published studies were reproducible and confirmed by Western Blot. Only 2 
published studies have used this technology to investigate acute leukaemias, both of which 
used the R&D array (158, 362). Ter Elst et al. confirmed baseline phosphorylation signals of 
the EGFR, PDGFR, Ron and Trk A receptors in 3 primary ALL samples (362). The results 
for these 4 RTKs were reproduced in the current study with EGFR and Ron the second and 
fourth highest mean expression across all 18 leukaemias investigated with the R&D arrays. 
The expression of Trk A and PDGFRβ in the current study was substantially lower, but this 
finding may be due to the heterogeneity of ALL. Marston et al. (158)  utilised the R&D 
arrays to compare RTK phosphorylation in 6 primary ALL samples after exposure to IR. 
Baseline phosphorylation of ErbB4 and FLT3 was found in 2 individual samples. 
Phosphorylation of multiple RTKs occurred after irradiation, including Mer, ErbB4, insulin 
and IGF-1R. In the analysis reported here Mer and ErbB4 were the seventh and ninth most 
phosphorylated RTKs detected by the R&D arrays. The RTKs EGFR, Mer, PDGFRβ,  Ron 
and Trk A have been identified in both previous and current studies, suggesting that these 
kinases are possible targets for further targeted therapy in childhood ALL. 
    
Unlike the R&D arrays, the Raybiotech arrays identified a restricted pattern of 
phosphorylated kinases, namely Axl, FGFR2, JAK2 and Txk. Increased phosphorylation 
signals for Axl and Txk were observed in the apoptotic proficient leukaemias and 
leukaemias with negative molecular MRD at less than 0.01%, both of which are markers for 
chemosensitivity. This different phosphorylation signature for Axl was not mirrored in the 
R&D array. The presence of constitutively phosphorylated Axl in the apoptotic proficient 
leukaemias (Raybiotech array) would be contrary to the pro – survival role this kinase 
exerts in chemoresistant AML (363). Low level phosphorylation of Axl was present in 15/18 
samples assayed on the R&D system, but did not correlate with the Axl signals identified in 
by the Raybiotech arrays. The presence of increased phosphorylation in the chemosensitive 
apoptotic proficient samples was unexpected. 
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 Similarly, increased JAK2 signal intensity was the dominant signature for 7/8 samples on 
the Raybiotech array and was associated with presentation WCC <50x09/L and samples 
with an apoptotic proficient phenotype. These results were not consistent with current 
evidence, since aberrant JAK2 activity appears restricted to Down Syndrome – associated 
ALL  (237, 240) and high risk leukaemias with normal cytogenetics and Bcr/Abl – like 
transcriptional signatures (222).  The samples which expressed phosphorylated JAK2 were 
not consistent with these populations because recurrent cytogenetic abnormalities were 
present in 6/8 leukaemias. The remaining 2 leukaemias, which did not demonstrate any 
cytogenetic abnormalities, were not from patients with DS and only 1 was flow – MRD 
positive at the end of induction of greater than 0.01%. Interpretation of the Raybiotech data 
is complicated by the unexpected correlation between markers of chemosensitivity and 
increased kinase signals and the lack of correlation between the 2 array systems.   
 
While no correlation was observed between the apoptotic phenotype and the 
phosphorylation signals detected by the R&D array, differential RTK phosphorylation 
signals were noted when samples were grouped by cytogenetics (EphA2, EphB2, FLT3), 
diagnostic white cell count (Mer and FGFR2) and MRD status by flow cytometry 
(PDGFRβ), but not molecular MRD.  
 
The lower phosphorylation of EphA2 was demonstrated in the cytogenetically favourable 
groups, t(12;21) and hyperdiploid, when compared with leukaemias with non-contributory 
cytogenetics.  Consistent with this finding, increased activity of EphA2 is associated with 
aggressive carcinomas (364, 365). In addition, reduced phosphorylation of EphB2 was also 
seen in the hyperdiploid group compared to the t(12;21) and non – contributory groups. 
The role of eph receptors in cancers is complicated because of promiscuous cross – talk 
(366) with other receptors and they possess the ability for bidirectional signalling (367, 368). 
Both EphA2 and EphB2 are potentially oncogenic (369, 370) and the increased signals of 
these 2 kinases in the leukaemias with non – contributory cytogenetics abnormalities 
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suggest these 2 RTKs may play a role in either the leukaemogenesis or chemoresistance of 
leukaemias with a non – contributory cytogenetics.      
 
In contrast, the level of FLT3 phosphorylation was significantly higher in the 3 
hyperdiploid leukaemias when compared with the remaining 15. Activating FLT3 
mutations have previously been described in ALL, with preponderance in hyperdiploid 
tumours (250, 371) supporting the findings of this study. While the adverse nature of 
activated FLT3 is well documented in AML (372), its role in ALL is uncertain since the 
survival rates of patients with hyperdiploid and infant ALL are dramatically different. The 
presence of activated FLT3 is consistent with published data and thus warrants further 
investigation for the use of kinase inhibitors in ALL.   
 
In this study, a positive relationship between the intensity phosphorylation signals for the 
Mer and FGFR2 RTK and high diagnostic WCC was observed in the samples assessed by 
the R&D Array. Both RTKs are associated with tumorigenesis (162, 262) and 
chemoresistance in cancers (89, 355).  While FGFR2 has not been identified in ALL, Mer 
contributes to the t(1;19) E2AX-PBX1 ALL gene expression signature (220, 373). The pro – 
survival  activity of Mer was demonstrated the reduction of cell survival of primary t(1;19) 
ALL cells (261) caused by small interfering RNA (siRNA) – mediated silencing of Mer. 
Increased leukaemia survival and chemoresistance associated with increased activity of 
Mer could contribute to the adverse impact of a high WCC identified in this study. In the 
future, it would be interesting to compare Mer gene expression with phosphorylation 
between high WCC and t(1;19) ALL subtypes to address potential different mechanisms of 
Mer hyperactivation. 
 
 A relationship was identified between the level of PDGFRβ phosphorylation and 
leukaemias with positive MRD greater than 0.01% when assessed by flow cytometry at the 
end of induction. This relationship was not observed when phosphorylation levels were 
compared in ALLs with positive MRD assessed by molecular techniques.  The differences 
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in correlations by MRD method may be explained partly by the fact that the cohorts 
examined by flow and PCR did not contain exactly the same samples but also by the 
incomplete correlation between the 2 techniques. While a high level of concordance 
between the 2 techniques has been reported (95, 96), this study has limited numbers of 
samples which might impact on the correlation between these different methods. The 
presence of PDGFRβ has been reported in 2 pre – B ALL cell lines at transcript level (374) 
and phosphorylation in primary ALL samples (362), suggesting it may be a putative target 
for therapy in a selected population of childhood ALL.  
 
In summary, there were limitations in this study, partly due to discordance in 
phosphorylation data between the 2 arrays, which may be attributable to differing affinity 
of the manufacturers’ antibodies but also possible under-detection due to the low protein 
levels in the size of samples available. In addition, ALL is a very heterogeneous disease in 
terms of clinical characteristics, cytogenetic profiles and chemosensitivity, which are 
difficult to fully represent in a small sample size. Nevertheless, within these limitations, it 
was possible to identify differential phosphorylation signals for specific tyrosine kinases 
that correlated with clinical and biological features in the 20 ALL samples investigated. The 
R&D array demonstrated increased mean FLT3 signal in the hyperdiploid leukaemias, 
which is consistent with published literature. This favourable cytogenetic group also 
demonstrated a reduction in signal from 2 RTKs, EphA2 and EphB2, both of which are 
potentially oncogenic.  The identification of increased EphA2 signal in leukaemias with 
normal cytogenetics and an adverse WCC risk may lead to the identification of a new risk 
category. Further investigation would be justified in a larger cohort with additional 
validation of mRNA expression of individual RTKs and Western Blotting to confirm levels 
of total and phosphorylated proteins.  
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4      Screening of cell line panel and primary ALL cells with library of RTK inhibitors 
4.1. Introduction  
The introduction of the small molecular TK inhibitor, imatinib, against the leukaemia – 
specific Bcr/Abl oncoprotein revolutionised the treatment of CML. The International 
Randomized Study of Interferon and STI571 (IRIS) trial demonstrated significant benefit 
over best practice of the time, with a dramatic increase in overall survival (375) and 
indicated the potential of targeted therapeutic approaches in malignancies. The therapeutic 
potential of targeting tyrosine kinases in malignancies has led to a proliferation of small 
molecule inhibitors.  Such small molecule kinase inhibitors offer investigators useful tools 
with which to rapidly decipher kinase pathways involved in important pathological 
processes. 
 
To complement the phospho – RTK array screening undertaken in the previous chapter, a 
small molecule inhibitor library was constructed, as a tool for identification of candidate 
kinases and the associated pathways that might be important for the survival and 
proliferation of ALL blasts.  Twenty primary leukaemias, with a representative range of 
clinical, biological and cytogenetic features, were used to assess the range of activity of 33 
molecules. 
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4.2. Generation and optimisation of RTK inhibitor library screen assay  
A library of 33 TKIs was purchased from Selleck Chemicals (Boston, MA, USA), which 
targeted a total of at least 43 putative kinase targets. The TKIs and their putative kinase 
targets are shown on table 2.5.  
 
The ATP – based metabolic assay, Promega CellTiter – Glo® (Madison, WA, USA) was used 
to measure cell viability of cell lines and primary ALL samples after treatment with the 
TKIs (Methods 2.11).  Using this method, at least 50% reduction in cell viability after 
treatment was selected as the margin to indicate activity of the novel TKIs.  
 
Three aspects of the assay were optimised before using it in the TKI screen.  These aspects 
were: (i) the duration of treatment, (ii) the concentrations of the drugs, and (iii) the culture 
medium in which the primary ALL cells were screened.  A series of preliminary 
experiments were performed, using the myeloid Kasumi – 1 cell line, which possesses 
t(8;21) and an activating KIT mutation  (Asn822Lys).  Inhibition of this KIT activity by what 
the tyrosine kinase inhibitor SU5614 reduces proliferation and induces apoptosis in 
Kasumi-1 cells (376). 
   
(i) Establishing optimal drug exposure time to leukaemia cells  
Using Kasumi-1 cells as a positive control for the assay, the optimal duration of drug 
exposure to detect activity was assessed with a time course experiment with 2 KIT 
inhibitors from the library. These inhibitors were imatinib (Abl/CSF-1R/KIT/PDGFR) and 
BIBF1120 (FGFR/FLT3/KIT/PDGFR/VEGFR).  The effect on cell viability was assessed after 
24, 48 and 72 hours.  With both inhibitors, the percentage of surviving cells decreased with 
increasing drug exposure up to 72 hours (figs 4.1a and b). The IC50 for both imatinib and 
BIBF1120 decreased with increased duration of treatment. The IC50 at 24 hour exposure for 
imatinib was 1.11µM compared to 0.161µM with 72 hour exposure. Similarly, with 
BIBF1120, the IC50 was 0.977µM and 0.052µM following 24 hour and 72 hour exposure 
respectively. The IC50 measured at 72 hours for both imatinib and BIBF1120 are consistent 
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with published data (339, 377) therefore validating this system.  There was little difference 
in cell kill following the 48 and 72 hour exposures, which is important in applying the assay 
to primary ALLs, since prolonged in vitro incubation of primary ALL cells can significantly 
reduce cell viability because of their propensity to undergo spontaneous apoptosis (378).  
 
   
  Figure 4.1a 
   
  Figure 4.1b 
 
Figure 4.1 Incubation of Kasumi – 1 cell line with Kit – inhibitors demonstrate a time dependent reduction 
in cell viability. Both (a) imatinib and (b) BIBF1120 demonstrated maximal inhibition of cell viability by 72 
hours. In keeping with published data both TKI induced responses at nanomolar concentrations. The 
difference in reduction of cell viability was minimal in cells incubated for 48 hours or 72hours.   
 
 
 
IC50 Imatinib 
24h 1.11µM 
48h 0.262µM 
72h 0.161µM 
  
 
IC50 BIBF1120 
24h 0.977µM 
48h 0.077µM 
72h 0.052µM 
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(ii) Establishing optimal drug concentrations 
While detailed incremental dose response evaluation is the ideal method to elucidate the 
potency of each drug, the number of concentrations applied in this screen is limited by the 
quantity of primary ALL material available.  Therefore an upper dose limit was selected, 
based on the well – established NCI – 60 DTP Human Tumor Cell Line Screen.  This screen 
uses a single dose of 10µM to investigate the activity of new compounds (379, 380). An 
additional lower dose was also included, to enable detection of low-dose activity and to 
establish dose – dependent efficacy of the TKIs to be established.  To identify what a 
suitable lower dose, the Kasumi – 1 cell line was treated with 8 TKIs, 5 of which inhibit Kit 
(imatinib, nilotinib, dasatinib, axitinib and sunitinib), and 3 of which do not (gefitinib 
[EGFR/HER2], brivanib [VEGFR/FGFR] and NVPAEW541 [IR/IGF – 1R]).  While all 5 KIT 
inhibitors induced a 50% reduction in cell viability a dose of 1µM, only 2 caused this 
reduction at a dose of 0.1µM (fig 4.2).  Since none of the 3 TKIs which do not target Kit 
induced a greater than 50% reduction in viability at a dose of 1µM, these data indicate that 
1µM drug is likely to be discriminatory in determining an active dose.  
 
Thus, for this study, a compound of interest was defined as a TKI exhibiting a greater than 
50% reduction in cell viability at 1µM and demonstrating a further response at 10µM. 
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Figure 4.2 Selective response to Kit – inclusive inhibitors in demonstrated in Kasumi – 1 cell lines when 
tested with a panel of 8 TKI.  All Kit – inclusive inhibitors demonstrated nanomolar activity.  The Kit – 
inclusive inhibitors imatinib, nilotinib dasatinib, axitinib and sunitinib demonstrated nanomolar activity in 
the Kasumi – 1 cell line. Brivanib, gefitinib and NVP - AEW541 did not induce significant cell death at 
nanomolar concentration. The concentration of 1µM was most discriminatory to identify possible Kit 
inhibitors. 
 
(iii) Establishing optimal culture conditions for ALL primary cells 
Primary ALL cells have limited viability when cultured in vitro. The reducing agent β – 
mercaptoethanol (BME) has been reported to improve the in vitro viability of lymphocytes 
in cell culture, by reducing oxidative stress and maximising the ability of lymphocytes to 
utilise essential amino acids (381). To optimise the culture media for in vitro incubation of 
the primary ALL cells for study of drug activity, the effects of BME on cell viability were 
investigated.  Serial dilutions of primary ALL cells from ALL-36 were incubated either in 
RPMI/10%FCS/1%pen/strep alone or with 50µM BME for 48 hours and the cell viability 
compared.  Consistent with published data, it was confirmed that viability of the cells 
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cultured with BME was consistently higher than cells cultured without BME (fig 4.3a and 
b). BME was subsequently included in the primary cell cultures during drug screening.  
 
  
    Figure 4.3a         
 
 
Cells per well Ratio of luminescence RPMI BME/RPMI 
50 000  1.68 
25 000 1.77 
50 000 1.94 
25 000 1.95 
10 000 1.5 
   
Figure 4.3b 
 
Figure 4.3 Correlation of relative luminescence with cell density and culture media. (a) The relative 
luminescence ratio of cells culture in RPMI and RPMI with 50 µM BME was determined. The relative 
luminescence was directly related to cell number, but addition of BME demonstrated a statistically significant 
increase in cell viability. (b) Luminescence was persistently higher in the RPMI/BME cultured primary cells at 
all concentrations of cells per well, except 5000 cells per well. 
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4.3. Proof of principle of TKI screen in a primary myeloid leukaemia (AML – 2)   
Optimisation of the TKI library screening method had been performed using cell lines.  
Before initiating the TKI library screen in the primary ALL samples, the optimised TKI 
library method was tested in primary myeloid leukaemia cells (AML – 2) carrying a 
specific, defined RTK – abnormality, FLT3 – ITD, which was expected to exhibit sensitivity 
to FLT3  inhibition.  
 
The activity of 20 TKIs was tested against AML – 2 using the optimised method.  A 
reduction in cell viability of greater than 50% was observed at 1µM in 10 of the 20 TKIs 
screened (fig 4.4).   Six of these TKIs (BIBF1120, CEP – 701, dovitinib, foretinib, sorafenib 
and sunitinib) are known to be FLT3 inhibitors and therefore the effect was predicted. The 
remaining active compounds were PHA739358 (Aurora kinase/Abl/RET), bosutinib 
(Abl/Src/Axl/Trk) and the EGFR/HER-2 inhibitors CI-1033 and BIBW-2992.  No effect was 
induced by the remaining inhibitors at 1µM, of which only the dual Aurora kinase/FLT3 
inhibitor VX-680 is active against FLT3 (347). These data, therefore, show that the optimised 
TKI library screen is able to target and distinguish molecules and pathways involved in 
disease pathology.  This method, if used in a larger cohort of primary ALLs, could be used 
to identify useful novel therapeutic targets and drugs. 
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Figure 4.4 Bar chart demonstrating activity of TKIs against AML – 2 at 1 and 10µM. Ten FLT3 – inclusive 
inhibitors demonstrate activity in the FLT3 mutated AML – 2 cells at 1µM. The experiment was performed 
once, with triplicate wells. Data plotted is the mean of the 3 wells, error bars are standard deviation of 
triplicate wells.  
 
 
4.4. Screen of B – precursor ALL cell lines with expanded TKI library  
Following the optimisation and proof of principle evaluation of the TKI library assay, a 
cohort of ALL cell lines (n=5) were screened and a cohort of primary ALLs (n=20) were 
evaluated (table 4.1). Compounds of interest which were defined as TKIs causing a greater 
than 50% reduction in cell viability at 1µM and a further response at 10µM were identified 
from a panel of 33 molecules.  
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TKI Putative primary targets 
JAK inhibitors 
AG490  JAK 2 – 3, EGFR  
CP690550 JAK 1 – 3  
IGF-1R/Insulin inhibitors 
GSK1904529A IGF – 1R/Insulin  
NVPAEW541 IGF – 1R/Insulin 
Irreversible EGFR/HER2 
BIBW-2992 EGFR/HER2 
CI – 1033 EGFR/HER2/HER4 
Restricted spectrum inhibitors 
AZD0530 Abl/Src/EGFR 
Bosutinib Abl/Src/Axl/EGFR/Trk 
Dasatinib Abl/Src/CSF-1R/Kit/PDGFRαβ 
Imatinib Abl/CSF-1R/Kit/PDGFRαβ 
Masitinib Kit/PDGFRαβ 
Nilotinib Abl/Kit/PDGFRαβ 
PF-04217903 Met 
PF-2341066 Met/ALK 
PHA739358 Aurora kinase A – C/Abl/Src/RET  
AMG – TIE-2 – 1  Tie – 2  
Multikinase inhibitors (VEGFR/PDGFR) 
Axitinib VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/FGFR 1  
Brivanib VEGFR 1 -3/FGFR 1 – 3  
Cediranib VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/FGFR 1  
Motesanib VEGFR 1 – 3/PDGFRα/Kit/RET  
Pazopanib VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/FGFR 1, 3 and 4 
Vandetanib VEGFR 1 -3/EGFR/RET 
Vatalinib VEGFR 1 – 3/PDGFRβ/Kit 
Multikinase inhibitors with FLT3 activity  
ABT-869 FLT3/VEGFR 1 – 3/PDGFRβ/CSF – 1R/Kit 
BIBF1120 FLT3/VEGFR 1 – 3/PDGFRαβ/FGFR 1 – 4/Src  
CEP-701 FLT3/VEGFR 1 – 2/PDGFRβ/RET/TrkA 
Dovitinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/FGFR 1 and 3 
Foretinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/FGFR 
1/Ron/Axl/Tie – 2  
NVPTAE684 FLT3/Met/ALK 
Sorafenib FLT3/VEGFR 2 -3/PDGFRβ/Kit/B – raf  
Sunitinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 1R/Kit/RET/FGFR1 
Tandutinib FLT3/PDGFRαβ/Kit 
VX-680 FLT3/Aurora kinase A – C/Abl  
 
Table 4.1 Expanded tyrosine kinase inhibitor library, with primary putative targets TKIs were chosen to 
cover the kinome. The inhibitors have been grouped together by principle activity: (i) Jak inhibitors, (ii) 
IR/IGF – 1R, (iii) EGFR/HER2 inhibitors, (iv) restricted inhibitors with no FLT3 activity, (v) multikinase 
inhibitors with no FLT3 activity and (vi) multikinase inhibitors with FLT3 activity.   
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4.4.1. Characteristics of ALL cell line panel for TKI library screen  
The 5 cell lines screened were representative of the heterogeneity of ALL with respect to 
cytogenetic variety and drug sensitivity (Table 4.2). As a proxy for chemosensitivity the cell 
lines were characterised for apoptotic response to IR – induced DNA damage (chapter 3.1).  
Three patterns of damage were identified. Nalm 17 and SupB15, were apoptosis proficient 
(suggesting chemosensitivity), while REH and SD - 1 were apoptosis defective (suggesting 
chemoresistance). Nalm 6 exhibited an intermediate response, with limited cleavage of 
procaspases and PARP – 1 after irradiation. This pattern of response is interpreted as a 
leukaemia with a moderate degree of chemoresistance. Normal accumulation of p53 in 
response to IR was present in all cell lines as previously described (315). 
 
Cell line Cytogenetics Apoptotic response to IR – induced DNA damage  
Nalm 6 t(5;12) Intermediate  
Nalm 17  Normal karyotype  Apoptosis proficient  
REH t(12;21) Apoptosis defective  
SD – 1 t(9;22) Apoptosis defective  
Sup – B15 t(9;22) Apoptosis proficient  
 
Table 4.2 Characteristics of B – cell precursor ALL cell lines. The 5 ALL cell lines were characterised for 
apoptotic response to IR – induced DNA damage. Cells were considered proficient if there was evidence of 
intrinsic apoptosis, demonstrated by activation of p53 with cleavage of PARP – 1 and procaspases 7. The cell 
lines Nalm17 and SupB15 demonstrated proficient apoptotic responses, while REH and SD – 1 were apoptosis 
defective. The t(5;12) cell line Nalm 6 demonstrated an intermediate response, with activation of p53 and 
limited PARP – 1 and procaspase cleavage.       
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4.4.2. Sensitivity of cell lines to TKIs at 1µM and 10µM 
There was significant heterogeneity of response of the 5 cell lines to many of the TKIs.  
Sixteen of the 33 TKIs demonstrated activity at 1µM, while 26/33 demonstrated activity in 
at least 1 cell line at 10µM.  Table 4.3 summarises the mean percentage of remaining viable 
cells at 1µM, with active TKIs, highlighted in green.  The response of SupB15 to PHA739358 
(Aurora kinase/FLT3) is highlighted in yellow because, while a reduction in cell viability 
greater than 50% was detected at 1µM, an increase was observed to above 50% at 10µM. 
This drug was thus not considered a compound of interest.   
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Tyrosine Kinase Inhibitors Nalm 6 Nalm 17 REHa SD-1ab SupB15b 
JAK inhibitors 
AG490  JAK 2 – 3, EGFR  91 (12) 94(5) 88(19) 74(7) 108(14) 
CP690550 JAK 1 – 3  103(35) 96(3) 107(15) 80(5) 106(7) 
IGF-1R/Insulin inhibitors 
GSK1904529A IGF – 1R/Insulin  90(8) 104(8) 96(3) 97(39) 106(26) 
NVPAEW541 IGF – 1R/Insulin 96(15) 91(12) 104(3)  103(10) 
EGFR/HER2 Quinazoline 
BIBW-2992 EGFR/HER2 88 (28) 68(45) 42(14) 35(16) 92(20) 
CI – 1033 EGFR/HER2/HER4 77(4) 77(27) 41(10) 22(17) 98(6) 
Restricted spectrum 
AZD0530 Abl/Src/EGFR 95 (32) 94(3) 91(29) 45(6) 64(10) 
Bosutinib Abl/Src/Axl/EGFR/Trk 35(7) 23(15) 38(0) 23(20) 30(11) 
Dasatinib Abl/Src/CSF-1R/Kit/PDGFRαβ 67(29) 70(22) 76(3) 32(15) 22(10) 
Imatinib Abl/CSF-1R/Kit/PDGFRαβ 80(16) 88(14) 91(2) 73(12) 60(11) 
Masitinib Kit/PDGFRαβ 113(45) 102(8) 83(6) 56(9) 53(13) 
Nilotinib Abl/Kit/PDGFRαβ 97(14) 94(5) 88(2) 72(9) 55(8) 
PF-04217903 Met 91(16) 94(8) 89(11) 82(12) 109(15) 
PF-2341066 Met/ALK 70(3) 72(36) 46(3) 35(5) 14(8) 
PHA739358 Aurora kinase A – C/Abl/Src/RET  73(22) 66(22) 66(14) 27(9) 25(12) 
TIE-2 Tie – 2  68(25) 94(3) 89(4) 52(22) 60(18) 
Multikinase inhibitors (VEGFR/PDGFR) 
Axitinib VEGFR 1 – 3/PDGFRαβ/CSF – 1R 
Kit/FGFR 1  
99(19) 85(13) 52(30) 70(24) 46(13) 
Brivanib VEGFR 1 -3/FGFR 1 – 3  71(12) 94(8) 97(13) 88(17) 113(9) 
Cediranib VEGFR 1 – 3/PDGFRαβ/CSF – 1R 
Kit/FGFR 1  
93(3) 92(2) 89(15) 65(5) 103(12) 
Motesanib VEGFR 1 – 3/PDGFRα/Kit/RET  113(19) 102(8) 85(1) 99(30) 103(13) 
Pazopanib VEGFR 1 – 3/PDGFRαβ/CSF – 1R 
Kit/FGFR 1, 3 and 4 
93(13) 92(15) 91(0) 64(20) 105(34) 
Vandetanib VEGFR 1 -3/EGFR/RET 71(11) 84(20) 92(12) 70(23) 60(15) 
Vatalinib VEGFR 1 – 3/PDGFRβ/Kit 105(28) 101(5) 76(16) 85(6) 101(4) 
Multikinase inhibitors with FLT3 activity 
ABT-869 FLT3/VEGFR 1 – 3/PDGFRβ/CSF – 1R/Kit 125(36) 95(5) 87(12) 2(2) 88(3) 
BIBF1120 FLT3/VEGFR 1 –3/PDGFRαβ/FGFR 1 – 4/Src  64(26) 86(31) 83(6) 42(4) 43(4) 
CEP-701 FLT3/VEGFR 1 – 2/PDGFRβ/RET/TrkA 25(7) 12(6) 35(16) 10(4) 19(5) 
Dovitinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 1R 
Kit/FGFR 1 and 3 
34(15) 35(15) 11(1) 19(8) 1(1) 
Foretinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 
1R/Kit/FGFR 1/Ron/Axl/Tie – 2  
77(20) 35 (9) 19(5) 12(15) 8(4) 
NVPTAE684 FLT3/Met/ALK 112(24) 68(38) 62(15) 35(10) 80(38) 
Sorafenib FLT3/VEGFR 2 -3/PDGFRβ/Kit/B – raf  81(2) 82(2) 90(5) 53(9) 77(17) 
Sunitinib FLT3/VEGFR 1 – 3/PDGFRαβ/CSF – 
1R/Kit/RET/FGFR1 
85(7) 79(19) 65(0) 62(26) 107(29) 
Tandutinib FLT3/PDGFRαβ/Kit 82(12) 95(10) 107(8) 64(25) 109(10) 
VX-680 FLT3/Aurora kinase A – C/Abl  86(13) 88(32) 64(5) 36(7) 22(13) 
Key: 
a – Apoptosis defective in response to IR – induced DNA damage  
b – Philadelphia positive cell line  
 
Table 4.3 Summary of inhibitors grouped by putative targets which demonstrated greater than 50% 
reduction in viability at 1µM in cell lines. Mean percentage of remaining viable cells at 1µM of 3 separate 
experiments in triplicate with standard deviation in parentheses. TKIs with activity in cell lines are 
highlighted in green. PHA739358 is highlighted in yellow, despite reducing cell viability >50% at 1µM, there 
was no further decrease at 10µM. 
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Three of 33 compounds were able to induce ≥50% reduction in viability at 1µM in all 5 cell 
lines (fig 4.5).  These inhibitors were dovitinib (VEGFR/PDGFR/FGFR/FLT3), CEP – 701 
(FLT3/Ret/Trk/VEGFR2), and bosutinib (Abl/Src/Axl/EGFR/Trk).  A further multikinase 
inhibitor, foretinib (Axl/CSF – 1R/FLT3/ Met/PDGFR/Ron/Tie – 2/VEGFR), inhibited 4/5 cell 
lines; only Nalm 6 was resistant at 1µM.  PF – 2341066 (Met/ALK) was active in 3/5 cell 
lines, while the Abl inhibitors, dasatinib and VX – 680, inhibited only the 2 t(9;22) cell lines.  
 
       
 
 
Figure 4.5 Summary of mean responses of cell lines to individual TKIs. Percentage viability documented is 
the mean of the 5 cell lines, with error bars as standard deviation. The TKIs which were most potent in 4 or 5 
cell lines were dovitinib, CEP-701, foretinib and bosutinib. While the mean reduction of cell viability was 
>50% in response to PF – 2341066, it demonstrated activity in only 3 of the 5 cell lines.   
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To investigate whether the 4 TKIs bosutinib, CEP – 701, dovitinib and foretinib work 
through a single pathway the putative targets of the drugs were compared (fig 4.6).    
 
 
 
 
Figure 4.6 Venn diagram demonstrating shared putative targets of bosutinib, CEP – 701, dovitinib, and 
foretinib. No unifying putative target was shared by the 4 TKIs. Three of the 4 TKIs demonstrate in vitro 
activity against FLT3, PDGFRβ and VEGFR RTKs.  
 
Three of these four compounds, CEP – 701, dovitinib and foretinib, are multikinase 
inhibitors with activity against common targets FLT3, VEGFR1, VEGFR2 and PDGFRβ. 
Bosutinib was initially designed as a dual non - receptor tyrosine Abl/Src inhibitor and has 
a more restricted spectrum of activity, with no identified activity against FLT3, FGFR, or 
PDGFR families; at nanomolar concentrations its principal  targets include Axl, EGFR and 
Trk (323). 
 
CEP – 701, dovitinib and foretinib do not have activity against Abl or Abl mutants, but yet 
reduced the viability of both t(9;22) Abl – dependent cell lines (SupB15 and SD – 1). This 
      Dovitinib  
 
       
          Bosutinib  
 
           
 
CEP - 701 
 
 
 
Foretinib  
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finding would suggest that at least one of their primary targets (including Axl, CSF – 1R, 
FGFR1/3, FLT – 3, Kit, Met, PDGFRα/β, Ret, Ron, Trk or VEGFR1 – 3) is important in the 
cell survival of t(9;22) cell lines, SupB15 and SD – 1.  
 
In summary, while a common target was not shared by the 4 most active TKIs against the 
panel of cell lines, common patterns were noted. RTKs common to at least 2/4 inhibitors 
included Axl, CSF-1R, FGFR1, Kit, PDGFRα, Trk A and VEGFR3.   Four RTKs, FLT3, 
PDGFRβ, VEGFR1 and VEGFR2, were common targets for 3 inhibitors.  It is possible that 
these TKIs target a combination of TKs which leads to reduced viability   Alternatively, the 
inhibitors may act against ‘off – target’ molecular sites which have not yet been identified. 
 
4.4.3. Sensitivity of cell lines to TKIs with activity in all cell lines at 10µM  
To minimise the chance that potentially important pathways were excluded by the 
definition of active compounds used in this study, the spectra of the TKIs which 
demonstrated a significant reduction in cell viability by greater than 50% at 10µM in all 5 
cell lines were assessed.  
 
Of the 33 TKIs tested 14 compounds were effective in all 5 cell lines at 10µM (fig 4.7).  These 
were: (i) FLT3 – inclusive multikinase inhibitors (ABT – 869, BIBF1120, CEP – 701, dovitinib, 
foretinib, NVPTAE684, sorafenib and sunitinib), (ii) EGFR/HER2 inhibitors (BIBW-2992 and 
CI – 1033) and  (iii) more restricted inhibitors bosutinib (Abl/Axl/EGFR/Trk), vandetanib 
(VEGFR/EGFR/RET), masitinib (Kit/PDGFR) and PF -2340166 (Met/ALK). The additional 
potential targets were therefore ALK, FGFR 2 and HER2 (fig 4.8).   
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Figure 4.7 Fourteen TKIs induced greater than 50% reduction in cell viability in all 5 cell line at 10µM. Cell 
viability was potently affected in all 5 cell lines by the inhibitors bosutinib, CEP – 701 and dovitinib at 1µM. A 
further 10 TKIs (BIBW – 2992, CI – 1033, masitinib, PF – 2341066, vandetanib, ABT – 869, BIBF1120, 
NVPTAE684, sorafenib and sunitinib) induced a global inhibition of all 5 cell lines at 10µM.  
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Figure 4.8 Venn Diagram comparing possible targets of TKIs with activity at 10µM and those with no 
significant activity at 10µM. The JAK, Insulin/IGF – 1R, Met, PDGFR and VEGFR pathways do not appear 
vital to the survival of childhood ALL blasts in this study.     
 
In summary, the patterns of putative targets of TKIs which demonstrate activity at 1µM 
and 10µM are very similar in the cell lines. The inclusion of the putative targets ALK, 
FGFR2 and HER2 at 10µM could be associated with on – or ‘off – target’ effects at this 
higher concentration.  
 
 
 
 
 
 
 
Putative targets limited to TKIs with 
activity in all cell lines at 10µM: 
 ABT – 869  
 BIBF1120 
 BIBW – 2992  
 Bosutinib 
 CEP – 701 
 Dovitinib 
 Foretinib 
 Masitinib 
 NVPTAE684 
 PF2341066 
 Sorafenib 
 Sunitinib 
 Vandetanib 
 
Putative targets restricted to TKIs with 
no significant inhibition at 10µM: 
• AG-490 
• CP – 690550 
• GSK1904592A 
• NVPAEW541 
• Motesanib 
• Pazopanib 
• PF – 04217903   
Common 
putative 
targets  
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4.4.4. Sensitivity of cell lines with defective apoptotic responses to IR – induced DNA    
damage to TKIs   
The greatest clinical need in drug development for childhood ALL is for treatment resistant 
sub-groups. A defective apoptotic response to IR – induced DNA damage in vitro, has been 
shown to be a proxy marker of chemoresistance (315). The pattern of sensitivity to the TKI 
panel in the apoptosis defective cell lines, REH and SD – 1 was therefore compared to TKI 
sensitivity in apoptosis proficient Nalm 17 and Sup B15 or the intermediate responding 
Nalm 6.   
 
Of the 33 TKIs tested, 2 revealed a differential effect on cell survival relating to apoptotic 
response to IR. These were the structurally related pan – EGFR inhibitors, CI-1033 and 
BIBW2992 (fig 4.9). Whilst all the cell lines responded to CI-1033 and BIBW2992 at the 
10µM level, it was the apoptosis defective cell lines, REH and SD – 1 that had the greatest 
response at the 1µM level. 
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Figure 4.9 Differential response demonstrated by apoptotic defective cell lines, REH and SD – 1, to the 
irreversible quinazoline inhibitors BIBW – 2992 and CI – 1033. These 2 TKIs demonstrated significant 
potency against the apoptotic deficient cells lines, REH and SD – 1, and thus may be important in the 
treatment of chemoresistant ALL.  
 
EGFR inhibitors have been shown to induce differentiation in myeloid leukaemias (382), 
this study is the first to investigate the activity in B – precursor ALL.  To investigate 
whether the activity was due to EGFR/HER2 inhibition or an ‘off – target’ effect REH and 
SD-1 cell were treated with 2 additional EGFR/HER2 inhibitors, gefitinib and BMS – 599626, 
that were not included in the original TKI library screen.  Gefitinib is a structurally related 
quinazoline inhibitor, but unlike BIBW-2992 or CI – 1033 does not bind irreversibly to the 
ATP – pocket of the receptors.   BMS – 599626 is an unrelated pyrrolotriazine analogue. 
Both of these inhibitors demonstrate nanomolar activity in cell – based assays where EGFR 
or HER2 are overexpressed or activated (155, 383, 384).  
 
The nanomolar activity of BIBW – 2992 and CI – 1033 was confirmed in both the apoptosis 
defective cell lines, REH and SD1 (fig 4.10a and b), however neither gefitinib nor BMS – 
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599626 exhibited sufficient activity against SD – 1 or REH to generate an IC50 below 10µM, 
suggesting inhibition of EGFR/HER2 is not the mechanism of action of CI – 1033 and BIBW 
– 2992. The absence of a response to all EGFR family of inhibitors tested, would suggest the 
activity of BIBW-2992 and CI-1033 in these cell lines is due to higher affinity to the target or 
an ‘off – target’ effect, for example FLT3. A recent series of reports have implicated FLT3 as 
an unexpected kinase target of CI – 1033 (385, 386). Both REH and SD – 1 exhibited 
sensitivity to the FLT3 – inclusive multikinase inhibitors, CEP – 701, dovitinib and foretinib 
(table 4.3). 
 
The restricted activity of the quinazoline inhibitors in the apoptosis defective cell lines, 
REH and SD – 1, suggests that this family of inhibitors may be active in chemoresistant 
leukaemias however, the mechanism of action is uncertain. It may be through FLT3, but 
this needs further investigation.  
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Figure 4.10a 
                      
   
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Significant nanomolar activity is limited to the irreversible quinazoline inhibitors BIBW – 2992 
and CI – 1033 in (a) REH and (b) SD – 1 cell lines. The EGFR/HER2 inhibitors gefitinib and BMS – 599626 did 
not demonstrate any activity against the REH and SD – 1 cell lines. These data suggest the activity of BIBW-
2992 and CI-1033 may not be via these axes in the childhood ALL cell lines investigated in this study.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10b  
 
 REH SD-1 
BIBW-2992 0.861µM 0.100 µM 
CI-1033 0.472µM 0.789 µM 
Gefitinib 13.85 µM Not converged 
BMS599626  >10 µM Not converged  
Figure 4.10c 
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4.4.5. TKI sensitivity in Philadelphia positive cell lines 
Ph+ leukaemias are generally chemoresistant and historically have a poor prognosis. The 
use of Bcr/Abl inhibitors in conjunction with chemotherapy has improved survival, but 
resistance to inhibitors is a concern. To investigate whether additional pathways could be 
targeted in Ph+ cell lines, the responses of the Ph+ ALL cell lines SupB15 and SD – 1 to the 
33 TKI panel were analysed. 
 
SupB15 and SD – 1, demonstrated sensitivity to the largest number of TKIs, 9 and 14 
compounds respectively.  Of these inhibitors, 3 with activity in SupB15 and 5 with activity 
in SD – 1, were known Abl inhibitors (table 4.4).  The absence of nanomolar response to 
imatinib and nilotinib is consistent with published data (387).   
 
  Ph+ cell lines Non – Ph+ cell lines  
 Putative targets SD – 1a SupB15a Nalm 6 Nalm 17 REH 
Abl inhibitors        
Imatinib  Abl/CSF-1R/Kit/PDGFR - - - - - 
Nilotinib  Abl/CSF-1R/Kit/PDGFR - - - - - 
Dasatinib  Abl/Src/CSF-1R/Kit/PDGFR + + - - - 
Bosutinib  Abl/Src/Axl/EGFR/TrkA + + + + + 
AZD0530 Abl/Src + - - - - 
VX – 680  Aurora/Abl/FLT3 + + - - - 
PHA739358  Aurora/Abl/RET + -* - - - 
Non – Abl inhibitors        
ABT – 869  VEGFR/PDGFR/CSF-1R/FLT3/KIT + - - - - 
BIBF1120  VEGFR/PDGFR/FLT3/FGFR/Src + + - - - 
BIBW – 2992  EGFR/HER2 + - - - + 
CI – 1033 EGFR/HER2 + - - - + 
CEP – 701  FLT3/VEGFR/RET/Trk + + + + + 
Dovitinib VEGFR/PDGFR/FLT3/FGFR + + + + + 
Foretinib VEGFR/PDGFR/FLT3/Met/Axl/Tie-2 + + - + + 
NVPTAE684  Met/ALK/FLT3 + - - - - 
PF – 2341066 Met/ALK + + - - + 
*PHA739358 demonstrated >50% reduction in viability in SupB15 at 1µM but no further reduction at 10µM 
 
 
 
Table 4.4 Summary of inhibitors which demonstrated activity in Ph+ cell lines at 1µM and 10µM. In 
addition to the recognised Abl – inhibitors BIBF1120 revealed activity restricted to the Ph+ ALL cells at 1µM.  
 
 
 
TKI with activity limited to Ph+ cell lines 
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The Ph+ ALL cell lines were sensitive to a range of TKIs. Of note, the activity of the 
multikinase inhibitor BIBF1120 (VEGFR/PDGFR/FGFR/FLT3) was restricted to the Ph+ cell 
lines only (table 4.4).  BIBF1120 is not a recognised Abl inhibitor but has extended activity 
against FGFR 1 – 4 and the Src family. The central role of Src family kinases in Ph+ ALL has 
been described (388, 389) and thus the activity may be mediated through Src – inhibition in 
Ph+ cells.   
 
Activity of 3 further non – Abl TKIs was observed in the Ph+ cell lines. These were the 
broad spectrum inhibitor ABT – 869 (VEGFR/FLT3/Kit/ PDGFRβ/CSF-1R) and NVPTAE684 
(Met/ALK/FLT3), which were active against SD – 1, and the multikinase inhibitor axitinib 
(VEGFR/PDGFRαβ/CSF1R/Kit/FGFR1), which was only effective against SupB15. There 
was no single target common to all TKIs shown to be active in the Ph+ ALL cell lines, 
although common targets for at least 2 of the inhibitors included FLT3, Met, PDGFRα/β and 
VEGFR. 
 
In summary, the differential activity of the Abl inhibitors dasatinib and VX – 680 in Ph+ 
ALL was expected.  The profound inhibition induced by BIBF1120 in both Ph+ cell lines 
implicates possible alternative RTK targets to Abl could be exploited in the treatment of 
Ph+ disease and warrant validation in a larger cohort of cell lines and/or primary ALLs. 
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4.5. RT q-PCR analysis of expression of putative targets of active TKIs  
To identify if putative targets of the TKIs which demonstrated activity in the cell lines were 
present in the cell lines tested, the presence of target transcripts was quantified by RT q-
PCR and the level of expression was then correlated with responses to the TKIs.  The 
expression levels are presented as threshold cycle (Ct) values for each target gene 
normalised to actin expression for each cell line (table 4.5). Transcript for FGFR1 was the 
only receptor to be expressed in all cell lines and FLT3 was expressed in 4 of the 5 cell lines. 
The relationship between expression of the target mRNA and with TKI activity at (i) the 
1µM concentration, (ii) the 10µM concentration only, (iii) activity  in apoptosis resistant and 
(iv) Ph+ cell lines was explored.  Results were obtained for all TKI targets except TIE2, for 
which mRNA could not be successfully amplified because of technical difficulties.  
 
(i) Expression of targets unique to TKIs active in at least 4 cell lines at 1µM 
The targets of dovitinib, foretinib, bosutinib and CEP – 701, the TKIs which demonstrated 
activity at 1µM in at least 4 cell lines, were AXL, CSF1R, EGFR, FLT3, FGFR1, FGFR3, KIT, 
MET, PDGFRA/B,  RET, RON, TIE2, TRKA and VEGFR 1 – 3. Only FGFR1 transcript was 
present in all cell lines but is the target of only 2 inhibitors, foretinib and dovitinib. The 
presence of FLT3 and VEGFR1 transcript in 4/5 cell lines could identify these RTKs as the 
potential targets of inhibition by dovitinib, foretinib and CEP – 701. The only cell line not to 
express FLT3 and VEGFR1 was Nalm 6. TRKA was expressed in 3/5 cell lines and may 
represent one target for bosutinib, since the lack of AXL and EGFR precludes these as 
targets. The absence of AXL, EGFR, MET, RET, VEGFR2 transcript in all 5 cell lines, 
excludes these RTKs as viable targets. TIE2 mRNA could not be successfully amplified 
because of technical difficulties.   
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 Nalm 6 Nalm 17 REH SD1 SupB15 
ALK Absent Absent Absent Absent Absent 
AXL Absent Absent Absent Absent Absent 
CSF-1R Absent Absent 16 14 12 
EGFR Absent Absent Absent Absent Absent 
HER2 Absent Absent Absent Absent 16 
HER3 Absent Absent Absent Absent Absent 
HER4 Absent Absent Absent Absent Absent 
FGFR1 11 6 8 10 9 
FGFR2 Absent Absent Absent Absent Absent 
FGFR3 Absent 11 16 16 Absent 
FGFR4 Absent 16 13 Absent Absent 
FLT3 Absent 16 8 16 7 
KIT Absent 17 17 Absent Absent 
MET Absent Absent Absent Absent Absent 
PDGFRα Absent Absent Absent Absent 11 
PDGFRβ Absent 17 13 Absent 16 
RON 16 14 Absent Absent Absent 
RET Absent Absent Absent Absent Absent 
TIE2 Failed Failed Failed Failed Failed 
TRKA Absent 17 14 Absent 16 
VEGFR1 Absent 14 15 16 11 
VEGFR2 Absent Absent Absent Absent Absent 
VEGFR3 16 Absent Absent Absent Absent 
 
Table 4.5 Transcript levels for each RTK expressed as Ct value – normalised – to – actin. Transcript for 
FGFR1 was the only putative target expressed in all 5 cell lines. No definitive signature was observed in the 
mRNA expression of the 5 ALL cell lines. 
 
(ii) Expression of targets specific to drugs active in all cell lines at 10µM 
Similarly, the targets limited to the TKIs that demonstrate activity in all 5 cell lines  at 10µM 
(ABT – 869, BIBF1120, BIBW – 2992, CI – 1033, masitinib, NVPTAE684, PF-2340166, 
sorafenib, sunitinib and vandetanib) were ALK, AXL, CSF1R, EGFR, FGFR1 – 4, FLT3, HER2, 
HER3, HER4, PDGFRA/B, RET, RON, TRKA, TIE2 and VEGFR1 – 3. The presence of FLT3 
and VEGFR 1 transcript in 4/5 cell lines may identify these RTKs as a potential target of 
inhibition. The absence of transcript for ALK, AXL, EGFR, FGFR2, MET, RET and VEGFR2 
in all cell lines exclude these RTKs as possible targets. The restricted expression of HER2 
(SupB15), RON (Nalm 6 and 17) and TRKA (Nalm 17, REH and SD – 1) reflects either the 
limited involvement of these pathways in survival or ALL heterogeneity.  
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(iii) Expression of targets of the pan – EGFR quinazoline inhibitors (BIBW – 2992 
and CI – 1033) targeting apoptosis defective leukaemias  
The drugs BIBW – 2992 and CI – 1033 exhibited activity to the apoptosis defective cell lines, 
REH and SD – 1. BIBW – 2992 and CI-1033 target the EGFR family, EGFR and HER 2 – 4, 
however neither REH nor SD – 1 expressed transcript from any of the EGFR family 
members. The only cell line to do so was SupB15 (expressing HER2) which did not 
demonstrate sensitivity at the 1µM level to either quinazoline. These results suggest that 
the activity of BIBW – 2992 and CI-1033 was not mediated through inhibition of EGFR 
family members. FLT3 has recently been identified as a novel target of BIBW – 1992 and CI 
– 1033 (385, 386) and expression of its transcript could be detected in both REH and SD – 1 
by RT – qPCR supporting FLT3 as a target of these drugs. Conversely, Nalm 17 and SupB15 
also expressed FLT3 transcript at similar levels but were not sensitive to either drug. A 
possible explanation for the lack of concordance between FLT3 expression and the TKI 
activity is that the level of mRNA expression of a target does not necessarily equate to 
activation of the RTK, which is a post – translational event.  A second explanation could be 
that a higher concentration of BIBW – 2992 and CI – 1033 is required to inhibit FLT3 in 
Nalm 17 and Sup B15, as demonstrated by the reduction in cell viability at 10µM only 
(section 4.3.4).   
 
(iv) Targets of TKIs active against Ph+ cell lines 
The targets of the TKIs which demonstrated activity at 1µM in the Ph+ ALL cells lines  
SD – 1 and SupB15 (ABT – 869, bosutinib, BIBF1120, BIBW – 2992, CEP – 701, CI – 1033, 
dasatinib, dovitinib, foretinib, NVPTAE684, PF – 2341066, PHA739358 and VX – 680) were 
ALK, AXL, CSF1R, EGFR, FLT3, FGFR1, FGFR3, KIT, MET, PDGFRA/B, RET, RON, TIE2, 
TRKA and VEGFR 1 – 3. Both the Ph+ cell lines expressed transcript for CSF – 1R, FGFR1, 
FLT3 and VEGFR1, possible targets of BIBF1120, CEP – 701, dovitinib and foretinib. Of all 
the 5 cell lines, only SupB15 expressed transcript for HER2 and PDGFRA.  However, TKIs 
with EGFR/HER2 activity did not demonstrate any activity against the cell line and no TKI 
individually targeted PDGFRα. 
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In summary, no relationship was evident between the level of transcript expression of a 
single RTK and response to a TKI. This expression analysis, however, does not exclude the 
possibility that a cell line expressing a target may not be sensitive to a corresponding TKI 
because of underlying mechanisms of resistance such an increased expression of efflux 
pumps or the upregulation of additional survival pathways.  
 
Overall, the TKI library screen of the cell lines has revealed 3 patterns of response. Firstly, 
the multikinase inhibitors with anti-FLT3 activity, CEP- 701, dovitinib and foretinib, 
displayed activity against multiple cell lines and thus could be a useful therapy for a 
variety of ALL subtypes.  Secondly, the irreversible quinazoline inhibitors, BIBW – 2992 
and CI – 1033, demonstrated activity in apoptosis defective cell lines which could suggest a 
potential role in the treatment of resistant leukaemias with defects in apoptosis. Finally, 
BIBF1120 which is not recognised to act through a Bcr/Abl mechanism exhibited activity in 
the high risk Ph+ leukaemia cell lines, and therefore may provide a mechanism to explore 
for the treatment of Ph+ ALL. 
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4.6. Screen of primary B – cell precursor ALL cohort with expanded TKI library  
The sensitivity of 20 primary ALL samples to the same library of 33 TKIs was investigated. 
MRD status at the end of induction therapy was used as a proxy for clinical 
chemosensitivity. The primary leukaemia cells were treated with 1µM and 10µM of each 
TKI for 48 hours, after which cell viability was assessed using the Promega CellTiter-Glo® 
assay. As for the cell line experiments, inhibitors were defined as active and of potential 
interest by their ability to reduce cell viability by greater than 50% at 1µM and exhibit a 
further cell viability reduction at 10µM.   
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Sample 
code 
Age  
(yrs) 
Sex WCC 
(x109/L)  
Cytogenetics Response  Flow 
MRD 
Molecular 
MRD  
ALL16 3.5 M 3.4 t(12;21) GER HR HR 
ALL20 12 F 109 46XX, t(3;10) t(9;16) +8 biallelic 
del p16 
GER Ind SR 
ALL21 12 F 8 t(12;21) GER NK NK 
ALL22 2 F 20 Normal GER SR SR 
ALL23 9.5 M 24 45XY, der19, t(1;19) GER HR SR 
ALL24 11 M 59.7 46XY, del9p21p21, monoallelic 
CDKN2A loss,13q14 loss 
PER HR HR 
ALL25 3 M 12.7 No report GER HR HR 
ALL26 0.5 M 110 t(9;11) GPR NK SR 
ALL27 9.5 M 26 46XY GER HR HR 
ALL28 8.5 M 4 Hyperdiploid GER HR SR 
ALL29 3 F 5 t(12;21) GER SR SR 
ALL30 10.5 F 83 47XX, t(12;21) GER SR SR 
ALL31 11 F 73 46XX, der 19 , t(1;19) GER SR SR 
ALL32 0.5 F 44.7 t(4;11) GPR NK SR 
ALL33 3 M 43 Hyperdiploid GER SR SR 
ALL34 10 M 15.8 t(12;21) GER HR NK 
ALL35 2 F 41 Hyperdiploid GER HR HR 
ALL36 16 F 60 46XX, t(2;12), p1p13(8) GER HR HR 
ALL37 2 F 45 Hyperdiploid GER HR HR 
ALL38 5 F 15 Normal GER HR SR 
    Key: 
    CR: Complete Remission 
    GER: Good early response (<25% blasts at day 8/15) 
    PER: Poor early response   (>25% blasts at day 8/15) 
    HR: High Risk (leukaemia cells detected >0.01%)  
    SR: Standard Risk (leukaemia cells not detected at 0.01%)  
    Ind:  Indeterminate  
    NK: Not known  
 
Table 4.6 Clinical and biological characteristics of primary ALL panel 
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4.6.1 Sensitivity of primary ALLs to TKIs at 1µM and 10µM 
Consistent with results from the cell line screen, there was heterogeneity in response to the 
inhibitors. Tables 4.7a and b summarise the responses of the 20 primary ALLS to each TKI 
at the 1µM concentration.  A total of 23/33 compounds reduced cell viability by greater than 
50% in 15 primary samples at 1µM and 25/33 reduced viability by greater than 50% at 
10µM.  Fig 4.11 demonstrates the number of primary leukaemias responding to each 
inhibitor at 1µM and the increase in responders at 10µM.  
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 ALL16 ALL20 ALL21 ALL22 ALL23 ALL24 ALL25 ALL26 ALL27 ALL28 
ABT869 95(5) 26(4) 106(54) 98(7) 129(11) 112(1) 138(51) 132(2) 106(31) 100(13) 
AG-490 121(4) 72(4) 112(5) 89(8) 106(3) 115(8) 77(20) 90(5) 67(17) 102(16) 
Axitinib 128(10) 57(4) 107(23) 97(14) 141(4) 133(8) 91(27) 146(2) 73(20) 131(30) 
AZD0530 134(11) 80(7) 87(40) 104(3) 110(11) 193(13) 95(3) 106(2) 139(10) 193(18) 
BIBF1120 80(5) 48(6) 92(5) 72(4) 100(5) 152(26) 52(14) 76(6) 57(3) 100(37) 
BIBW-2992 38(4) 23(3) 54(14) 51(3) 67(2) 71(9) 66(10) 88(5) 58(21) 47(7) 
Bosutinib 132(2) 20(3) 93(3) 110(15) 91(11) 176(12) 91(6) 59(2) 66(5) 104(15) 
Brivanib 107(9) 86(1) 107(11) 79(7) 99(6) 148(21) 128(10) 99(3) 88(6) 103(13) 
Cediranib 122(11) 59(9) 116(6) 93(17) 119(6) 133(4) 112(14) 124(2) 110(39) 319(50) 
CEP-701 45(3) 16(6) 84(8) 82(14) 100(4) 148(6) 64(12) 66(4) 34(9) 100(16) 
CI-1033 34(1) 52(5) 60(6) 40(4) 83(4) 118(5) 80(15) 108(9) 62(14) 44(2) 
CP690550 114(8) 67(6) 112(12) 60(13) 99(4) 133(7) 104(3) 87(4) 113(22) 100(5) 
Dasatinib 159(8) 15(7) 106(9) 202(6) 94(8) 243(44) 76(10) 94(3) 156(52) 382(72) 
Dovitinib 57(1) 9(1) 66(8) 55(7) 51(3) 121(10) 68(11) 14(1) 60(8) 49(7) 
Foretinib 13(2) 18(5) 73(5) 46(4) 76(1) 55(3) 63(13) 140(14) 20(3) 75(10) 
GSK1904592A 114(4) 99(2) 126(12) 88(10) 97(5) 105(12) 109(35) 95(11) 97(22) 99(6) 
Imatinib 108(8) 60(4) 107(19) 95(10) 92(8) 157(28) 94(38) 76(2) 95(22) 106(4) 
Masitinib 126(4) 42(2) 96(11) 82(2) 98(2) 149(17) 78(25) 104(11) 136(36) 142(13) 
Motesanib 108(8) 57(2) 115(17) 85(12) 95(3) 163(31) 95(9) 76(4) 116(22) 120(7) 
Nilotinib 114(11) 100(2) 103(9) 110(8) 81(9) 132(34) 120(15) 97(8) 64(17) 87(10) 
NVPAEW541 116(5) 108(19) 155(44) 101(7) 104(10) 134(12) 87(6) 84(4) 144(37) 113(2) 
NVPTAE684 17(3) 21(4) 92(7) 76(4) 104(12) 111(3) 126(18) 44(5) 42(13) 66(26) 
Pazopanib 119(9) 53(9) 92(4) 87(11) 98(13) 210(44) 96(16) 84(7) 171(36) 89(8) 
PF-04217903 107(9) n/a 119(15) 96(8) 107(3) 129(13) 121(31) 90(8) 89(11) 113(10) 
PF-2341066 41(3) 41(5) 77(9) 64(5) 96(4) 74(9) 78(3) 111(12) 197(51) 73(13) 
PHA739358 109(10) 107(30) 113(2) 92(8) 98(14) 150(12) 122(35) 46(2) 110(22) 88(4) 
Sorafenib 122(3) 77(7) 101(3) 103(18) 108(15) 150(9) 53(12) 193(21) 53(6) 105(4) 
Sunitinib 90(11) 16(2) 97(8) 68(13) 105(10) 65(5) 77(14) 44(3) 96(7) 87(2) 
Tandutinib 126(9) 70(9) 110(2) 75(8) 104(4) 124(13) 86(12) 70(11) 102(10) 97(17) 
TIE2 114(8) 36(2) 104(4) 87(13) 91(12) 65(4) 106(23) 175(21) 49(6) 108(11) 
Vandetanib 117(52) 52(3) 93(6) 95(3) 96(9) 188(22) 82(17) 90(3) 164(37) 91(6) 
Vatalinib 109(1) 65(15) 101(12) 71(3) 96(3) 97(10) 109(10) 87(8) 46(11) 92(9) 
VX680 98(8) 63(5) 102(14) 106(9) 107(13) 84(4) 137(24) 82(8) 118(7) 95(17) 
 
   Key:  
 
 
 
 
 
 
 
  
 
 
Table 4.7a Summary of responses of primary ALLs to TKI panel at 1µM. The percentage of cell viability of 
primary ALLs after 48 hours incubation with 1µM of TKI is expressed in this table. It is the mean reading of 
cells in triplicate, with standard deviation in parentheses. The highlighted data are those TKIs which 
demonstrate over 50% cell killing in specific cell lines. 
 
 
  Percentage of cell viability at 1µM ≤50% = TKI of interest 
   
  Percentage of cell viability at 1µM <50% but no further  reduction at 10µM 
   
  Percentage of cell viability at 1µM >50% 
   
  Technical failure 
   
  Primary ALL which did not demonstrate sensitivity to any TKI 
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 ALL29 ALL30 ALL31 ALL32 ALL33 ALL34 ALL35 ALL36 ALL37 ALL38 
ABT869 66(31) 84(10) 59(1) 93(7) 109(13) 150(9) 78(10) 88(17) 87(11) 101(5) 
AG-490 125(16) 55(17) 50(14) 87(10) 107(34) 100(4) 90(8) 101(13) 91(13) 100(14) 
Axitinib 124(26) 91(2) 59(7) 259(255) 136(9) 231(31) 151(24) 70(4) 108(9) 79(22) 
AZD0530 58(22) 101(69) 50(3) 85(20) 117(54) 142(14) 104(7) 100(31) 92(10) 144(13) 
BIBF1120 76(11) 41(16) 58(7) 98(28) 41(14) 63(8) 107(19) 49(10) 66(11) 31(10) 
BIBW-2992 9(3) 59(17) 36(6) 92(10) 123(31) 25(2) 69(10) 57(3) 62(7) 30(4) 
Bosutinib 49(6) 94(4) 57(5) 95(9) 94(32) 108(20) 123(5) 61(8) 83(2) 33(1) 
Brivanib 116(28) 73(16) 49(6) 101(5) 123(17) 99(17) 105(7) 85(17) 106(1) 87(6) 
Cediranib 110(9) 74(13) 70(10) 94(8) 101(12) 146(22) 147(7) 102(11) 102(7) 78(10) 
CEP-701 45(4) 60(10) 74(12) 77(16) 45(12) 32(13) 78(3) 54(7) 60(4) 26(5) 
CI-1033 6(1) 79(82) 37(4) 73(10) 59(15) 17(1) 83(3) 42(20) 50(3) 63(7) 
CP690550 110(9) 59(13) 51(7) 94(9) 118(23) 113(70) 121(7) 126(42) 93(5) 140(22) 
Dasatinib 34(8) 85(9) 67(5) 93(1) 306(45) 165(11) 266(21) 68(9) 139(2) 155(32) 
Dovitinib 28(5) 76(18) 34(3) 64(2) 89(1) 41(3) 43(3) 69(15) 29(1) 65(8) 
Foretinib 20(5) 56(4) 37(1) 78(8) 57(31) 33(5) 88(13) 82(7) 64(1) 18(2) 
GSK1904592A 141(19) 94(8) 58(1) 92(17) 72(31) 112(31) 112(21) 84(5) 98(2) 117(27) 
Imatinib 111(18) 109(10) 57(6) 134(68) n/a 128(33) 102(4) 94(21) 101(2) 104(9) 
Masitinib 104(2) 91(11) 58(6) 96(6) 105(9) 102(7) 130(20) 91(19) 98(4) 112(13) 
Motesanib 118(15) 60(11) 53(4) 91(16) n/a 120(25) 115(12) 100(13) 104(3) 113(12) 
Nilotinib 107(19) 132(19) 44(4) 104(13) 83(17) 122(8) 169(4) 57(3) 92(1) 66(3) 
NVPAEW541 142(15) 110(9) 52(5) 108(22) 106(11) 95(5) 105(12) 112(32) 102(8) 99(14) 
NVPTAE684 51(6) 45(11) 48(4) 67(35) 175(38) 26(1) 53(1) 103(44) 59(2) 37(7) 
Pazopanib 141(27) 145(31) 44(5) 91(2) 114(25) 151(19) 122(9) 82(9) 103(6) 96(31) 
PF-04217903 159(26) 104(17) 46(4) 118(35) 94(8) 90(6) 104(3) 99(10) 103(3) n/a 
PF-2341066 57(11) 46(6) 49(4) 69(35) 76(10) 23(20) 88(10) 59(6) 75(5) 39(3) 
PHA739358 87(11) 80(4) 50(1) 94(5) 78(8) 80(3) 70(1) 92(8) 94(4) 150(41) 
Sorafenib 97(12) 106(6) 77(8) 97(12) 71(12) 143(30) 153(6) 71(6) 92(2) 34(8) 
Sunitinib 93(4) 117(12) 54(4) 106(9) 116(4) 67(6) 67(8) 105(6) 77(6) 53(10) 
Tandutinib 137(16) 99(17) 58(5) 99(13) 91(14) 116(27) 104(12) 93(6) 91(1) 130(22) 
TIE2 50(7) 78(15) 60(3) 94(17) 95(19) 61(5) 155(29) 72(11) 76(1) 33(9) 
Vandetanib 71(6) 83(9) 56(4) 86(16) 79(20) 113(5) 145(15) 89(7) 92(3) 93(13) 
Vatalinib 89(14) 58(36) 65(4) 99(2) 82(27) 81(16) 82(6) 84(4) 87(3) 72(14) 
VX680 104(10) 142(72) 71(7) 103(8) 110(40) 101(13) 89(2) 112(11) 89(3) 79(7) 
 
Key:  
 
 
 
 
 
 
 
  
 
 
 
Table 4.7b Summary of responses of primary ALL cells to TKI panel at 1µM. The percentage of cell viability 
of primary ALLs after 48 hours incubation with 1µM of TKI is expressed in this table. It is the mean reading of 
cells in triplicate, with standard deviation in parentheses. The highlighted data are those TKIs which 
demonstrate over 50% cell killing in specific cell lines. 
 
  Percentage of cell viability at 1µM ≤50% = TKI of interest 
   
  Percentage of cell viability at 1µM <50% but no further reduction at 10µM 
   
  Percentage of cell viability at 1µM >50% 
   
  Technical failure 
   
  Primary ALL which did not demonstrate sensitivity to any TKI 
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Figure 4.11 Number of primary cells demonstrating activity at 1µM reveals no global inhibition by a single 
TKI. Dose – dependent reduction in viability in primary cells was induced by 25/33 TKI when inhibitor 
concentration was increased to 10 µM.  
 
Overall, 15/20 primary leukaemias exhibited sensitivity to any of the TKIs at 1µM, of which 
14 responded to ≥2 compounds. As expected, given the heterogeneity of ALL, there were 
no inhibitors were active against all primary ALLs at 1µM. This finding was in contrast to 
the cell line experiments previously performed, where bosutinib, CEP-701 and dovitinib 
inhibited viability in all 5 cell lines.  Two of these agents, CEP – 701 and dovitinib, had the 
broadest activity in the primary ALLs, inhibiting 8 and 7 ALL respectively. Bosutinib, in 
contrast, demonstrated limited inhibition in only 3/20 primary ALLs.   At 10µM, all of the 
primary ALLs demonstrated sensitivity to a range of TKIs, with each ALL responding to an 
average of 17 different inhibitors (range 8 – 25). 
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TKI Putative targets Primaries Cell lines 
Foretinib VEGFR1 -3, PDGFRαβ, CSF1R, FLT3, KIT, FGFR1, Tie -2, Met, 
Ron, Axl 
8/20 4/5 
Dovitinib VEGFR1 -3, PDGFRαβ, CSF1R, KIT, FGFR1, FLT-3 8/20 5/5 
NVPTAE684 ALK, FLT3 8/20 1/5  
CI-1033 EGFR/HER2 8/20 2/5 
BIBW2992 EGFR/HER2 7/20 2/5 
CEP-701 FLT3, VEGFR1 -2, TrkA, RET 7/20 5/5 
PF-2341066 Met, ALK 6/20 3/5 
BIBF1120 VEGFR1 -3, PDGFRαβ, CSF1R, KIT, FGFR1 - 4, FLT3 5/20 2/4 
TIE2 Tie-2 4/20 0/5 
Bosutinib Axl, Abl, Src 3/20 2/5 
Dasatinib PDGFRαβ, CSF1R, KIT, Abl, Src 2/20 2/5 
PHA739358 Aurora kinase, RET 2/20a 2/5 
Sunitinib VEGFR1 -3, PDGFRαβ, CSF1R, FLT3, KIT 2/20 0/5 
ABT869 VEGFR1 -3, PDGFRαβ, CSF1R, FLT3, KIT 1/20 1/5 
Brivanib VEGFR1 -3, PDGFRαβ, CSF1R, KIT 1/20 0/5 
Vatalinib VEGFR1 -3, PDGFRαβ, CSF1R, KIT 1/20 0/5 
Sorafenib VEGFR1 -3, PDGFRαβ, CSF1R, FLT3, KIT 1/20 0/5 
Pazopanib VEGFR1 -3, PDGFRαβ, CSF1R, KIT 1/20b 0/5 
Nilotinib PDGFRαβ, CSF1R, KIT 1/20 0/5 
Masatinib  PDGFRαβ, KIT 1/20 0/5 
PF – 04217903 Met 1/20 0/5 
AZD0530 Abl, Src, EGFR 1/20 1/5 
AG-490 JAK2, EGFR 1/20 0/5 
 
a – PHA739358 demonstrated >50% reduction in cell viability at 1µM in ALL26 – GFER and ALL31 – KMER 
but did not demonstrate a further reduction at 10µM 
b – Pazopanib demonstrated >50% reduction in cell viability at 1µM in but did not demonstrate a further 
reduction at 10µM 
 
Table 4.8 Summary of TKI which demonstrated ≥50% reduction at 1µM and further reduction at 10µM in 
20 primary samples. The TKIs highlighted in grey demonstrate activity in at least 5/20 primary ALLS.  
   
 
Table 4.8 ranks the TKIs exhibiting activity in the primary ALLs at 1µM and compares with 
the effect in the cell lines.  Consistent with the responses observed in the cell lines, the 8 
most active TKIs could be categorised into 3 groups: (i) multikinase inhibitors with FLT3 
activity (foretinib, CEP701, dovitinib and BIBF1120), (ii) EGFR/HER2 quinazoline 
irreversible inhibitors (BIBW-2992 and CI - 1033) and (iii) combined Met/ALK inhibitors 
(NVPTAE684 and PF – 2341066). The greatest number of primary samples affected by a 
single TKI at nanomolar doses was 8 leukaemias. Four TKIs induced a significant amount 
of cell killing in the most ALL samples (n=8 for all four drugs); these included foretinib 
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(FLT3/Met/ PDGFR/VEGFR), dovitinib (FGFR/FLT3/PDGFR/VEGFR), NVPTAE684 
(Met/ALK/FLT3) and CI – 1033 (EGFR/HER2).    
 
The TKIs which had the broadest effect across the primary ALLs were those including FLT3 
– inhibitory activity; foretinib (n=8), dovitinib (n=8), CEP – 701 (n=7) and BIBF1120 (n=5). 
BIBF1120, which demonstrated activity restricted to Ph+ cell lines, was active in 5/20 
primary leukaemias; none of the cohort were Ph+.  
  
NVPTAE684 (ALK/Met/FLT3) and CI – 1033 (pan – EGFR) also exhibited broad activity, 
inhibiting 8/20 leukaemias. This was in contrast to the cell line screen, in which the activity 
of CI – 1033 and NVPTAE684 was limited. 
 
The characteristics of the primary ALLs that were most sensitive and most resistant to  the 8 
TKIs (foretinib, dovitinib, NVPTAE684, CI – 1033, BIBW – 2992, CEP – 701, PF – 2341066 
and BIBF1120) selected as having the greatest activity against the full panel were compared 
to assess whether any features might correlate with response.  No statistically significant 
differences between these 2 groups were found when comparing age, WCC, cytogenetics, 
MRD status determined by flow and PCR techniques (table 4.9).  
 
In summary, in the TKI library used in this study, compounds with activity against EGFR 
RTK families or FLT3/PDGFR/FGFR/VEGFR (multikinase) demonstrated the broadest 
activity in primary ALLs. This spectrum of activity was comparable to that observed in the 
cell line screen.  
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Table 4.9 Correlation of TKIs responses to the clinical and biological features of leukaemias.  No 
significant correlations were observed between response to TKI and biological or clinical parameters.   
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4.6.2 Resistance of primary ALLs to TKI at 1µM and 10µM  
Table 4.10 shows the 16/33 TKIs screened in the primary samples which did not reduce cell 
viability by greater than 50% at 1µM and 10µM.  All primary ALLs tested were resistant to 
both JAK inhibitors at 1µM and furthermore, 18/20 did not respond to AG – 490 and 18/19 
were resistant to pan – JAK inhibitor CP – 690550 at 10µM. Similarly, all primary ALLs 
were resistant to both IR/IGF – 1R inhibitors, GSK1904592A and NVPAEW541, at 10µM. 
 
TKI Putative Targets No. Primary cells not 
responding 
IR/IGF – 1R inhibitor  
NVPAEW541 IGF-1R/Insulin 20/20 
GSK1904592A IGF-1R/Insulin 20/20 
JAK inhibitor  
AG-490 JAK2 and JAK3, EGFR 18/20 
CP-690550 JAK 1 – 3 18/19* 
Aurora kinase inhibitor  
PHA739358 Aurora A – C, Abl, Src, RET 20/20 
VX-680 Aurora, Abl, Src, FLT3 18/20 
Multikinase inhibitors with no FLT3 – activity 
Pazopanib VEGFR1 -3, PDGFRβ, CSF1R, Kit, FGFR1 19/20 
Axitinib VEGFR1 -3, PDGFRα/β, CSF1R, Kit, FGFR1 18/19* 
Brivanib VEGFR 1 – 3, FGFR1 – 3 19/20 
Motesanib VEGFR 1 – 3, PDGFRα, Kit, RET 14/20 
Restricted inhibitors 
Imatinib Kit, Abl, Arg, PDGFRα/β, CSF – 1R 18/19* 
Nilotinib Abl ,Arg, PDGFRβ, Kit 14/20 
AZD0530 Src, Kit, EGFR 16/20 
PF04217903 Met 15/18* 
FLT3 – specific inhibitor  
Tandutinib FLT3, Kit, PDGFRβ 17/20 
  
*Reduced denominators because of technical failures. 
 
Table 4.10 Summary of 16 TKIs which did not induce greater than 50% reduction in viability at 10µM. All 
TKIs tested against 20 primary cells unless otherwise stated. 
 
The aurora kinase inhibitors VX680 and PHA739358 did not show any high level of activity 
in the primary ALL panel. Only 3/20 primary ALLs responded to VX680 at the 10µM 
concentration and none of the 20 primary ALLs demonstrated any response to PHA739358. 
This lack of Aurora Kinase inhibitor activity is consistent with the cell line results, where 
Aurora Kinase inhibitor activity was demonstrated only in the Ph+ cell lines. As none of the 
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primary ALLs was Ph+ this activity of the Aurora Kinase inhibitors could not be confirmed 
in primary cells. 
 
Other relatively inactive TKIs included pazopanib (CSF-1R/FGFR/Kit / PDGFR/VEGFR), 
axitinib (CSF-1R/FGFR /Kit/PDGFR/VEGFR) and brivanib (FGFR/VEGFR). These 3 
inhibitors, originally designed as anti – angiogenic agents, demonstrate activity against 
FGFR and VEGFR. Inhibitors with dominant activity limited to the IGF-1R, JAK and Met 
pathways were amongst the least active against cell lines and the primary ALLs, suggesting 
that these pathways are not major targets for the primary ALL cohort screened in this 
study. 
 
Primary ALLs were highly sensitive to the multikinase TKIs foretinib, dovitinib and CEP – 
701 which all target FLT3. Activity against FLT3 has not been demonstrated in kinase 
assays at doses under 1µM for axitinib (331) or 20µM for pazopanib (390).  These data are 
consistent with FLT3 being an important target for primary ALL. Contrary to this, the more 
restricted FLT3 inhibitor tandutinib, failed to reduce viability in 17/20 primary ALL 
screened, even at 10µM.  Twelve of these 17 demonstrated inhibition by other putative 
FLT3 inhibitors at 1µM (table 4.7a and b).  Resistance to tandutinib was also evident in the 
cell lines, with only SD – 1 exhibiting an appreciable response at 10µM. The discrepancy in 
activity exhibited by the FLT3 – inclusive multikinase TKIs and tandutinib may be due to 
the differing capabilities of these drugs to inhibit wild type and mutant receptors (338), 
with tandutinib more active against FLT3 mutant receptors. 
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4.6.3 Comparison of putative targets of most and least active inhibitors in primary  
 ALLs  
To further elucidate which targets may have therapeutic value in ALL, putative targets of 
the 9 most active inhibitors were compared with the targets of the 12 TKIs which did not 
inhibit viability greater than 50% at 10µM in at least 17/20 primary leukaemias (see fig 4.12).   
 
                                 
 
Figure 4.12 Venn diagram comparing putative targets of TKIs with activity at 1µM to those with no 
significant activity at 10µM in primary ALL samples.  Similar patterns of activity were demonstrated in the 
cell line and primary ALL experiments, with limited impact on survival from TKIs inhibiting the JAK, 
Insulin/IGF – 1R and Aurora kinase pathways.  
 
The putative targets limited to the TKIs with activity at 1µM included ALK, Axl, HER2, 
Ron and Tie – 2, while the targets limited to those inhibitors which did not induce 
responses at 10µM were JAK 1/3, Insulin/IGF1-R and Aurora kinases (fig 4.15). The targets 
which were common to both TKI responses were the same as those present in the cell lines. 
 
 
To date, there is only limited published evidence of the relevance of HER2, Trk and Axl in 
ALL. The protein expression of HER2 in chemoresistant ALL has been demonstrated in 
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small studies (391, 392) and surface expression Trk family members in adult ALL has 
recently been reported (268). The overexpression of Axl in leukaemias with normal 
cytogenetics and MLL – rearrangements was reported in a study defining the gene 
expression profiles of adult leukaemias(223), but has not been reported in childhood ALL.  
ALK, Ron and Tie – 2 over-expression have not been reported in childhood ALL.   
 
In summary, these results suggest a limited role for JAK, Aurora kinases, IGF – 1R, and Abl 
as targets in the treatment of paediatric non – Ph + ALL, whereas Axl, ALK, HER2, Ron, Tie 
- 2 or Trk A may play a role. 
 
4.6.4 Sensitivity of primary ALLs to TKIs with activity at 10µM alone  
To ensure that no potentially important targets were omitted the spectra of activity of the 
TKIs which demonstrated a significant dose – dependent response, reducing cell viability 
greater than 50% at 10 µM in all 20 primary cells, were assessed. Of the 33 TKIs, a total of 6 
TKIs fulfilled these criteria, namely bosutinib, dovitinib and foretinib, the FLT3 – inhibitor 
sorafenib (B – Raf/FLT3/Kit/PDGFRβ/VEGFR2 – 3) and the VEGFR inhibitors, cediranib 
(VEGFR1-3/CSF-1R/PDGFRα/β/Kit/FGFR1) and vandetanib (VEGFR1-3/EGFR/RET). A 
further 8 TKIs demonstrated activity in 18 or more of the primary cells, and these were the: 
(i) FLT3 – inclusive inhibitors (BIBF1120, CEP – 701, NVPTAE684 and sunitinib), (ii) the 
EGFR/HER2 quinazolines (BIBW – 2992 and CI – 1033) and (iii) the restricted inhibitors 
masatinib (Kit/PDGFR) and PF – 2341066 (Met/ALK). Therefore, apart from B – Raf, no 
additionally potentially active targets were identified (fig 4.13).    
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Figure 4.13Venn diagram comparing putative targets of TKIs with activity only at 10µM to those with no 
significant activity at 10µM in primary ALL samples. Similar patterns of activity were demonstrated in the 
cell line and primary ALL experiments, with limited impact on survival from TKIs inhibiting the JAK, 
Insulin/IGF – 1R and Aurora kinase pathways. 
 
4.6.5 Association of clinical features of leukaemias sensitive to TKI 
The relationship between the specific targets identified in the primary leukaemia as 
sensitive to TKIs and clinical features of the primary cells, including MRD status, 
cytogenetics, age and white cell count was investigated.  
 
4.6.5.1 Association of MRD status with proportion of leukaemias sensitive to TKIs 
Details of flow MRD status were available for 16 samples and molecular MRD status for 19 
samples. The samples were stratified by high and standard MRD risk. No significant 
association was observed between the MRD status, either detected by flow cytometry or 
PCR, and responses to TKIs (table 4.11). 
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 Flow MRD  Molecular MRD  
TKI Standard 
risk 
(n=7) 
High 
risk 
(n=9) 
Not 
known  
(n=4) 
Fisher’s exact 
(p-value) 
Standard 
risk 
(n=12) 
High 
risk 
(n=7) 
Not 
known 
(n=1) 
Fisher’s exact 
(p-value) 
ABT-869 0 0 1 n/a 1 0 0 1 
AG-490 1 0 0 0.44 1 0 0 1 
AZD0530 1 0 0 0.44 1 0 0 1 
BIBF1120 2 2 1 1 4 1 0 0.6 
BIBW-2992 3 2 2 0.6 6 1 0 0.17 
Bosutinib 1 1 1 1 3 0 0 0.26 
Brivanib 1 0 0 0.44 1 0 0 1 
CEP-701 3 2 2 0.6 5 2 0 0.66 
CI-1033 4 3 1 0.62 5 3 0 1 
Dasatinib 1 0 1 0.44 2 0 0 0.51 
Dovitinib 2 3 3 1 5 3 0 1 
Foretinib 4 2 2 0.30 6 2 0 0.63 
Masitinib 0 0 1 n/a 1 0 0 1 
Nilotinib 1 0 0 0.44 1 0 0 1 
NVPTAE684 3 2 3 0.60 6 2 0 0.63 
Pazopanib 1 0 0 0.44 1 0 0 1 
PF04217903 1 0 0 0.44 1 0 0 1 
PF2341066 3 1 2 0.26 5 1 0 0.33 
PHA739358 1 0 1 0.44 2 0 0 0.51 
Sorafenib 0 1 1 1 1 0 0 1 
Sunitinib 0 0 2 n/a 2 0 0 0.51 
Tie – 2 1 2 1 1 3 1 0 1 
Vatalinib 0 1 0 1 0 1 0 0.39 
 
Table 4.11 Association of MRD risk category with proportion of cells displaying sensitivity to a TKI at 
1µM. No direct associations were identifiable between MRD status and response to specific TKIs.   
 
 
4.6.5.2 Association of cytogenetic finding with sensitivity to TKIs 
Cytogenetic data was available on 20 ALL (table 4.12). No correlation was demonstrable 
between the cytogenetic characteristics and TKI sensitivity.  The FLT3 inhibitors, dovitinib, 
sunitinib and NVPTAE684 demonstrated activity in the MLL – rearranged infant ALL. 
 
 
 
 
 
 
 
                                                                                                   TKI Library Screening  
149 
 
TKI TEL/AML 
(n=5) 
Complex 
(n=1) 
Non-contributory 
(n=6) 
t(1;19) 
(n=2) 
Hyperdiploid 
(n=4) 
MLL 
(n=2) 
p – value 
(Chi 
square) 
JAK inhibitors  
AG-490 0 0 0 1 0 0 1 
CP690550 0 0 0 0 0 0 1 
Insulin/IGF-1R inhibitors  
GSK1904592A 0 0 0 0 0 0 1 
NVPAEW541 0 0 0 0 0 0 1 
EGFR/HER2 inhibitors  
BIBW-2992 3 0 2 1 1 0 0.64 
CI-1033 3 0 2 1 1 0 0.67 
Restricted spectrum inhibitors  
AZD0530 0 0 0 0 0 0 1 
Bosutinib 1 0 2 0 0 0 1 
Dasatinib 1 0 1 0 0 0 1 
Imatinib 0 0 0 0 0 0 1 
Masitinib 0 0 1 0 0 0 1 
Nilotinib 0 0 0 1 0 0 1 
PF-04217903 0 0 0 1 0 0 1 
PF-2341066 3 0 2 1 0 0 0.35 
PHA739358a 0 0 0 0 0 1 1 
TIE-2 1 0 3 0 0 0 1 
Multikinase inhibitor with no FLT3 activity  
Axitinib 0 0 0 0 0 0 1 
Brivanib 0 0 0 1 0 0 1 
Cediranib 0 0 0 0 0 0 1 
Motesanib 0 0 0 0 0 0 1 
Pazopaniba 0 0 0 1 0 0 1 
Vandetanib 0 0 0 0 0 0 1 
Vatalinib 0 0 1 0 0 0 1 
Multikinase inhibitor with FLT3 activity  
ABT – 869 0 0 1 0 0 0 1 
BIBF1120 1 0 3 0 1 0 0.59 
CEP-701 3 0 3 0 1 0 0.44 
Dovitinib 2 0 1 1 3 1 0.52 
Foretinib 3 0 4 1 0 0 0.22 
NVPTAE684 3 0 3 1 0 1 0.14 
Sorafenib 0 0 1 0 0 0 1 
Sunitinib 0 0 1 0 0 1 1 
Tandutinib 0 0 0 0 0 0 1 
VX680 0 0 0 0 0 0 1 
 
a- A reduction in cell viability >50% was detected at 1µM, no dose – dependent response was observed. 
 
Table 4.12 Association of cytogenetics and responses to individual TKIs. No significant relationship was 
identified between the response of leukaemias to TKIs and the somatic cytogenetic findings The cohort 
consisted of 20 leukaemia samples of which 4 had normal cytogenetic analyses, 2 ‘non – contributory’ 
cytogenetic abnormalities, 5 t(12;21), 4 hyperdiploid, 2 MLL – rearranged infant leukaemias, 2 t(1;19) and 1 
sample had 46XY, del9p21p21, monoallelic CDKN2A loss, 13q14 loss.  Of the 2 leukaemias with ‘non – 
contributory’ cytogenetic findings, one had  46XX, t(2;12), p1p13(8) 46XX (2) ETV6 neg and the other was 
46XX, t(3;10) t(9;16) +8 biallelic del p16. 
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4.6.5.3 Association of NCI/Rome criteria with TKI sensitivity  
The panel of primary ALLs was stratified by NCI/Rome age risk criteria (standard risk <10 
years and adverse risk >10 years) and the relationship with TKI sensitivity analysed.  Two 
of twenty samples were infant ALL and were excluded from analysis as they represent a 
separate risk group.  No statistically significant difference was demonstrated. 
 
TKI Targets Age p – value (Fisher’s) 
  1 – 10 (n=12) >10 (n=6)  
Foretinib VEGFR/Met/PDGFR/Ron/FLT3 6 2 0.64 
CI-1033 EGFR/HER2 6 2 0.64 
CEP-701 FLT3/VEGFR/PDGFR/RET/Trk 6 1 0.32 
BIBW-2992 EGFR/HER2 5 2 1 
Dovitinib FLT3/VEGFR/PDGFR/FGFR 5 2 1 
NVPTAE684 ALK/Met/FLT3 4 3 0.63 
PF-2341066 Met/ALK 3 3 0.34 
BIBF1120 VEGFR/PDGFR/FGFR/FLT3 2 3 0.27 
TIE-2 Tie – 2  3 1 1 
Bosutinib Abl/Src/Axl/EGFR/Trk 2 1 1 
Dasatinib Abl/Src/CSF-1R/Kit/PDGFR 1 1 1 
Sorafenib VEGFR/PDGFR/FLT3 1 0 1 
Vatalinib VEGFR/PDGFR 1 0 1 
ABT-869 VEGFR/PDGFR/FLT3 0 1 0.34 
AG-490 JAK 0 1 0.34 
AZD0530 Abl/Src 0 1 0.34 
Brivanib VEGFR/PDGFR 0 1 0.34 
Masitinib Kit 0 1 0.34 
Nilotinib Abl/Src/CSF-1R/Kit/PDGFR 0 1 0.34 
Pazopanib VEGFR/PDGFR 0 1 0.34 
PF-04217903 Met 0 1 1 
PHA739358 Aurora/RET 0 1 0.34 
Sunitinib VEGFR/PDGFR/Kit/FLT3 0 1 0.33 
a- A reduction in cell viability >50% was detected at 1µM, no dose – dependent response was observed 
 
Table 4.13 Association of NCI/Rome age risk criteria with proportion of cells responding to individual 
TKIs (excluding 2 Infant ALL).  TKIs highlighted in grey demonstrated activity in ≥5/20 samples. No 
significant relationships were identified between response to TKI and NCI/Rome risk criteria. Fisher’s exact 
test was used to analyse the proportion of primary ALLs sensitive to each TKI when samples were stratified 
by age. 
 
Finally, the WCC at the time of presentation was assessed to determine if there was 
relationship with the proportion of responses to the TKIs.   NCI/Rome adverse WCC 
features were present in 6 of the leukaemias studied. No statistically significant difference 
was noted in the samples responding to each TKI. 
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TKI Targets WCC 
(x 109/L) 
Fisher's exact test 
(p-value) 
  <50 (n=14) >50 (n=6)  
CEP-701 FLT3/VEGFR1-2/PDGFR/RET/Trk 6 1 0.35 
CI-1033 EGFR/HER2 6 2 1 
Foretinib FLT3/VEGFR/PDGFR/Axl/Ron/Met 6 2 1 
BIBW-2992 EGFR/HER2 5 2 1 
Dovitinib FLT3/VEGFR/PDGFR/CSF-1R/Kit/FGFR 5 3 0.64 
NVPTAE684 FLT3/Met/ALK 4 4 0.32 
PF-2341066 Met/ALK 3 3 0.30 
TIE-2 Tie – 2  3 1 1 
BIBF1120 FLT3/VEGFR/PDGFR/FGFR/Src 2 3 0.13 
Bosutinib Abl/Src/Axl/EGFR/Trk 2 1 1 
Dasatinib Abl/Src/CSF-1R/Kit/PDGFR 1 1 0.52 
Sorafenib FLT3/VEGFR 1 0 1 
Vatalinib VEGFR 1 0 1 
ABT-869 FLT3/CSF-1R/Kit/VEGFR/PDGFR 0 1 0.3 
AG-490 JAK/EGFR 0 1 0.3 
AZD0530 Abl/Src 0 1 0.3 
Brivanib VEGFR/FGFR 0 1 0.3 
Masitinib CSF-1R/Kit/PDGFR 0 1 0.3 
Nilotinib Abl/CSF-1R/Kit/PDGFR 0 1 0.3 
Pazopanib VEGFR/PDGFR 0 1 0.3 
PF-04217903 Met 0 1 0.3 
PHA739358 Aurora/Abl/Src/RET 0 2 0.08 
Sunitinib FLT3/CSF-1R/Kit/PDGFR/VEGFR 0 2 0.08 
 
Table 4.14 Association of WCC standard and adverse risk criteria with proportion of TKIs displaying 
nanomolar activity to individual TKIs.  TKIs highlighted in grey demonstrated activity in ≥5/20 samples. No 
significant relationships were identified between response to TKI and NCI/Rome risk criteria. 
 
Overall the TKI library screen of the 20 primary ALLs revealed multikinase inhibitors with 
FLT3 activity (foretinib, dovitinib, CEP – 701, NVPTAE684) and the irreversible quinazoline 
pan – EGFR inhibitors (BIBW – 2992 and CI – 1033) displayed broad activity across the ALL 
panel.  The sensitivity to TKIs was not related to clinical and biological parameters.    
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4.7 Discussion 
In this study, ALL cell lines and primary cells were screened using a kinase inhibitor library 
to identify compounds which reduce cell viability, to candidate kinase therapeutic targets 
and infer pathways involved in ALL cell survival and proliferation. The library of 
inhibitors was constructed from drugs in early phase trial development to cover as much of 
the kinome as possible. The putative targets of the inhibitors in the library were based on 
the published recognised targets of the inhibitors, typically from in vitro kinase assays.   
 
A drug screening approach assessing the viability of treated cells was adopted because 
cryopreserved cells are of sufficient quality for interrogation and the system is flexible 
enough to include newly available molecules, with the aim of quickly identifying clinically 
applicable compounds for translation into early phase clinical trials. 
An alternative screening approach has been described, using siRNA to interrogate freshly 
harvested leukaemias (263). A limiting factor for this method is the need to obtain fresh 
bone marrow as thawed aliquots of cryopreserved marrow are not of sufficient quality to 
undertake reliable screening (personal communication Dr M. Loriaux, Oregon Health & 
Sciences University). Much like a drug screen, this screening approach is confounded by 
false positive and negatives, through off – targets effects and technical difficulties (393).   
 
Not unexpectedly, no individual TKI was identified which globally inhibited all of the 
primary and cell line leukaemias. Three categories of TKI demonstrated activity in subsets 
of the cell lines and primary cells studied: (i) multikinase inhibitors with FLT3 activity 
(BIBF1120, CEP – 701, dovitinib and foretinib), (ii) the aniline – quinazoline group of EGFR 
inhibitors (BIBW – 2992 and CI – 1033) and (iii) combined Met/ALK inhibitors (NVPTAE684 
and PF – 2341066). The putative targets of these 3 categories were diverse, including the 
EGFR, FGFR, PDGFR and VEGFR families and related classes of RTKs such as CSF – 1R, 
FLT3 and KIT.  In the cell line experiments FLT3 was the common target for TKIs which 
demonstrated activity at 1µM. Although limited to a small cell line panel, the results could 
not demonstrate a relationship between expression of a single RTK transcript and 
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sensitivity to a TKI. This could suggest TKIs are likely to be most effective by 
simultaneously targeting multiple TKs rather than acting on individual kinases.  
 
(i) Multikinase inhibitors with FLT3 activity (BIBF1120, CEP – 701, dovitinib and 
foretinib) 
In both cell lines and primary cells the activity of the FLT3 – inclusive multikinase 
inhibitors (BIBF1120, CEP – 701, dovitinib and foretinib) is of interest as FLT3 is almost 
universally expressed in B – precursor ALL (394, 395). Activating mutations are present in 3 
– 5% of the ALL population (396) with a predominance in the hyperdiploid (8 - 25%) and 
MLL – rearranged infant leukaemias (3 - 20%) (371, 397-399). Furthermore, increased 
activity in these leukaemias may be due to overexpression of wild type receptors (220, 221, 
252).   
 
The role of FLT3 as a therapeutic target has been investigated in childhood ALL. Sensitivity 
to nanomolar concentrations of the FLT3 inhibitors, CEP – 701 and PKC412/midostaurin, 
was demonstrated in ALL cells with high expression of wild type FLT3 transcript 
(hyperdiploid and MLL – rearranged leukaemias) while higher concentrations did not 
inhibit cell lines or primary cells with low FLT3 expression (397, 398, 400).  
 
In this study anti – leukaemic activity was demonstrated by FLT3 – inhibitors in cytogenetic 
subtypes of ALL which have not previously reported, namely ALL with normal karyotype 
and t(12;21). Unfortunately due to limited material the FLT3 status of these leukaemias 
could not be determined. A possible explanation for this unexpected activity is the doses 
used in this study exceed those used in previous in vitro studies by 10 to 20 – fold (397, 398, 
400). A second reason may be the chemical structure and properties of the investigated 
inhibitors are different to those previously investigated in ALL and may thus bind 
irreversibly to the receptors leading to more potent inhibition and activity. Third, the 
higher doses of the FLT3 – inclusive inhibitors may have additional off – target effects 
which could contribute to their efficacy. The secondary kinase profiles of some of the FLT3 
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targeting TKIs used in this study (dovitinib, foretinib, BIBF1120) are different to the 
inhibitors previously investigated in ALL.  Concomitant inhibition of FLT3 with other RTKs 
could lead to a reduced viability of the tumour cells. The FLT3 – inclusive inhibitor CEP – 
701 has an extended kinase inhibitory profile against the Trk family of receptors, which 
have recently been implicated in leukaemogenesis. Expression of Trk A – C has been 
demonstrated in adult myeloid and lymphoid leukaemias (268) and phosphorylated Trk A 
and B were recently identified in childhood ALL (362). Trk may play a role in 
chemoresistance as receptor stimulation increased survival in response to IR – induced 
damage and inhibition abrogated this anti – apoptotic effect. The confirmation of Trk A 
transcript in Nalm 17, REH and SupB15 and the activity of bosutinib (Abl/Src/Axl/Trk) in a 
limited number of non – Ph+ primary cells warrants further investigation.  
 
In contrast to the broad spectrum activity demonstrated by the FLT3 – inclusive 
multikinase inhibitors, the FLT3/Kit/PDGFR inhibitor tandutinib demonstrated limited 
activity at 10µM in the primary cells; only 3/20 were sensitive at this dose in addition each 
of these samples demonstrated sensitivity to at least one other FLT3 inhibitor at nanomolar 
concentrations. This restricted activity may be due to the fact that tandutinib preferentially 
inhibits mutant FLT3 receptors (338, 401) which may suggest that these 3 samples may 
possess mutant receptors. The other 12 samples which were sensitive to FLT3 – inclusive 
multikinase inhibitors were not sensitive to tandutinib.   
 
Overall, the data from this primary screen suggests that there may be role for further 
research into the role of FLT3 – inclusive multikinase TKIs in ALL, in leukaemis that are not 
limited to the hyperdiploid and infant ALL categories.  
 
(ii) Aniline – quinazoline group of EGFR inhibitors (BIBW – 2992 and CI – 1033) 
The second group of TKIs which were active in the cell lines and primary leukaemias were 
the irreversible aniline – quinazoline inhibitors (BIBW-2992 and CI – 1033). The selective 
inhibition of the apoptosis defective cell lines REH and SD -1 initially supported a role for 
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EGFR or HER2 in chemoresistance, but this differential activity did not extend to the 
primary leukaemias, where activity was not restricted to MRD positive leukaemias. While 
HER2 has been described in both adult and paediatric ALL and was associated with poor 
responses to chemotherapy, gene expression of HER2 and EGFR in childhood leukaemias is 
at relatively low levels (391, 392) (chapter 3). The low level of EGFR family expression, 
together with the absence of response to other EGFR/HER2 inhibitors in the cell line screen 
supports the idea of off – target activity by the quinazolines. Further evidence is supplied 
by recent publications reporting the induction of cell cycle arrest and intrinsic apoptosis in 
AML and Jurkat cell lines by CI - 1033, neither of which expresses EGF family receptors at 
protein level (386, 402). These data are in conflict with the initial in vitro kinase assays, 
which demonstrated highly restricted activity of CI – 1033 against the EGFR family of 
kinases (320, 403). Fabian et al. has demonstrated CI – 1033 is significantly more 
promiscuous than originally thought (404), binding up to 36 kinases including members of 
the Abl, Src and Eph receptor family. It is possible that more of these targets are involved in 
cell line biology compared with primary cells. Another possible mechanism of action of 
these TKIs in the ALL cell lines and primary cells could be through FLT3 inhibition as 
Nordigarden et al. (385) demonstrated CI – 1033 induced cell death in primary FLT3 – ITD 
AML cells in vitro and in a murine xenograft model. These data are consistent with the 
original proof of principle experiment with AML – 2 (section 4.2), as both of these inhibitors 
reduced viability of the FLT3 – ITD primary at 1µM.  Thus, the broad activity of CI-1033 
and BIBW – 2992 in the primary cell may be due to FLT3 inhibition, which is corroborated 
by the significant degree of overlap demonstrated by the FLT3 – inclusive multikinase and 
the quinazoline inhibitors. Further work will be required to investigate whether other 
mechanisms of action exist in pre – B ALL. 
 
(iii) Combined Met/ALK inhibitors (NVPTAE684 and PF – 2341066). 
The third group of active inhibitors was the combined Met/ALK inhibitors, NVPTAE684 
and PF – 2341066 which were active in 8 and 6 primary ALL samples respectively. All 6 
primary leukaemias which were sensitive to PF-2341066 were also sensitive to 
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NVPTAE684, suggesting a possible common target. In the cell lines, NVPTAE684 was 
active in only in SD – 1, while REH, SD – 1 and SupB15 were sensitive to PF-2341066. 
Neither ALK nor Met were expressed at mRNA level in the cell lines investigated. While 
NVPTAE684 demonstrates activity against FLT3, PF-2341066 does not have recognised anti 
– FLT3 activity. The primary target of PF-2340166 is Met and expression of this receptor has 
been reported in ALL, most abundantly in t(12;21) ALL  (276). However, contrary to 
providing a survival advantage, stimulation of the receptor by the cognate ligand 
Hepatocyte Growth Factor (HGF) increases sensitivity to doxorubicin – induced apoptosis 
in t(12;21) leukaemia cells. It would appear in the context of t(12;21) it is unlikely that Met 
play an important role in cell survival in ALL. The notion that Met has no significant 
survival role in the ALLs in this study is supported by the limited activity of the restricted 
and potent Met inhibitor, PF – 04217903, in the cell lines and primary cells.  
A pro – apoptotic role for the over-expressed wild type ALK receptor has been 
demonstrated in the T – ALL cell line, Jurkat (405) whereas, the NPM – ALK mutation 
recurrently present in anaplastic lymphoma is a constitutively activate kinase with anti – 
apoptotic properties (218). This mutant form has not been described in ALL, however the 
mechanism of action of NVPTAE684 and PF – 2341066 in this leukaemia screen remains 
uncertain. More detailed kinase profiling of this drug may elucidate the mechanisms of 
action.    
 
Inhibitors to which cell lines and primary cells were resistant to at 10µM  
The cell line and primary screen defined 3 categories of TKIs with limited activity at 10µM 
concentrations suggesting these are not viable targets for treating ALLs in this study. These 
3 groups of TKIs included: (i) IGF – 1R inhibitors, (ii) JAK family inhibitors and (iii) the 
Aurora kinase inhibitors.  
 
(i) IR/IGF – 1R inhibitors 
The lack of response exhibited by the leukaemias in this study to treatment with IR/IGF – 
1R inhibitors correlates with limited activity demonstrated previously in murine preclinical 
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models of ALL and solid tumours (406, 407). However, recent publications have suggested 
that IGF - 1R provides a survival advantage to ALL cells in vitro (408).  Furthermore, 
growth inhibition and induction of apoptosis was also reported in the pre – B ALL cell lines 
Nalm 6, REH and SupB15 after IGF-1R inhibition (409).  A reason for this discrepancy could 
be the concentrations of IGF – 1R inhibitor required to achieve growth reduction or 
apoptosis were higher than those utilised in this study. The demonstration of a limited dose 
– dependent reduction in viability in 5 primary samples from patients with adverse 
features or outcome, including CDKN2A deletion, MLL – rearrangement, a relapse of 
t(12;21) disease and a death from disease, may yet support IGF – 1R as a possible target in 
childhood ALL.  
 
(ii) JAK inhibitors 
The JAK inhibitors also demonstrated limited response in both the cell lines and primary 
cells. Recent description of JAK activation in DS – ALL and high risk leukaemias has 
piqued interest in this pathway. The lack of activity in the primary cell panel to JAK 
inhibitors in this study may due to the primary cells not overexpressing CRLF2 or 
possessing  activating  JAK mutations, both of which are relatively rare events in paediatric 
ALL, only 3% in the unselected ALL population (222).  
 
(iii) Aurora kinase inhibitors (AKIs) 
While investigation of the role of Aurora kinases is not central to this study, the dual 
Aurora kinase/RTK inhibitors, PHA739358 and VX-680, were included in the drug library 
for their putative RTK target inhibition. The lack of activity in both cell lines and primary 
cells by these 2 inhibitors in this study is contradictory to a recent publication, which 
reported the novel Aurora kinase inhibitor, MLN8237, demonstrated activity in murine 
ALL xenografts (410). Although MLN8237 is not in the drug library investigated in this 
study, it has a similar profile of Aurora kinase inhibition to VX – 680 and PHA739358 
(Aurora A – C). The lack of activity in this study may be because the leukaemias assayed do 
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not overexpress the Aurora kinases or they may possess the T217D mutation in Aurora A, 
recognised to induce resistance to AKIs (411).  
 
Overall, in summary of this chapter, while it was not possible to identify an inhibitor which 
uniformly inhibited the cell line and primary leukaemias or implicate a single common 
RTK in the proliferation or survival of ALL, 3 groups of TKIs which demonstrated 
significant activity in cell lines and primary cells were identified. Of the candidate TKIs 
identified in this screen, a decision was made to further explore the compounds foretinib 
and dovitinib in preclinical studies.  This decision was in part based on the broad spectrum 
of activity of foretinib and dovitinib demonstrated in the cell line and primary screens. Both 
compounds demonstrated activity in all cell lines which was not restricted by cytogenetic 
or apoptotic phenotype. In the primary cells, these TKIs were active against the most 
number of samples (n=8).  As demonstrated in this study the TKIs with the most 
promiscuous spectra appear to be most effective and these TKIs have broad inhibitory 
profiles. Despite this promiscuity, early clinical trials have demonstrated these drugs are 
well tolerated and safe (412, 413). The predominant side effects in adult studies are nausea, 
fatigue and hypertension. In addition, previous experience in adults may expedite the 
transfer of these inhibitors to clinical trials in childhood leukaemias. 
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5 Preclinical investigation of the multikinase inhibitors, foretinib and dovitinib  
5.1. Introduction  
The results from the preceding chapter identified 6 TKIs that were candidates for further 
investigation, foretinib (FLT3/Met/PDGFR/VEGFR), dovitinib 
(FGFR/FLT3/PDGFR/VEGFR),          NVPTAE684 (ALK /FLT3/Met), CI – 1033, BIBW2992 
(EGFR/HER2) and CEP – 701(FLT3/Trk A/VEGFR). These TKIs were selected because they 
all were active at 1µM, in at least 7/20 primary ALL samples. 
 
From these candidates, foretinib and dovitinib were chosen for further investigation based 
on the combined evidence of  anti – leukaemic activity in the cell lines and primary cell 
studies and evidence that these TKIs are well tolerated in adult clinical studies and the lack 
of published literature for their use in paediatric ALL. 
 
Foretinib and dovitinib were designed as anti – angiogenic agents, with the principal 
targets PDGFR and VEGFR families (table 5.1). Foretinib was specifically designed to target 
Met, an RTK associated with invasive tumours (414). Foretinib was the first in class Met 
inhibitor entering clinical trials and has completed phase 1 investigation (413). Dovitinib 
has an extended FGFR spectrum of activity, another RTK family associated with 
angiogenesis. 
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Kinase  Dovitinib Foretinib 
Axl - 11 
CSF-1R 36 - 
FGFR1 8 660 
FGFR3 8 - 
FLT3 1 3.6 
KIT 2 6.7 
Met - 0.4 
PDGFRA 200 3.6 
PDGFRB 27 9.6 
Ron - 3 
Tie – 2 - 1.1 
VEGFR 1 10 6.8 
VEGFR 2 13 0.86 
VEGFR 3 8 2.8 
 
    Table 5.1 Kinase targets of foretinib and dovitinib with biochemical IC50 values (nmol/L) (297, 415) 
 
Both TKIs are currently being investigated in clinical trials.  Dovitinib is being investigated 
in phase 2 trials in FGFR1 – expressing breast cancer (416), melanoma (417) and urothelial 
cancer (418). Phase 2 trials are currently underway to investigate the efficacy of foretinib in 
squamous cell carcinoma of head and neck (419) and ‘triple negative’ breast cancer (420). 
Neither of these two TKIs has been investigated in childhood ALL.  
 
5.2. Assessment of responses of ALL cell lines and primary cells to TKIs  
In the cell line screen, both foretinib and dovitinib demonstrated activity against the 
Philadelphia positive cell lines, SD – 1 and SupB15.  Foretinib and dovitinib also inhibited 
8/20 primary leukaemias, none of which possessed the chromosome translocation t(9;22). 
The possibility that foretinib and dovitinib might also inhibit Bcr/Abl led to the inclusion of 
a third Ph+ cell line, TOM – 1; any novel agent demonstrating activity against this 
inherently resistant leukaemia is worthy of further investigation. Assessment of the 
putative RTK targets by RT q – PCR revealed TOM – 1 expressed transcript for FGFR1, 
FLT3, PDGFRB and VEGFR1 at comparable levels to the other cell lines.  
 
To further investigate the potency of these agents, both drugs were re – tested against the 6 
cell lines, Nalm6, Nalm 17, REH, SD – 1, SupB15 and TOM – 1 to detail their dose – 
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response curves. Serial 8 point dilutions of foretinib and dovitinib covering the 
concentration range 0.001 - 10µM were tested. Cell viability was assessed after 72 hours by 
determining alterations in luminescence with Promega CelTitre – Glo® (section 2.11). The 
data presented are the mean of three separate experiments, each repeated in triplicate, with 
error bars representing standard deviation. The dose response curves from the mean of the 
3 experiments were analysed, and the IC50 of the cell lines were calculated by non – linear 
regression using Graphpad Prism vers5. 
 
5.2.1. Foretinib dose response assessment in cell lines  
Fig 5.1 shows the sensitivity profiles of the 6 cell lines investigated.  Nalm 17 (IC50 0.43 µM), 
REH (IC50 0.19µM), SD – 1 (IC50 0.27µM) and SupB15 (IC50 0.27µM) all demonstrated 
sensitivity to foretinib at doses under 1µM. Both the t(9;22) cell line TOM – 1 and t(5;12) 
Nalm 6 were less sensitive to foretinib, although responded at low micromolar 
concentrations. 
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Figure 5.1 Dose response curves of the 6 pre – B ALL cell lines against foretinib. Four of the 6 cell lines 
investigated demonstrated responses to foretinib at nanomolar concentrations, REH (0.19µM), SD – 1 
(0.27µM), SupB15 (0.27µM) and Nalm 17 (0.43µM). The cell lines Nalm 6 and TOM – 1 demonstrated low 
micromolar responses, IC50 1.96µM and 1.84µM respectively. Data presented are the mean of 3 experiments, 
performed in triplicate. Error bars are standard deviations for the mean of the 3 experiments. Curves were 
analysed with Graphpad Prism 5 software to determine the calculated IC50. 
 
 
5.2.2. Dovitinib dose response assessment in cell lines 
Fig 5.2 shows the dose response curves for the cell lines treated with increasing 
concentrations of dovitinib. All 6 cell lines demonstrated greater than 50% reduction in cell 
viability at 1µM. The most sensitive cell line SupB15 exhibited an IC50 0.19µM, whereas the 
most resistant cell lines were Nalm 6 and TOM – 1, with IC50 0.84µM and 0.5µM, 
respectively.    
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Figure 5.2 Dose response curves of the 6 pre – B ALL cell lines against dovitinib. All 6 cell lines investigated 
demonstrated responses to dovitinib at nanomolar concentrations, SupB15 (0.19µM), SD – 1 (0.2µM), REH 
(0.23µM), and Nalm 17 (0.28µM). The cell lines Nalm 6 and TOM – 1 demonstrated low micromolar 
responses, IC50 0.84µM and 0.5µM respectively. Data presented are the mean of 3 experiments, performed in 
triplicate and plotted. Error bars are standard deviations for 3 experiments. Curves were analysed with 
Graphpad Prism 5 software to determine the calculated IC50. 
 
In summary, the potent nanomolar activity observed in the original library screen was 
confirmed for both TKIs. Response to foretinib or dovitinib was not limited to a specific 
cytogenetic subtype or apoptotic phenotype. In general, dovitinib was more potent, except 
in REH, which exhibited a slightly lower IC50 in response to foretinib (0.19 µM cf. 0.23µM). 
 
5.2.3. TKI activity in ALL primary cells (ALL – 20)  
Dose response curves over a dose range 0.01 – 10µM for the sample ALL – 20 which had 
exhibited a response to foretinib and dovitinib at 1µM in the primary cell screen, were then 
determined. Primary cells were incubated with DMSO (0.1% - 0.0001%) to ensure that the 
viability of the primary cells would not be negatively affected by the diluent. No alteration 
in viability was present at DMSO concentration of 0.1% (fig 5.3a). ALL – 20 was slightly 
more sensitive to foretinib (IC50 0.129µM) compared to dovitinib (IC50 0.133µM fig 5.3b).  
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  Figure 5.3a 
 
   
  Figure 5.3b 
 
Figure 5.3 Dose response curves were determined for DMSO, dovitinib and foretinib in primary ALL cells. 
(a) The TKIs were dissolved in DMSO. To assess whether DMSO would have any impact on primary ALL 
viability a dose curve was determined for primary sample ALL – 20 ALL – 20 cells were incubated with 
increasing concentration of DMSO 0.00001 – 0.1% and cell viability estimated by Promega CelTitre – Glo® at 
48h. DMSO did not reduce cell viability of ALL – 20. (b) Dose response curves were detemined for ALL – 20 
against dovitinib and foretinib (0.01 - 10µM). The experiments were performed in triplicate and error bars are 
standard deviation of mean.  
 
In summary, foretinib and dovitinib demonstrated in vitro anti – leukaemic activity in both 
cell lines and primary ALL at nanomolar concentrations, which was not restricted by 
cytogenetic subgroup. 
DMSO 
Foretinib 
Dovitinib 
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5.3. Effects of TKIs on cell cycle profiles of ALL cell lines   
The effects of foretinib and dovitinib on the cell cycle profiles of 6 cell lines were 
investigated. 
  
5.3.1. Effects of foretinib on cell cycle profiles  
Cells were treated with 3 concentrations of foretinib, 0.15µM, 0.5µM and 1µM, and 
alterations in the cell cycle profile assessed at 24, 48 and 72 hours.  These concentrations 
were chosen to assess whether the effects were dose – dependent. The lowest dose was sub 
– IC50 for all cell lines, while 0.5µM and 1µM were above the IC50 of Nalm 17, REH, SD -1 
and SupB15. The 2 most resistant cell lines, Nalm 6 and TOM -1, with micromolar IC50 were 
treated with 5µM foretinib for 48 and 72 hours to further characterise the effects of 
foretinib. All cells were treated with a corresponding concentration of DMSO to act as 
control. 
 
Significant alterations in the cell cycle profile were present in all 6 cell lines at all 
concentrations of foretinib tested. Three patterns of response were observed with foretinib 
concentrations up to 1µM.   
 
The first pattern of response was exhibited by the cell lines REH and SupB15 and 
demonstrated an arrest at G2/M by 24 hours followed by subsequent cell death.  
After the initial cell cycle arrest, there was a reduction in the G2/M peak and subsequent 
accumulation of cells in sub – G1. This finding is consistent with the induction of cell death. 
Cell death increased from 48 to 72 hours and the magnitude of accumulation was dose 
dependent. Some differences in the detail of the pattern of response existed between the 2 
cell lines.  
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Figure 5.4 Foretinib induces significant changes in the cell cycle profile of the REH t(12;21) cell line. 
Incubation with foretinib induces G2/M arrest followed by accumulation of sub – G1 (cell death) in a dose – 
and time – dependent manner. Experiments were performed 3 times, in triplicate. Cell numbers are on y – 
axis and intensity of Propidium Iodide fluorescence is expressed on the x - axis.   
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   24h    48h      72h 
             
 
 
Figure 5.5 Foretinib induces significant changes in the cell cycle profile of the SupB15 t(9;22) cell line. 
Incubation with foretinib induces G2/M arrest followed by accumulation of cells in G1 (cell death) in a dose – 
and time – dependent manner. Experiments were performed 3 times, in triplicate. Cell numbers are on y – 
axis and intensity of Propidium Iodide fluorescence is expressed on the x - axis.   
 
 
The second pattern of response was exhibited by the cell lines, Nalm 17 and SD – 1. 
Following treatment with foretinib, cells accumulated in sub – G1 by 24 hours, with a 
reduction in G1 and S – phases (fig 5.6).  Unlike the cell lines, REH or SupB15, there was no 
concomitant G2/M arrest. Accumulation of sub – G1 cells in the SD – 1 cell line increased as 
the concentration increased from 0.15µM to 1µM, as early as 24 hours. Cell death in 
response to foretinib in SD – 1 was both time – and concentration – dependent.  
 
The induction of cell death in Nalm 17 appeared relatively dose – independent, with a 
similar pattern of cells accumulating in sub – G1 at all time-points (fig 5.7). A similar 
reduction in G1, S and G2/M occurred at all time – points and concentrations. The induction 
of cell death was time – dependent.  
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      24h     48h     72h 
                     
 
 
Figure 5.6 Foretinib induces significant changes in the cell cycle profile of the SD – 1 t(9;22) cell line. 
Incubation with foretinib induces accumulation of cells in the sub – G1 phase (cell death) in a dose- and time – 
dependent manner. Experiments were performed 3 times, in triplicate.  Cell numbers are on y – axis and 
intensity of Propidium Iodide fluorescence is expressed on the x - axis.   
           
 
 
 
 
Figure 5.7 Foretinib induces reduction in G1 and S – phase of Nalm 17 cell lines at all concentration by 24h. 
Foretinib induces significant accumulation of cells in sub – G1 (cell death) by 24h. Experiments were 
performed 3 time times, in triplicate. Cell numbers are on y – axis and intensity of Propidium Iodide 
fluorescence is expressed on the x - axis.   
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The third pattern was observed in the 2 most foretinib – resistant cell lines, Nalm 6 and 
TOM – 1. Neither of these cell lines exhibited significant cell death in concentrations of 
foretinib up to 1µM (fig 5.8a and 5.9a).  Both cell lines demonstrated a reduction in the 
proportion of cells in G1 with a concomitant accumulation of cells in G2/M. The induction 
of G2/M arrest was present by 24 hours at all 3 concentrations of foretinib. Subsequent to 
the cell cycle arrest, a population displaying polyploidy is detectable after 48 hours 
treatment. Foretinib 1µM induced a degree of cell death in Nalm 6, but not TOM – 1. 
 
  24h   48h   72h 
              
 
Figure 5.8a 
 
          
 
 
Figure 5.8b 
Figure 5.8a Foretinib induced significant alterations in TOM – 1 t(9;22) cell line at all concentrations 0.15 - 
1µM. (a) Foretinib induced G2/M arrest in all concentrations, but no increase in cells in the sub – G1 phase, at 
72h incubation the emergence of a polyploid population (8n) was obvious (b) Foretinib induced the 
accumulation of a 8n population of cells (polyploidy) in the TOM – 1 cell line after 24h incubation at all 
concentration. Baseline control cell profile at 24h is described in grey, with alterations in revealed in white.  
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Figure 5.9a  
 
 
  Figure 5.9b 
 
 
Figure 5.9 Foretinib induced significant alterations in Nalm 6 t(5;12) cell line at all concentrations 0.15 - 
1µM. (a) Foretinib induced G2/M arrest in all concentrations, but no increase in cells in the sub – G1 phase (b) 
Foretinib induced the accumulation of a 8n population of cells (polyploidy) in the Nalm 6 cell line after 24h 
incubation at all concentration. Baseline control cell profile at 24h is described in red, with alterations in 
revealed in white.  
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To assess whether doses in excess of the IC50 would induce cell death in these cell lines, 
Nalm 6 and TOM – 1 were treated with 5µM foretinib. Fig 5.10a and 5.10b show the 
accumulation of cells in sub – G1 at 48 hours in Nalm 6 but not in TOM - 1. By 48 hours, 
Nalm 6 growth was abrogated while TOM -1 demonstrates persistent accumulation of 
G2/M.  
   48h   72h  
   
                             
 
        
   
 
                        Figure 5.10a   
 
   48h   72h 
 
                   
 
 
 
Figure 5.10b 
 
Figure 5.10 Higher doses of foretinib (5µM) revealed different impacts on the Nalm 6 and TOM – 1 cell 
lines. (a) Nalm 6 treated with foretinib5µM demonstrated accumulation of dead cells by 72h. (b) TOM – 1 
cells treated with foretinib 5µM demonstrated G2/M arrest, but no accumulation of sub – G1 cells by 72h. 
 
In summary, foretinib induces significant alterations in the cell cycle profiles in all cell lines 
investigated. The induction of cell death was demonstrated in Nalm 17, REH, SD – 1 and 
SupB15 at nanomolar concentrations, while Nalm 6 required micromolar concentrations. 
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TOM – 1 exhibited significant alterations the G2/M transition, with associated polyploidy 
but no cell death.  These data are consistent with the dose response curves in 5.2.1. A 
possible explanation for the heterogeneous patterns of response is foretinib does not work 
through a single target in the cell lines investigated.    
 
5.3.1.1 Emergent population in Nalm 6 and TOM - 1 confirms polyploidy   
To investigate the nature of the polyploid population which was induced by foretinib 1µM 
in Nalm 6 and TOM - 1, the nuclei of these cell lines were stained with DAPI to evaluate 
nuclear changes after 72 hours of foretinib 1µM. Fig 5.11 and 5.12 demonstrate the increase 
in size and the nuclear aggregations seen in nuclei of both Nalm 6 and TOM – 1, consistent 
with polyploidy. The DAPI staining is consistent with the increase in nuclear content 
demonstrated on flow cytometry.   
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Figure 5.11a                       Figure 5.11b  
              
Figure 5.11c          Figure 5.11d  
 
Figure 5.11 Foretinib 1µM induces alterations in nuclear size and aggregation in Nalm 6 and TOM – 1 cell 
lines by 72h. The nuclei increase in size from (a) Nalm 6 control to (b) Nalm 6 Foretinib 1µM 72h and (c) TOM 
-1 control to (d) TOM – 1 1µM 72h. 
 
5.3.2. Effects of dovitinib on cell cycle profiles  
The effect of dovitinib was studied in the 6 cell lines at a single concentration, 1µM, and 
changes in cell cycle profile assessed at 24, 48 and 72 hours.   Significant alterations were 
observed in the cell cycle profiles of all cell lines by 24 hours. Dovitinib induced significant 
cell death in Nalm 17, REH, SD – 1 and SupB15 as early as 24 hours (figs 5.12 and 5.13) and 
progressed in time – dependent manner. 
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Figure 5.12a  
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Figure 5.12b  
 
Figure 5.12 Dovitinib induced significant alterations in Nalm 17 and REH cell lines at 1µM. (a) Dovitinib 
induced profound accumulation of dead cells (sub – G1) in (a) Nalm 17 and (b) REH cell lines.   
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Figure 5.13a 
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Figure 5.13b 
 
Figure 5.13 Dovitinib induced significant alterations in SD – 1 and SupB15 cell lines at 1µM. (a) Dovitinib 
induced profound accumulation of dead cells (sub – G1) in (a) SD -1 and (b) SupB15 cell lines.   
 
 
The G2/M arrest exhibited in response to foretinib was not present in REH or SupB15, but 
was present in Nalm 6 and TOM -1.  Despite the nanomolar IC50 of Nalm 6 and TOM -1, no 
significant cell death was induced at 1µM.  The G2/M arrest induced by dovitinib in Nalm 6 
and TOM -1 did not result in the polyploidy noted in response to foretinib (fig 5.15). 
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Figure 5.14a  
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     Figure 5.14b  
 
Figure 5.14 Dovitinib induced significant alterations in Nalm 6 t(5;12) and TOM – 1 t(9;22) cell lines at 
1µM. Dovitinib induced G2/M arrest in (a) Nalm 6 and (b) TOM - 1 by 24h. No increase in cells in the sub – 
G1 phase was induced in either cell line.  
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Figure 15.5a      Figure 15.5b  
 
Figure 5.15 Dovitinib does not induce polyploidy in (a) Nalm 6 or (b) TOM – 1 after 72h incubation. 
Population of cells shaded in grey represent cell line treated with DMSO 0.1% at 24h. Alterations in cell cycle, 
G2/M, are induced in both cell lines by dovitinib, represented by the white population.  
 
In summary, dovitinib induced profound cell death in 4/6 cell lines and cytostasis in the 
remaining 2 at a single concentration. These data are consistent with the dose response 
curves described in 5.2.2, where the Nalm 6 and TOM – 1 cell lines were least sensitive to 
dovitinib.    
 
5.4. Characterisation of changes in cyclin B1 after foretinib – treatment 
Next the effect of foretinib on proteins involved in the G2/M transition was investigated.  
Normal progression through mitosis requires the accumulation of cyclin B1 and for it to 
bind to cdc2.  The cdc2 – cyclin B1 complex is involved in early mitotic events, such as 
chromosomal condensation, dissolution of the nuclear envelope and assembly of spindle 
poles (421) .  The G1, S and G/2M checkpoints of the cell cycle are governed by p53 and its 
downstream effector p21, the universal cyclin – dependent kinase inhibitor.  The responses 
of cyclin B1, p53 and p21 were characterised by Western Blot to investigate the alterations 
induced by foretinib induced in cell cycle. 
Cell lines were treated with foretinib 1µM and 30µg of cell lysate subjected to SDS – PAGE, 
followed by immunoblotting for cyclin B1 and p53.  
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                                                REH        SupB15 
 
Figure 5.16 Foretinib 1µM induces the reduction in cyclin B1 and variable p53 accumulation in the 
sensitive cell lines, REH and SupB15. Western Blot analysis demonstrated foretinib induced the 
accumulation of p53 and decrease in cyclin B1 in a time – dependent manner in REH and SupB15. Both cell 
lines demonstrated G2/M arrest at 24h, the peak of cyclin B1 expression.   
 
Fig 5.16 shows changes in the expression of cyclin B1 in the 2 cell lines, REH and SupB15, 
following treatment with foretinib, both of which displayed G2/M arrest followed by cell 
death in the cell cycle profile experiments.  Foretinib induces a reduction in cyclin B1 
expression in SupB15 as early as 4 hours and expression continues below baseline at 48 
hours. The expression of cyclin B1 in REH remains stable until 24 hours thereafter it 
decreases significantly. In both cell lines foretinib significantly induced the accumulation of 
total p53 by 24 hours. The increase in p53 correlated with the decreased expression of cyclin 
B1.   
 
In the 2 cell lines which did not demonstrate G2/M arrest, Nalm 17 and SD – 1, cyclin B1 
expression was variable. In Nalm 17, cyclin B1 expression did not alter with foretinib 
treatment up to 48 hours (fig 5.17).  The accumulation of p53 in the Nalm 17 cell line was 
delayed until 48 hours. SD – 1 demonstrated a rapid reduction in expression of cyclin B1 by 
8 hours of treatment, with disappearance by 48 hours. SD – 1 did not exhibit a significant 
accumulation of p53 in response to foretinib.  Maximal p53 expression was evident by 24 
hours, which coincided with the degradation of cyclin B1. The level of total p53 decreased 
thereafter.  
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   Nalm 17     SD – 1 
 
Figure 5.17 Foretinib 1µM induces the variable responses in cyclin B1 and p53 accumulation in the 
sensitive cell lines, Nalm 17 and SD -1. Western Blot analysis reveals foretinib induced accumulation of p53 
in Nalm 17 at 48h, but not in SD – 1. Neither cell line demonstrated G2/M arrest after incubation with 
foretinib.  
 
The cell lines most resistant to foretinib, Nalm 6 and TOM-1, both demonstrated an initial 
increase in cyclin B1, with maximal expression present at 24 hours (fig 5.18). Subsequently, 
the expression decreased below baseline expression by 72 hours.  Both Nalm 6 and TOM – 1 
exhibited marked accumulation of p53 by 24 hours. Nalm 6 exhibited a subsequent 
reduction in intensity with a return to just above baseline levels at 72 hours. The expression 
of p53 in TOM – 1 continued to increase in intensity until 72 hours. 
 
               
                         
    Nalm 6    TOM – 1 
 
Figure 5.18 Foretinib 1µM induces the accumulation and subsequent reduction in cyclinB1 Nalm6 and   
TOM – 1. Western Blot analysis demonstrated foretinib induced G2/M arrest in both cell lines. Significant p53 
accumulation was present in both cell lines in response to foretinib. 
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Western Blots were performed to assess whether the accumulation of p53 lead to an 
increase in the downstream effector p21.  Nalm 6, Nalm 17, REH and TOM -1 (all which 
displayed significant accumulation of p53) were treated with 1µM foretinib and cells were 
harvested after 24, 48 and 72 hours of treatment.   Nalm 6, REH and TOM-1 showed 
induction of p21 after treatment with foretinib, but Nalm 17 did not.  
 
                                            
 
Figure 5.19 Foretinib treatment induces the expression of p21 in a time dependent manner in the cell lines 
which demonstrate G2/M arrest.  Western Blot analysis reveals the foretinib – sensitive cell lines Nalm 17 and 
REH demonstrated differing patterns of p21 accumulation on response to treatment. Both Nalm 6 and TOM – 
1 demonstrated obvious accumulation of p21 on treatment, despite the lack of cell death at the same dose.   
 
5.5. Accumulation of p53 is not due to foretinib – induced DNA damage 
To exclude DNA damage as a mechanism of p53 accumulation, γH2AX foci, a marker of 
DNA double stranded breaks (DSB), were counted after immunofluorescence staining. This 
was evaluated in the Nalm 17 cell line, which accumulated p53 by 48 hours, as the rate of 
proliferation was sufficiently slow to allow visualisation of the γH2AX foci. Nalm 17 cells 
were exposed to 3 conditions: (i) untreated, (ii) irradiation with 2Gy IR to induce DNA DSB 
to act as positive controls and harvested after 2h or (iii) treated with foretinib 1µM for 24h. 
Cells were prepared as described in methods and materials (section 2.15).  One hundred 
cells from 3 separate wells were counted for each condition. The degree of DSB, reflected as 
the percentage of cells with greater than 10 γH2AX foci present assessed. The experiment 
was performed twice. Fig 5.20 shows the increase in γH2AX foci visualised after IR in 
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comparison with the baseline Nalm 17 cells. The fraction of cells that exhibited >10 foci 
increased from 14% (±4.3) to 89% (±9.2) (p = 0.00001) after IR – induced DNA damage.  
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  Figure 5.20a  
 
  Figure 5.20b  
 
Figure 5.20c 
 
Figure 5.20 Visualisation of γH2AX foci reveals accumulation of p53 in response to foretinib is not due to 
DNA DSB. Foci are demonstrated in (a) the untreated Nalm 17 cell line. (b) IR induced significant increases in 
the number of foci in Nalm 17 cells exposed to 2Gy irradiation. (c) No increase in γH2AX foci is evident in the 
Nalm 17 cells treated with foretinib 1µM at 24h.  
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Figure 5.21 The number of cells with greater than 10 γH2AX foci increases after exposure to 2Gy IR, but 
not  foretinib 1µM 24h. The cell line, Nalm 17, revealed a significant increase in the number of γH2AX foci 
after 2Gy irradiation, but not after treatment with foretinib. The experiment data presented is the mean of 2 
experiments, performed in triplicate; error bars are standard deviation.  
 
 
 Baseline 2Gy 1h Foretinib 24h 
γH2AX foci  <10 >10 <10 >10 <10 >10 
Percentage 86 14 11 89 86 15 
Std dev 4.3 4.3 9.2 9.2 3.5 3.5 
 
Table 5.2 Significant increases in γH2AX foci were induced by IR but not foretinib. Cells with greater than 
10 foci increased from 14% to 89% after IR exposure (p = 0.00001) and 14% to 15% after foretinib (p = 0.947) 
 
There was no significant increase in the proportion of cells with >10 foci after 24 hours 
treatment with foretinib (14% (±4.3) to 15% (±3.5), p = 0.947). The lack of accumulation of 
γH2AX foci excluded induction of DNA damage by foretinib as a mechanism of p53 
accumulation. 
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5.6.  Foretinib inhibits the pro – survival  Akt pathway 
The Akt pathway regulates anti – apoptotic and pro – survival functions. To assess whether 
foretinib inhibited the Akt axis, the Nalm and REH 17 cell lines, which are constitutively 
Akt phosphorylated, were treated with foretinib.  Cells were treated with foretinib at IC50 
(Nalm 17 0.43µM and REH 0.19µM) and 1µM and harvested at 24h.  A reduction in the 
level of phosphorylation was evident, which was not associated with a reduction in total 
Akt. This reduction in p-Akt preceded the accumulation of p53.  
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 Figure 5.22a  
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Figure 5.22b 
 
Figure 5.22 Foretinib induces alteration in the p – Akt status of the constitutively activated cell lines Nalm 
17 and REH. Reduction in p – Akt is demonstrated at both IC50 and 1µM in (a) Nalm 17 and (b) REH cell lines. 
 
In summary, foretinib induced changes in the cell cycle profiles of all cell lines. These 
alterations were reflected in differing patterns of accumulation of cyclinB1, p53 and p21.  
Foretinib leads to the reduction of Akt phosphorylation at IC50 concentrations. 
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5.7. TKIs mediate anti – leukaemic effect via apoptosis 
Next, the mechanism of cell death identified in the cell cycle profiles was studied in cell 
lines after treatment with foretinib and dovitinib.  
 
5.7.1. Foretinib induces apoptosis in cell lines  
The ability of foretinib to induce apoptosis in the t(9;22) cell lines SD – 1 and SupB15 was 
evaluated by assessing for DNA fragmentation (354) (section 2.14).  Cells were treated with 
foretinib 1µM and harvested at 24, 48 and 72 hours. Apoptosis was confirmed by the 
presence of 100bp DNA fragments (fig 5.23).   
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Figure 5.23 Foretinib 1 µM induces apoptotic DNA fragmentation in SD – 1 and SupB15. Apoptosis is 
demonstrated by the induction of the 100bp DNA fragments after incubation with foretinib.   
 
To investigate whether the intrinsic or extrinsic apoptotic pathways were activated 
immunoblotting for PARP – 1 cleavage was characterised in cell lines treated with foretinib.  
Cells were incubated with foretinib 1µM and harvested at 24, 48 and 72 hours. The cleavage 
of the PARP -1 protein into its 89kDa and 116kDa fragments confirmed that the cell death 
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was induced by intrinsic pathway apoptosis.  Apoptosis was induced in Nalm 17, REH, SD 
– 1 and SupB15, while neither Nalm 6 nor TOM -1 demonstrated cleavage of PARP – 1 
protein (fig 5.24a and b).   
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Figure 5.24 Foretinib induced PARP – 1 cleavage in pre – B ALL cell lines. (a) Foretinib 1µM induces the 
intrinsic apoptotic pathway in Nalm 17, REH, SupB15 and SD – 1 cell lines. No evidence of intrinsic apoptosis 
was observed in the Nalm 6 and TOM -1 cell lines. These findings correlate with alterations noted in the cell 
cycle profiles.  (b) PARP -1 cleavage is induced in the sensitive cell lines Nalm 17, REH and SupB15 at lower 
doses and shorter time courses.   
 
To investigate whether IC50 concentrations of foretinib could induce apoptosis, the cell lines 
Nalm 17, REH and SupB15 were treated with concentrations of foretinib for 24 hours and 
then assessed for PARP-1 cleavage by immunoblotting (fig 5.24b). REH and SupB15 
demonstrated foretinib – induced apoptosis at IC50 concentrations by 24 hours however 
Nalm 17 did not demonstrate cleavage at the lower dose at the earlier time course. 
 
 
 
Full length PARP – 1  
Cleaved PARP – 1  
Full length PARP – 1 protein 
Full length PARP – 1  
Cleaved PARP – 1  
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5.7.2. Dovitinib induces apoptosis in SupB15 t(9;22) cell line  
To assess the mechanism of cell death in response to dovitinib, a dose response course was 
performed on the cell line SupB15. Cells were harvested after 4 hours incubation with 
dovitinib 0.01 – 1 µM and immunoblotted for cleavage of PARP – 1 protein. The dose 
response course in SupB15 cells reveals PARP – 1 cleavage was present at concentrations as 
low as 0.01µM after 4 hours.  
              
 
Figure 5.25 Dovitinib dose course in the SupB15 t(9;22) cell line demonstrated cleavage  of PARP – 1 
protein. Western Blot analysis demonstrates apoptosis was evident at 4h in doses as low as 0.01µM, by the 
cleavage of PARP - 1. The amount of apoptosis increased in a dose – dependent manner. 
 
In summary both foretinib and dovitinib induces apoptotic cell death in childhood ALL cell 
lines at nanomolar concentrations.  
 
5.8. TKIs demonstrate synergy when combined with conventional chemotherapy  
Because TKIs would not be used as monotherapy in clinical practice the question whether 
the drug could sensitise ALL cells to conventional chemotherapeutic agents used in the 
induction and maintenance phases of current ALL protocols was assessed. The agents 
investigated were the steroid dexamethasone, the anti – metabolites methotrexate, 
cytarabine and fludarabine, DNA – damaging agents (doxorubicin and mitoxantrone) and 
the mitotic spindle poison, vincristine. While fludarabine and mitoxantrone are not used in 
frontline therapy, they are both components in relapse and refractory chemotherapy 
protocols; therefore, modelling interactions may yield clinically significant information. 
 
Full length PARP – 1  
Cleaved PARP – 1  
Actin  
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Foretinib was tested in combination with all 7 chemotherapeutic agents, while dovitinib 
was tested with the agents, dexamethasone, doxorubicin and vincristine, which are used in 
remission – induction regimens.  
 
Interactions between the TKIs and chemotherapy were assessed using the Median Effect 
model of drug – dose effect, as described by Chou – Talalay (351, 352).  Combination 
indices (CI) were calculated using the Calcusyn (BIOSOFT, Cambridge, UK) algorithm and 
the combinations were evaluated as synergistic, additive or antagonistic. A CI < 1 indicated 
synergy, CI = 1 indicated additivity and a CI >1 indicated antagonistic effects. 
 
5.8.1. Foretinib combinations with cytotoxics demonstrate synergy  
To assess the effect of combining TKIs with chemotherapy, dose response curves for each 
cell line were generated for: (i) foretinib/dovitinib alone, (ii) conventional chemotherapy 
alone and (iii) the combination of a fixed sub – IC50 dose of foretinib/dovitinib with an 
increasing dose of chemotherapy.  
 
A concentration for each cell line was established by a dose-finding experiment which 
would reduce cell viability but no more than 50%.  Cell lines which exhibited a nanomolar 
IC50 were treated with dose range 0.1 – 0.5µM to establish a suitable concentration.  Nalm 6 
and TOM – 1 were treated with foretinib 0.1 - 5µM. Fig 5.26a and 5.26b show the dose 
response curves for the cell lines.   
 
The foretinib concentrations for co–treatment were 0.125µM for SD – 1 and SupB15, 
0.175µM for REH and 0.25µM for Nalm 6, Nalm 17 and TOM-1.   
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 Figure 5.26a 
   
 
Figure 5.26b 
 
Figure 5.26 Dose finding response curves for the combination therapy for cell lines (a) Nalm 17, REH, 
SupB15, SD – 1 and (b) Nalm 6 and TOM – 1. Dose response curves were repeated to determine a dose at 
which the TKI induced less than a 50% reduction of cell viability.  
 
Dose response curves were subsequently generated for serial dilutions of chemotherapy 
alone and in combination with fixed dose of foretinib.  
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5.8.1.1 Foretinib in combination with dexamethasone 
Table 5.3 illustrates foretinib was able to sensitise all 6 lines to dexamethasone, with CI <1 
in all cell lines. The cell lines Nalm 6, REH and SD – 1 demonstrated resistance to 
dexamethasone monotherapy in concentrations up to 10µM (fig 5.27a - c).  Antagonistic 
interactions were observed in Nalm 6, SD – 1 and SupB15, but only at combined 
concentrations of foretinib and dexamethasone which had already reduced cell viability 
greater than 50%.  
 
The most significant results were the sensitisation of the steroid – resistant cell lines Nalm 
6, REH and SD – 1 to low concentrations of DXM, 0.01 - 1µM Marked changes in cell 
viability were observed Nalm 17, REH and SupB15, with the combination of foretinib and 
0.001µM dexamethasone reducing cell viability greater than 50% (fig 5.27).   
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Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Dexamethasone 0.001 0.1 0.6 0.7 0.4 0.4 7.9 
(µM) 0.01 0.1 0.5 0.7 0.3 0.6 0.0 
  0.1 0.1 0.4 0.7 0.3 4.6 0.1 
  1 0.8 0.3 0.7 0.5 44.4 0.1 
  10 6.8 0.3 0.7 2.2 442.4 0.1 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Dexamethasone 0.001 +++++ +++ ++ +++ +++ ---- 
(µM) 0.01 +++++ +++ ++ +++ +++ +++++ 
  0.1 ++++ +++ ++ +++ ---- ++++ 
  1 ++ +++ ++ +++ ---- ++++ 
  10 ---- +++ ++ --- ----- ++++ 
         
  Key: 
  
     
   
     
    
 
Table 5.3 Summary of the responses of combination therapy for foretinib and dexamethasone described as 
Combination Indices. Predominant interactions between foretinib and dexamethasone were synergistic in the 
6 cell lines.  
 
 
 
 
 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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  Figure 5.27a 
   
  Figure 5.27b 
   
  Figure 5.27c 
 
Figure 5.27 Foretinib sensitises the steroid – resistant cell lines Nalm 6, REH and SD -1. The red line 
demonstrates the percentage cell viability induced by foretinib alone. For combinations to be synergistic, the 
reduction in viability needs to be below the chemotherapy alone and the red line. Steroid resistant cell lines 
(a) Nalm 6, (b) REH and (c) SD – 1 are sensitised to DXM by foretinib. Points represent the mean of 3 
experiments performed in triplicate, with error bars representing standard deviation.   
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5.8.1.2 Foretinib in combination with the anti – metabolites 
As a class, anti – metabolite monotherapy, demonstrated significant anti – leukaemic 
activity.  Only SD – 1 displayed resistance to any of the anti – metabolic chemotherapies, 
with cell viability remaining at greater than 50% in response to fludarabine 10µM. The 
impact of concurrent treatment with foretinib and the anti - metabolites was predominantly 
synergistic (CI<1) (tables 5.4a and b).  The exceptions were the combination with cytarabine 
in REH and with methotrexate in SD – 1. The effects of concurrent treatment did not appear 
to be class – dependent, as differences in quality of interaction were drug – specific. 
 
SD – 1 displayed disparate responses to each of the drugs (see fig 5.28a – c). Foretinib 
sensitised the fludarabine – resistant cell line to 10µM and displayed synergy with 
cytarabine at concentrations 0.001 – 0.1µM. However, SD – 1 demonstrated no effect on the 
sensitivity to methotrexate at all dose levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                   Preclinical Investigations  
194 
 
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Cytarabine  0.001 0.1 0.5 0.8 0.5 0.3 0.3 
(µM) 0.01 0.3 0.5 1.7 0.7 0.4 0.4 
  0.1 0.4 0.5 6.7 0.6 0.8 0.4 
  1 0.7 0.5 12.5 1.1 2.7 0.5 
  10 2.7 1.9 10.6 1.6 25.6 1.4 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Cytarabine  0.001 +++++ +++ ++ +++ +++ ++++ 
(µM) 0.01 +++ +++ --- ++ +++ +++ 
  0.1 +++ +++ ---- +++ ++ +++ 
  1 ++ +++ ----- ± --- +++ 
  10 --- --- ----- --- ----- --- 
          
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Methotrexate  0.001 0.1 0.4 0.7 2.3 0.3 0.7 
(µM) 0.01 0.1 0.4 0.6 1.1 0.3 1.1 
  0.1 0.2 0.4 0.4 1.9 0.2 0.2 
  1 0.9 0.4 1.2 16.6 0.8 0.3 
  10 7.7 0.3 9.6 152.8 4.7 1.5 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Methotrexate 0.001 +++++ +++ ++ --- ++++ ++ 
(µM) 0.01 +++++ +++ +++ ± ++++ ± 
  0.1 ++++ +++ +++ --- ++++ ++++ 
  1 + +++ -- ----- ++ ++++ 
  10 ---- +++ ---- ----- ---- --- 
         
  Key: 
  
     
   
     
    
 
Table 5.4a Summary of the responses of combination therapy for foretinib and the anti – metabolites 
described as Combination Indices. Data is presented for interactions of foretinib in combination with 
cytarabine and methotrexate. Interactions represent the mean of 3 experiments performed in triplicate.   
 
 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Fludarabine   0.001 0.1 0.5 0.7 0.5 0.3 0.3 
(µM) 0.01 0.1 0.5 0.1 0.6 0.3 0.0 
  0.1 0.1 0.5 1.2 0.6 0.3 0.3 
  1 0.5 0.4 1.0 0.6 0.3 0.4 
  10 3.0 1.7 0.8 0.3 1.4 1.5 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Fludarabine  0.001 +++++ +++ ++ +++ +++ +++ 
(µM) 0.01 +++++ +++ ++++ +++ ++++ ++++ 
  0.1 ++++ +++ - +++ ++++ ++++ 
  1 +++ +++ ± +++ +++ +++ 
  10 --- --- ++ +++ --- --- 
         
  Key: 
  
     
   
     
    
 
Table 5.4b Summary of the responses of combination therapy for foretinib and the anti – metabolite 
fludarabine, described as Combination Indices. Data is presented for interactions of foretinib in combination 
with fludarabine. Interactions represent the mean of 3 experiments performed in triplicate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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  Figure 5.28a 
   
  Figure 5.28b 
   
  Figure 5.28c  
Figure 5.28 Combination of foretinib with anti – metabolites demonstrates differing responses in SD – 1 
(a) synergy in combination with fludarabine and (b) cytarabine, but (c) no effect on the methotrexate 
response curve. Points represent the mean of 3 experiments performed in triplicate; error bars Std deviation.    
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REH exhibited an early synergistic response to cytarabine with a reduction in cell viability 
to 50% at 0.001µM, while higher doses demonstrated antagonism.   Foretinib exhibited 
synergy when combined with methotrexate and fludarabine in REH (fig 5.29).  
 
   
 
Figure 5.29 Foretinib demonstrates early synergy and late antagonism in combination with cytarabine in 
the REH cell line. Points represent the mean of 3 experiments performed in triplicate, with error bars 
representing standard deviation.   
 
While the Chou – Talalay modelling of interactions of foretinib and the anti – metabolites 
was synergistic in TOM -1 (CI<1), the dose response curves did not appear to support these 
results. Fig. 5.30a - c show the reduction in viability when foretinib was combined with 
cytarabine (0.001 – 0.01µM), methotrexate (0.001 – 0.1µM) and fludarabine (0.001 – 0.1µM) 
were either equal to or less than foretinib alone. This would suggest that despite the 
mathematical modelling, these were antagonistic interactions.    
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  Figure 5.30a  
   
  Figure 5.30b  
   
  Figure 5.30c 
 
Figure 5.30 Combination therapy with foretinib and anti – metabolites in cell line TOM – 1 result in 
reduced cell viability (a) cytarabine, (b) methotrexate and (c) fludarabine. Interactions between foretinib 
and the anti – metabolites appear antagonistic. Points represent the mean of 3 experiments performed in 
triplicate, with error bars representing standard deviation.   
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The most marked reduction in cell viability in response to low doses of cytarabine, 
fludarabine and methotrexate (0.001 – 0.1µM) was observed in Nalm 17 and SupB15. These 
interactions were strongly to moderately synergistic at these doses. In both cell lines 
concurrent treatment with foretinib (0.25µM and 0.125µM respectively) with 0.001µM of 
the 3 anti – metabolite cytotoxic agents resulted in a >50% reduction in cell viability at 72 
hours.  
 
5.8.1.3 Foretinib in combination with DNA – damaging agents 
Treatment with doxorubicin and mitoxantrone as single agents resulted in profound loss of 
viability in all cell lines.  Both mitoxantrone and doxorubicin exhibited strong synergistic 
interactions (CI<1) when combined with foretinib in all cell lines (table 5.5). Antagonism 
was present in SD – 1 and SupB15, however the cell viability has reduced >50% at these 
concentrations (0.1 - 1µM fig 5.31). 
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                           Figure 5.31 a 
                              
                             Figure 5.31 b                             
                              
                             Figure 5.31 c 
Figure 5.31 Combination of foretinib and DNA – damaging agents in SupB15 and SD -1 cell lines. 
Interactions between foretinib and (a) doxorubicin and (b) mitoxantrone in SupB15 demonstrate significant 
reduction in cell viability. (c) Combination of doxorubicin and foretinib in SD -1 reveal significant reduction in 
cell viability. Points represent the mean of 3 experiments performed in triplicate, with error bars representing 
standard deviation.   
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Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Doxorubicin 0.0001 0.1 0.5 0.7 0.7 0.3 0.2 
(µM) 0.001 0.1 0.7 0.8 0.5 0.3 0.8 
 0.01 0.1 0.9 1.5 0.5 0.4 0.3 
 0.1 0.3 0.4 0.7 1.0 1.1 0.6 
 1 0.9 1.6 2.2 1.6 9.3 0.1 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Doxorubicin 0.0001 +++++ +++ +++ +++ ++++ ++++ 
(µM) 0.001 +++++ +++ ++ +++ ++++ ++ 
  0.01 +++++ + --- +++ +++ +++ 
  0.1 +++ +++ ++ ± ± +++ 
  1 + --- --- --- ---- ++++ 
   
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Mitoxantrone 0.001 0.2 0.4 0.7 0.5 0.4 0.639 
(µM) 0.01 0.4 0.3 0.7 1.1 1.0 0.4 
 0.1 0.7 0.2 1.8 1.7 8.7 1.0 
 1 1.9 1.8 6.1 0.2 85.8 0.1 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Mitoxantrone 0.001 ++++ +++ +++ +++ +++ ++ 
(µM) 0.01 +++ ++++ ++ ± ± +++ 
 0.1 ++ ++++ --- --- ---- ± 
 1 --- --- ---- ++++ ----- ++++ 
         
  Key: 
  
     
   
     
    
 
Table 5.5 Summary of the responses of combination therapy for foretinib and the DNA – damaging agents 
described as Combination Indices. Data is presented for interactions of foretinib in combination with (a) 
doxorubicin and (b) mitoxantrone. Interactions represent the mean of 3 experiments performed in triplicate. 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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5.8.1.4 Foretinib in combination with vincristine 
The effect of foretinib and vincristine was predominantly synergistic at lower doses 
(table5.6). However, antagonism was present in REH and TOM – 1 and the degree of 
antagonism increased with vincristine concentration (fig 5.32). 
 
 
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Vincristine 0.0001 0.1 0.5 0.8 0.5 0.2 0.32 
(µM) 0.001 0.1 0.5 2.0 0.7 0.8 1.3 
  0.01 0.5 0.7 5.7 1.4 6.1 8.4 
  0.1 4.2 2.9 17.9 16.7 49.6 54.0 
 
Interaction 
Foretinib (µM) 
    0.25 0.25 0.175 0.125 0.125 0.25 
Vincristine 0.0001 +++++ +++ +++ +++ ++++ +++ 
(µM) 0.001 ++++ +++ --- ++ ++ -- 
 0.01 +++ +++ ---- --- ---- ---- 
 0.1 ---- --- ----- ----- ----- ----- 
         
  Key: 
  
     
   
     
 
 
Table 5.6 Summary of the responses of combination therapy for foretinib and vincristine described as 
Combination Indices. Combination therapy demonstrates a predominantly synergistic effect at lower 
vincristine doses, but antagonism predominates as vincristine concentration increases. Interactions represent 
the mean of 3 experiments performed in triplicate. 
 
 
 
 
 
 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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   Figure 5.32a 
     
  Figure 5.32b 
 
Figure 5.32 Combination of foretinib with vincristine demonstrates synergy at low doses in both (a) REH 
and (b) TOM – 1 cell lines. Points represent the mean of 3 experiments performed in triplicate, with error 
bars representing standard deviation.   
 
In summary, the dominant impact of foretinib in combination with cytotoxic agents was 
one of synergy. In particular foretinib was able to sensitise resistant cell lines to 
chemotherapy and it did so in cell lines which did not display a significant response to 
foretinib alone.  
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5.8.2 Assessment of combination of foretinib and cytotoxics in primary ALL – 20   
To determine whether foretinib was able to sensitise the primary leukaemia ALL – 20 to 
chemotherapeutic agents, cells were treated the cells with a fixed sub – IC50 dose of foretinib 
0.0075µM, in combination with dexamethasone, doxorubicin, mitoxantrone, cytarabine, 
methotrexate or vincristine. ALL – 20 demonstrated profound in vitro resistance to 
methotrexate monotherapy. An increase in cell viability corresponded with dose 
increments up to 1µM, twice that of baseline (fig 5.33). 
Significant sensitisation was exhibited in response to combination therapy of foretinib with 
all classes of chemotherapy. Table 5.7 summarises the responses to combination therapy. In 
particular, the methotrexate resistance was negated (fig 5.33); low doses of methotrexate 
induced a significant reduction in viability, >75% with 0.001µM methotrexate and 0.075µM 
foretinib. 
 
   
 
Figure 5.33 Methotrexate resistance in primary sample ALL -20 is abrogated by sub – IC50 dose of foretinib. 
Foretinib demonstrates potent ability to reverse methotrexate resistance in primary cells (ALL – 20). 
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  Dose  CI Interaction 
Dexamethasone (µM) 
0.001 0.3 +++ 
0.01 0.3 +++ 
0.1 0.5 +++ 
0.25 0.9 ± 
0.5 1.3 -- 
Cytarabine (µM) 
0.001 0.4 +++ 
0.01 0.4 +++ 
0.1 0.3 +++ 
1 0.2 ++++ 
10 0.2 ++++ 
Methotrexate (µM) 
0.001 0.7 +++ 
0.01 0.8 ++ 
0.1 0.8 ++ 
1 0.8 ++ 
10 0.9 ± 
Vincristine (µM) 
0.0001 0.5 +++ 
0.001 0.5 +++ 
0.01 0.5 +++ 
0.1 0.7 ++ 
Doxorubicin (µM) 
0.00001 0.5 +++ 
0.0001 0.5 +++ 
0.001 0.5 +++ 
0.01 0.9 ± 
0.1 1.3 --- 
Mitoxantrone (µM) 
0.00001 0.4 +++ 
0.0001 0.4 +++ 
0.001 0.5 +++ 
0.01 0.8 ++ 
0.1 6.0 ---- 
 
   Key: 
 
     
   
      
 
 
Table 5.7 Foretinib demonstrates ability to sensitise the primary ALL sample (ALL – 20) to a wide variety 
of chemotherapeutic agents. The predominant interaction is synergistic with Combination Indices less than 1 
(CI <1). 
 
 
 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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5.8.3 Dovitinib combinations with cytotoxics demonstrate synergy in cell lines  
The interaction of dovitinib with the induction agents, dexamethasone, doxorubicin and 
vincristine was then examined. Cell lines were co – treated with fixed sub – IC50 dovitinib 
doses. Dovitinib predominantly demonstrated synergy in combination with 
dexamethasone in all 6 cell lines (tables 5.8a and b).  
 
 
  
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Dovitinib (µM) 
    0.25 0.1 0.1 0.075 0.075 0.1 
Doxorubicin 0.0001 0.6 0.5 0.8 1.0 171000 2.2 
(µM) 0.001 2.4 0.5 0.7 0.5 0.8 0.8 
 0.01 3.0 0.3 0.4 0.5 0.2 0.2 
 0.1 3.8 0.2 1.0 1.0 0.4 0.6 
 1 0.3 0.7 5.4 5.1 4.1 3.0 
 
Interaction 
Dovitinib (µM) 
   0.1 0.1 0.075 0.075 0.1 0.25 
Doxorubicin 0.0001 +++ +++ ++ ± ----- --- 
(µM) 0.001 --- +++ +++ +++ ++ ++ 
 0.01 --- +++ +++ +++ ++++ ++++ 
 0.1 ---- ++++ ± ± +++ +++ 
 1 ++++ +++ ---- ---- ---- --- 
         
  Key: 
  
     
   
     
 
Table 5.8a Summary of the responses of combination therapy for dovitinib and cytotoxic agents described 
as Combination Indices. Data is presented for interactions of dovitinib in combination with (a) 
dexamethasone and (b) doxorubicin. Interactions represent the mean of 3 experiments performed in triplicate. 
 
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Dovitinib (µM) 
    0.25 0.1 0.1 0.075 0.075 0.1 
Dexamethasone 0.001 0.7 0.4 0.6 1.3 1.4 1.9 
(µM) 0.01 0.3 0.4 0.6 0.4 0.0 0.2 
 0.1 0.2 0.3 0.6 0.3 0.1 0.2 
 1 0.3 0.6 0.9 0.5 0.9 0.5 
 10 0.2 3.4 3.5 3.2 9.1 3.8 
 
Interaction 
Dovitinib (µM) 
   0.1 0.1 0.075 0.075 0.1 0.25 
Dexamethasone 0.001 ++ +++ +++ -- --- --- 
(µM) 0.01 ++++ +++ +++ +++ +++++ ++++ 
 0.1 ++++ +++ +++ +++ ++++ ++++ 
 1 ++++ +++ ± +++ ± +++ 
 10 ++++ --- --- --- ----- --- 
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
                                                                                                   Preclinical Investigations  
207 
 
 
Drug 
Nalm 6 Nalm17 REH SD-1 Sup B15 TOM-1 
Combination index 
Dovitinib (µM) 
    0.25 0.1 0.1 0.075 0.075 0.1 
Vincristine  0.00001 0.8 0.4 3385.0 1.2 171000.0 3.4 
(µM) 0.0001 2.8 0.4 1881.0 0.5 0.9 1.5 
 0.001 1.7 0.2 28.3 0.2 0.2 0.2 
 0.01 1.2 0.6 7.4 0.5 1.1 0.5 
 0.1 0.9 4.8 7.4 4.7 6.5 3.4 
 
Interaction 
Dovitinib (µM) 
   0.1 0.1 0.075 0.075 0.1 0.25 
Vincristine 0.00001 ++ +++ ----- - ----- ---- 
(µM) 0.0001 --- +++ ----- +++ ± --- 
 0.001 --- ++++ ----- ++++ ++++ ++++ 
 0.01 --- +++ ---- +++ ± +++ 
 0.1 ± ---- ---- ---- ---- ---- 
         
  Key: 
  
     
   
     
 
 
Table 5.8b Summary of the responses of combination therapy for dovitinib and cytotoxic agents described 
as Combination Indices. Data is presented for interactions of dovitinib in combination with vincristine. 
Interactions represent the mean of 3 experiments performed in triplicate. 
 
 
Dovitinib sensitised the steroid – resistant cell lines, Nalm 6, SD – 1 and REH to 
dexamethasone. The cell line Nalm 17 developed steroid resistance while in culture; despite 
this finding, dovitinib co – treatment sensitised the cells to dexamethasone (fig 5.34).   
 
 
 
 
 
 
 
 
 
    
            Synergistic interaction  
            Antagonistic interaction  
            Additive interaction  
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  Figure 5.34a 
 
   
  Figure 5.34b 
 
Figure 5.34 Dovitinib sensitises the steroid – resistant cell lines Nalm 6 and Nalm 17. The red line 
demonstrates the percentage cell viability induced by dovitinib alone. For combinations to be synergistic, the 
reduction in viability needs to be below the chemotherapy alone and the red line. Steroid resistant cell lines 
(a) Nalm 6 and (b) Nalm 17 are sensitised to DXM by foretinib. Data presented is the mean of 2 experiments, 
undertaken in triplicate. Error bars are standard deviation.   
 
The impact of dovitinib on doxorubicin was found to be generally synergistic (table 5.8a). 
Antagonism was displayed in Nalm 6 at concentrations 0.001 – 0.1µM and REH 0.01 - 1µM. 
Despite the CI>1 exhibited in these 2 cell lines, the reduction in cell viability of the 
combination was always more than either the TKI alone or doxorubicin.  
Finally, the effect of dovitinib and vincristine was largely antagonistic, with Nalm 6 and 
REH exhibiting CI>1 for most concentrations (table 5.8b). The only cell line to demonstrate 
synergy at concentrations 0.0001 – 0.01µM was Nalm 17.  
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 Overall, these data indicate foretinib and dovitinib are able to sensitise ALL cell lines to 
conventional chemotherapeutic agents. The combination of dexamethasone and TKI (either 
foretinib or dovitinib) induced the most reliable synergy. While some evidence of 
antagonism is present these interactions are limited to individual cell lines and specific 
chemotherapies.  
 
5.8.4 Steroid sensitisation induced by foretinib in REH cell line is not due to apoptosis   
The cell line REH is profoundly resistant to glucocorticoid induced cell death (422).  The 
strong synergy demonstrated by foretinib and dexamethasone in REH was investigated to 
determine whether the synergy arose because of an increase in apoptosis.   Cellular 
responses to co-treatment with foretinib and dexamethasone were assessed using an 
Annexin V/PI assay. REH cells were treated with dexamethasone 0.1µM alone, foretinib 
0.25µM alone and in combination with dexamethasone, and then assayed for Annexin 
positive cells at 24, 48 and 72 hours (fig 5.35). Dexamethasone alone did not induce 
significant apoptosis at the three time points (p values = 0.69, 0.56 and 0.15 respectively). 
An apoptotic response to foretinib was seen at all time-points.  No appreciable difference 
between the apoptosis induced by foretinib alone or in combination with dexamethasone 
was identified (p – values = 0.49, 0.63 and 0.8 at 24, 48 and 72 hours respectively) (fig 5.34). 
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Figure 5.34a                  Figure 5.34b 
          
  
 
Figure 5.34c      Figure 5.34 d 
 
Figure 5.35 Combination of foretinib and dexamethasone in REH cell line does not induce an increase in 
apoptosis after 72 hours treatment. Assessment of foretinib to induce apoptosis was assessed in the 
dexamethasone – resistant REH cell line. Cells were exposed to different conditions, (a) DMSO 0.1% (b) 
dexamethasone monotherapy (c) foretinib 0.25µM monotherapy (d) dexamethasone 0.1µM and foretinib 
0.25µM. Percentage expressed are the population of apoptotic cells under each condition after 72 hours 
treatment.     
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  Percentage of population 
  Live  Apoptotic  Dead 
24 hours DMSO 0.1% control 90 (±4) 6 (±3) 4 (±2) 
Dexamethasone (DXM) 0.1µM 90 (±3) 6 (±3) 4 (±1) 
Foretinib 0.250µM 76 (±1) 13 (±1) 10 (±1) 
DXM 0.1µM +  Foretinib 0.250µM 77 (±3) 13 (±2) 9 (±1) 
48 hours DMSO 0.1%control 88 (±5) 7 (±3) 4 (±2) 
DXM 0.1µM 87 (±4) 9 (±3) 4 (±1) 
Foretinib 0.250µM 74 (±1) 15 (±1) 11 (±1) 
DXM 0.1µM +  Foretinib 0.250µM 74 (±1) 16 (±3) 10 (±1) 
72 hours DMSO 0.1% control 83 (±4) 7 (±1) 10 (±3) 
DXM 0.1µM 87 (±1) 5 (±1) 7 (±1) 
Foretinib 0.250µM 60 (±1) 25 (±2) 14 (±2) 
DXM 0.1µM +  Foretinib 0.250µM 58 (±2) 25 (±1) 16 (±1) 
 
Table 5.9 Percentage of apoptotic cells in response to dexamethasone, foretinib or combination. Percentage 
given is the mean experiments performed in triplicate, with standard deviation in parentheses.  
 
 
5.9 Assessment of in vivo efficacy of foretinib and dovitinib in murine primagraft 
model  
To investigate the in vivo impact of the TKIs, a murine xenograft model of the primary B – 
precursor leukaemia ALL – 20 was established.   Immune deficient mice were inoculated 
with leukaemia cells (section 2.19) obtained from a diagnostic B – precursor ALL bone 
marrow sample, with the adverse NCI/Rome risk criteria for WCC (109 x 109/l) and age 
(12yrs) (table 2.2). The experiments were planned by Dr Wilson and carried out by Dr 
Wilson and Mrs Tracey Perry, laboratory technician to the Kearns Group. Mrs Perry helped 
with inoculation of mice, gavaging of TKIs, bleeding of mice and harvesting of mice. Dr 
Wilson harvested mice and prepared blood and organ samples for flow cytometry. Dr 
Wilson and Mrs Perry performed flow cytometry as described in section 2.16.   
 
5.9.1 Engraftment kinetic experiments for ALL – 20  
Fluorescent – activated cell sorting (FACS) immunophenotyping, performed at 
Birmingham Children’s Hospital (BCH) as part of the routine diagnostic service, 
demonstrated ALL – 20 as a B – cell precursor ALL, demonstrating surface markers CD45 
(pan – leukocyte) 80%, CD19 (pan – B) 90%, CD10 (common ALL antigen) 87%, and CD34 
8%.  Four per cent of cells expressed Tdt and cytoplasmic µ was present in 14%.  These data 
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support the diagnosis of common ALL that was made on morphological grounds by study 
of bone marrow smears. The maturity of the leukaemia population in the murine xenograft 
was defined according to CD45, CD34, CD19 and CD10 expression. The panel of 
fluorochromes used for the xenograft model (table 2.8) demonstrated concordance with the 
original BCH findings in the leukaemia sample prior to injection, with 73% of total cells 
staining for human CD45 (hCD45+) of which 93% were CD19+/CD10+ ,  confirming B – cell 
origin and an immature B – cell precursor phenotype. Fewer than 1% of the cells were 
CD34+, indicating the leukaemia was not stem cell – like in origin (fig 5.36a). 
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Figure 5.36a 
 
                
 
 
Figure 5.36b 
 
 
 
Figure 5.36c 
 
Figure5.36 Immunophenotyping of ALL – 20 cells with the fluorochrome panel. (a) ALL – 20 cells labelled 
with the fluorochrome panel prior to injection revealed a phenotype consistent with the original diagnostic 
investigations performed at BCH, CD45+CD34-CD19+CD10+. (b) Representative FACS analysis from 
passaged ALL – 20 harvested from the liver of mouse 5. Engrafted cells demonstrate a similar original 
immunophenotype, CD45+CD34-CD19+CD10+. (c) FACS analysis of cells engrafted in spleen of mouse 5 
displayed evolution of a CD34+ more stem – like sub - clone. The leukaemia infiltrating the liver and bone 
marrow however were CD34-CD1910+. 
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Leukaemia cells were washed, counted and suspended in 1ml PBS prior to injection.  1x106 
cells per mouse were injected via lateral tail vein into 8 immune deficient (NOD/Scid/IL2rγ 
NOG) mice (all male) and the presence of human leukaemia blasts were assessed by 
sampling of murine blood. Engraftment was defined as the presence of at least 1% of all live 
cells staining for hCD45+ cells in the peripheral murine blood (423). Engraftment of ALL – 
20 was rapid, with all 8 mice exhibiting greater than 1% hCD45+ cells in murine blood by 
day 15, mean 14.2 % (SD± 7.1%).  There was an insignificant reduction (p = 0.65) in 
peripheral hCD45+ at day 28, with mean engraftment 12.5% (SD± 7.5%) (fig 5.37).  
 
    
 
Figure 5.37 Initial engraftment kinetics experiments revealed rapid engraftment of the ALL – 20 sample. 
Peripheral engraftment of hCD45 cells was evident in peripheral murine blood samples by day 15. Each time 
point is the mean engraftment of all mice alive at the time of sampling. Error bars are standard deviations.   
 
The median survival of the mice was 34 days.  Two of eight corpses were macerated and 
could not be analysed.  Infiltration of bone marrow and spleen was assessed in the 
remaining 6 mice. Infiltration of the livers in 4 mice by FACS analysis, which confirmed 
significant engraftment of ALL – 20 in all organs. The mean percentage of CD45+ 
infiltrating all harvested murine organs was 77.31% (SD±10.48%). Table 5.10 shows the 
initial engraftment, percentage of tumour infiltration of each organ at death and survival 
for each of the mice.  
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 Percentage human CD45 (%) Survival 
Mouse Day 8 blood Bone marrow Liver Spleen Days 
1 18 58.5 90.9 86.6 36 
2 24.8 No viable cells No viable cells No viable cells 36 
3 19.2 No viable cells No viable cells No viable cells 34 
4 13.1 61.6 84.7 72.7 36 
5 17.5 73.3 92.5 79.1 34 
6 2.6 57.4 90.9 80.9 34 
7 9.4 69 Not done 70.9 34 
8 8.9 71.9 Not done 75.8 34 
 
Table 5.10 Summary of hCD45 engraftment in peripheral blood and murine organs at terminal cull from 
the initial experiment to determine the engraftment kinetics of ALL – 20. High levels of engraftment were 
present in evaluable murine organs. No viable cells were present in mouse 2 and mouse 3 as the corpses were 
macerated and analysis was not possible. 
 
The scatter plot Fig. 5.38a reveals a greater mean tumour load in the liver (89.8±3.5%) than 
the bone marrow (65.3±7%) or spleen (77.7±5.8%), which was statistically significant higher 
(p <0.0001 by one – way ANOVA). 
 
FACS analysis of the composition of the xenograft leukaemia confirmed the recapitulation 
of the original phenotype. Fig 5.37b shows the relative engraftment of CD34+ and CD34- 
cells. One outlier is present, with evidence of a sub – clone developing in the spleen of 
mouse 5. The predominant immunophenotype in mouse 5 spleen was CD45+CD34+ CD19+.  
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  Figure 5.38a      Figure 5.38b  
 
 
Figure 5.38 The murine xenograft demonstrates the hepatotropic nature of ALL – 20 which reconstituted 
the original CD45+CD34-19+10+phenotype. (a) Significantly higher tumour load was present in all livers 
harvested from evaluable mice (ANOVA one – way p<0.0001). (b)  The engrafted leukaemia recapitulated 
original CD45+CD34-19+10+ phenotype. The emergence of a CD34+ clone was evident in the spleen of mouse 
5.    
 
To assess the stability of the ALL – 20 xenograft, the VDJ gene rearrangements in the 
original primary tumour and leukaemia harvested from bone marrow, liver and spleen 
from mice were examined.  PCR was performed using primers for framework region 3A 
(Fr3A) and J1H heavy chain joining fragment (J1H) regions. Products were visualised on a 
4% agarose gel (fig 5.39), extracted and sequenced.  Sequencing of these rearrangements 
revealed identical products in all cells. In summary, the ALL – 20 xenograft model 
demonstrates rapid and reliable engraftment, with recapitulation of the original 
immunophenotype and clonal stability. 
 
             1   2   3   4   5   6   7   8  9  10  11 12 13 14   15 16  17   
 
 
 
Figure 5.39 Stability of VDJ rearrangements of ALL – 20 is demonstrated in the expression of the identical 
product from diagnostic sample and samples harvested from mouse livers and spleens.  Utilising the 
primers for Fr3A and J1H, the PCR product was run on 4% agarose gel. The product visualised in Lane 1 is 
the VDJ product from the original diagnostic bone marrow sample for ALL – 20. The products in lane 2 – 5 
were derived from the spleen and liver harvested from mouse 1, products in lane 6 – 7 derived from the liver 
of mouse 7, products in lane 8 – 11 the spleen and liver from mouse 2 and the products in lane 12 – 17 from 
the bone marrow, spleen and liver harvested from mouse 3.      
 
  
100bp 
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5.9.2 Assessment of in vivo activity of foretinib 
After establishing the characteristics of the ALL – 20 xenograft; the efficacy of foretinib was 
investigated in this xenograft model. Ten immunodeficient mice were used in this 
experiment, with 5 in each cohort. Two cycles of foretinib 30mg/kg/day by oral gavage, 5 
days on and 9 days off were administered to the treatment group, while control group were 
treated with an equal volume (100µl) of DMSO by oral gavage. The following criteria, 
based on the PPTP model, were used to initiate treatment and assess responses (423, 424): 
 Peripheral engraftment of leukaemia was defined as the presence of >1% human 
CD45 cells (hCD45) in peripheral murine blood and the trigger for commencing TKI 
treatment; 
 The presence of >25% hCD45 cells in peripheral murine blood was classified as an 
event and the efficacy of the drug was calculated until that point. 
 
1x106 cells were injected via lateral tail vein. Engraftment at day 8 was confirmed by blood 
sampling, with hCD45 cells in the range 2.5 – 19%.  Treatment was commenced in 5 mice. 
There was no difference in the engraftment level between treatment and control groups 
11.7±6.2% vs. 12.7±5.4% respectively (p = 0.79).  The first cycle of foretinib was administered 
on days 8 to 12 and the second cycle days 21 to 25 after inoculation. 
 
Early deaths occurred at day 9, when a control mouse was sacrificed because of poor 
health. A treatment cohort mouse also died at day 9 after the third treatment gavage (4.4), 
and thus had received only 2 full doses of foretinib. The organs of both mice were 
harvested and engraftment analysed by FACS. Engraftment was present in both bone 
marrows, 58.9% engraftment in the control compared with 10% in the treated mouse. The 
peripheral engraftment was comparable on day 8, 13.5% (vehicle) compared with 17.3% 
(foretinib).  Preferential engraftment was present in the liver of the treated mouse, with 
45.8% hCD45+ cells compared to the 9.2% in the spleen.  
 
                                                                                                   Preclinical Investigations  
218 
 
After completion of the first cycle of treatment (day 8 to 12), engraftment increased from 
12.7 to 19.5% at day 15 in the control cohort (n=4 after early loss) and from 11.7% to 25% in 
the foretinib – treated cohort (n=4 after early loss). The level of engraftment at day 15 in 
each cohort was not significantly different (p= 0.34 fig 5.40).  
              
                     
Figure 5.40 Peripheral engraftment of hCD45 cells in murine blood did not demonstrate a significant 
difference between the control and foretinib – treated cohorts. Each point is the mean engraftment of the 
mice alive at the time point, error bars are standard deviation. 
 
By the PPTP criteria for assessing response to therapy, the foretinib cohort reached an 
“event” (>25% of murine peripheral consisting of human leukaemia cells) while the control 
cohort did not. There was no significant difference in the level of engraftment of hCD45 
cells in murine peripheral blood at day 21 (control group 10.5%, foretinib treated 4.7%, p = 
0.27), but there was a statistically significant reduction in engraftment after the first course 
of treatment, mean 25±8.6 % reduced to 4.7±0.02% (p = 0.04, paired t - test). The reduction in 
hCD45 engraftment present in the control cohort was not significant (p = 0.17 paired t – 
test).  Fig. 5.41 shows the survival curves for the 2 cohorts, with median survival in the 
vehicle – treated cohort 36 days compared to 30 days (p – value = 0.269 Log – Rank test). 
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Figure 5.41 Kaplan – Meier curve for foretinib – treated mice compared to vehicle mice. No statistically 
significant difference in the median survival was demonstrated between the 2 cohorts. The median survival 
for mice treated with foretinib was 30 days in comparison with 36 days for the control mice. 
 
 
 Blood hCD45 (%) Terminal engraftment hCD45 (%) Survival  
Mouse Day 7 Spleen Liver Bone marrow Days  
Control cohort  
1.1 11.4 71.9  68.9 36 
1.2 4.9 71.95 68.73 17.9 36 
2.3 13.89 61.9 49.67 53.3 36 
2.4 13.53 - 71.95 58.85 9 
2.5 19.86 63.13 - - 36 
Foretinib – treated cohort  
3.1 11.36 74.85 75.53 48.1 36 
3.2 9.92 10.75 68.25 18.93 30 
4.3 2.5 65.15 28.89 28.52 36 
4.4 17.33 9.21 75.11 10.05 9 
4.5 17.37 1.92 45.76 3.57 22 
 
Table 5.11 Summary of hCD45 engraftment in peripheral blood at time of starting foretinib and murine 
organs at terminal cull from control and foretinib – treated cohorts. 
 
A second foretinib – treated mouse died post – gavage on day 21, but by then it had 
received all doses in the first cycle of treatment and the first dose of the second cycle. The 
bone marrow, liver and spleen did not have a significant tumour load, with engraftment of 
                                                                                                   Preclinical Investigations  
220 
 
hCD45 at 1.1%, 3.5% and 1.9% respectively. Peripheral engraftment for this mouse had 
remained stable post the first course of treatment, day 8 (17.4%) and day 15 (17.2%). 
 
A third, moribund mouse from the treated cohort was sacrificed, after receiving 2 full 
cycles, on day 30.  The liver and spleen were haemorrhagic and there was limited 
infiltration of bone marrow, liver and spleen, with hCD45 counts of 16.5%, 28.2% and 10.1% 
respectively.   
 
The remaining 2 treatment and 4 vehicle mice were culled at day 36 because of poor health 
and bone marrow, liver and spleen harvested. Comparison of the 4 control mice which 
survived to day 36 to the treated cohort demonstrated higher average infiltration of hCD45 
in bone marrow, 46.6% compared to 38.3%. The tumour load in the liver (63.8% control; to 
71.6% treated) and the spleen (68.6% control; 70% treated) was lower in the control cohort.  
 
The majority of the hCD45 population in each of the organs in the control mice were a 
recapitulation of  the original B – precursor leukaemia, with a mean CD34-CD19+10+ cell 
count of  70.95% (±16.4) in the bone marrow, 69.1% (±16.4) liver and 92.85% (±0.63) in the 
spleen.  Treated mice displayed mean CD34-19+10+ cell counts of 75% in the bone marrow 
and 78% in the spleen, but only 47% in the liver. Mouse 3.1 had only 28% of the 
CD45+CD34- cells that were CD1910+ despite a single CD10+ population.   
 
The efficacy of the current treatment schedule for foretinib was not proven.  There was 
survival advantage in this study.  However, a statistically significant reduction in 
peripheral engraftment was observed after the first cycle of treatment.    
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5.9.3 Assessment of in vivo activity of dovitinib 
Using the ALL – 20 model the in vivo efficacy of dovitinib was assessed.  Eleven immune 
deficient mice (NOD/Scid) were used in this experiment, 6 dovitinib – treated mice and 5 
control mice. 1x106 cells per mouse were inoculated via the lateral tail vein on day 1. The 
treatment cohort was planned to receive 3, 5 – day cycles of 65mg/kg/d dovitinib by oral 
gavage on days 7 – 11, 14 – 18 and 20 – 24 
 
Peripheral engraftment was assessed on day 4 post – inoculation because of early 
engraftment, with a mean hCD45+ cell counts of engraftment 0.61% (SD±0.82%), range 0 – 
2.9%. Therapy was unable to start at a weekend and thus treatment was started at day 7.  
Engraftment in the randomised control group of 5 mice was 1.02% (SD ±1.1%) and in the 6 
treatment mice was 0.32% (SD± 0.25%). There was no statistically significant difference 
between the two groups (p = 0.25 t – test).  
   
 
Figure 5.42 Peripheral engraftment of hCD45 in murine blood in response to dovitinib treatment. Each 
point is the mean engraftment of the mice alive at the time point, error bars are standard deviation. No 
difference was present between the 2 cohorts at time of commencing dovitinib therapy.  
 
Peripheral engraftment in the murine blood at day 24 (after the third cycle of treatment) 
demonstrated a lower CD45+ cell count in the dovitinib treatment cohort (n=5), mean 
peripheral hCD45 29.62% (SD±8%) compared to the control 45.56% (SD±5.28%), p=0.012 t – 
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test (fig 5.42).   Peripheral sampling was only possible in 3/5 vehicle mice because of high 
blood viscosity. Despite the reduced engraftment in the treatment group, according to 
PPTP classification an event had occurred (hCD45>25%), and so objective response could be 
documented. 
  
The median survival for the control group was 26 days and the dovitinib – treated cohort 29 
days (fig 5.43, p=0.08 by log – rank Mantel – Cox test). The median survival was not related 
to the level of engraftment, with the 4 shortest survivals (day 25) displaying a wide range of 
day 4 engraftment, 0.1% - 2.9% (table 5.12).  
 
   
Figure 5.43 Kaplan – Meier curve for dovitinib compared to vehicle mice. No statistically significant 
difference was demonstrated between the 2 cohorts. The median survival for mice treated with dovitinib was 
29 days in comparison with 26 days for the control mice. 
 
Tumour load was estimated by weighing the harvested organs and tumour infiltration was 
measured by FACS analysis. A statistically significant difference in spleen weight was 
observed with 0.3g (±0.09g) in the control cohort and only 0.115g (±0.069g) in the treated 
group (p = 0.0029, t – test) (fig 5.44). No difference in liver mass was observed (2.3 g 
compared to 2.1g, t – test p= 0.59). 
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Four of the five control mice (2.1, 3.3, 4.2, 4.5) and 1 dovitinib – treated mouse (4.4) died 
during a weekend; consequently, the organs were haemorrhagic and necrotic at time of 
analysis.  No viable cells were evaluable for control mouse 4.5, which was excluded from 
FACS analysis.  
                
Figure 5.44 Spleens harvested from mice in the control group were significantly heavier than the dovitinib 
– treated cohort (p = 0.0029).    
 
 Blood hCD45 (%) Terminal engraftment hCD45 (%) Survival  
Mouse  Day 4 Spleen Liver Bone marrow Days 
Control cohort  
1-3 0.9 92.2 95 42.6 25 
2-1 2.9 24.2 97 39.4 25 
3.3 0.6 100 66.7 23.8 26 
4-2  0 66.6 8 No viable cells 29 
4-5  0.7 No viable cells No viable cells No viable cells 26 
Treatment cohort  
1-1 0.1 91.1 70.9 99.2 25 
1-2 0.4 88.1 89.7 57.4 29 
3-2 0 86 97.3 69 29 
4-1 0.6 54.4 97.1 36.6 29 
4-3 0.5 90.2 80 51.8 29 
4-4 0.1 No viable cells 54 17.1 25 
 
Table 5.12 Summary of hCD45 engraftment in peripheral blood and murine organs at terminal cull from 
control and dovitinib – treated mouse cohorts. The bone marrow of the control mice 4.2, all organs from 
mouse 4.5 and the spleen of treated mouse 4.4 were necrotic at time of FACS analysis.  
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Fig 5.45a - c shows the hCD45 engraftment of the dovitinib – treated and control cohorts at 
time of terminal cull. Mean engraftment was lower in the control group in bone marrow 
(26% vehicle cf. 55% dovitinib) and liver (61% cf. 82%), but higher in the spleen (71% cf. 
68%).     
  
  Figure 5.45a      Figure 5.45b                                                                         
    
    Figure 5.45c  
 
Figure 5.45 FACS analysis of organs at terminal cull in control and dovitinib – treated cohorts. No 
statistically significant differences in the tumour load were identified in the organs of mice treated with 
DMSO or dovitinib.  
 
Analysis of the levels of engraftment did not reveal a difference in liver (p = 0.63) or spleen 
(p = 0.83), however there was a trend to reduced hCD45 engraftment in the bone marrow (p 
= 0.07) of the vehicle cohort. The composition of the infiltrating leukaemia recapitulated the 
CD45+CD34-leukaemia in all organs. Evaluation of the maturity of the cells depended on 
the degree of cell death present in the organs, with CD45+CD34-CD19+CD10+ cells the 
major population in each mouse.  
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In summary, in this aggressive ALL xenograft model 65mg/kg/day, dovitinib does not offer 
a survival advantage. However, the level of peripheral engraftment at day 24 was 
significantly different. Evaluation of the level of engraftment was difficult because of 
necrosis of the murine organs, which reflects major infiltration and necrosis. Further dosing 
schedules for both TKIs warrant further exploration.    
 
5.10 Discussion 
In this study the in vitro and in vivo anti – leukaemic properties of the 2 candidate TKIs, 
foretinib and dovitinib, identified as potential therapeutic candidates in the cell line and 
primary cell screens have been investigated.  Both TKIs profoundly affected the expression 
of cell cycle – regulating proteins, induced apoptosis and sensitised leukaemic cells to 
conventional chemotherapeutic agents.  While the effects of these TKIs are well 
documented in solid tumours, this study is the first to investigate the role of foretinib or 
dovitinib in childhood acute lymphoblastic leukaemia. 
 
The results demonstrate that both foretinib and dovitinib exert a significant anti – 
leukaemic effect at nanomolar concentrations in cell lines and primary cells.  Of the 2 TKIs, 
dovitinib demonstrated a lower IC50 in 5/6 cell lines; whereas foretinib was more potent in 
REH and the primary cells, ALL – 20.   
The differences in potency might arise because the two drugs act against different RTKs, 
although they include a similar spectrum, VEGFR, PDGFR, Kit and FLT3 (table 5.1). 
Whether the difference in molecular structure or the avidity for the RTKs explains the 
differences in response were not assessed in this study. Dovitinib is more potent when 
assessed by in vitro kinase assay against FLT3 and FGFR1 (415).  It has additional activity 
against CSF – 1R and FGFR3, which is not reported in foretinib. Foretinib, in turn, possesses 
activity against Met, Ron and Tie – 2.  As observed in the previous chapter, all the cell lines 
express FGFR1 mRNA transcript but the level of expression did not predict sensitivity to 
the TKI. This lack of correlation with a specific receptor in the cell lines investigated could 
indicate that numerous pathways are targeted by the TKIs. The wide range of 
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concentrations required to inhibit the cell lines is consistent with the possibility that anti – 
leukaemic effects are mediated through different pathways in different leukaemias.    
 
The difference in potency was evident in the cell cycle profiles when cells were treated with 
1µM of either drug. While both TKIs induced accumulation of sub – G1 cells in 4/6 cell lines 
dovitinib induced more cell death in Nalm 17, REH, SD – 1 and SupB15, at an earlier time 
point. Dovitinib did not induce the G2/M arrest present in REH and SupB15, which 
supports the notion that TKIs do not affect the cells through identical mechanisms of action. 
 
The induction of G2/M arrest in cancer cells has been reported in response to treatment 
with foretinib (425-427) and dovitinib (428) . The G2/M transition of eukaryotic cells into 
mitosis is governed by Plk-1, cyclin B1 and Cdc25; and the checkpoint is regulated by the 
cyclin – kinase inhibitor p21. The accumulation and subsequent degradation of cyclin B1 is 
required for cells to progress successfully through mitosis.  In hepatic, ovarian and CML 
cell lines, foretinib – induced G2/M arrest has been reported with associated reduction in 
cyclin B1 (426, 427). In the present study, 4 cell lines, REH, SupB15, Nalm 6 and TOM – 1 
demonstrated G2/M arrest, although differing patterns of expression of cyclin B1 were 
identified.  
 
In REH and SupB15, the G2/M arrest was associated with an early reduction in cyclin B1 
expression, followed by apoptosis. This pattern of arrest and apoptosis has been reported in 
the CML cell line, K562 (425).  Dufies et al.. reported foretinib – induced reduction of cyclin 
B1 mediated via JNK – dependent mechanisms which lead to degradation of the mitotic 
transitional proteins, Plk – 1, cyclin B1 and Cdk1 (cdc2), resulting in G2/M arrest, 
polyploidy and apoptotic death by mitotic catastrophe (425). The group found that caspase 
inhibition reduced the accumulation of cells in sub – G1 and was associated with an 
increase in polyploid cell numbers. In the current study, a reduction in cyclin B1, G2/M 
arrest and apoptosis was present in REH and SupB15 but neither cell line displayed 
increased polyploid cell numbers in response to foretinib treatment.   
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G2/M arrest and polyploidy was present in Nalm 6 and TOM – 1, although these cell lines 
did not demonstrate significant cell death.  Here, cell cycle arrest was preceded by an 
accumulation of cyclin B1, similar to that seen in the cell lines which did undergo 
apoptosis.   
 
A similar phenomenon of G2/M arrest and polyploidy associated with an increase in cyclin 
B1 has been reported with the cyclin – dependent kinase inhibitor, butyrolactone (429). 
Butyrolactone is cdc2 inhibitor in non – synchronised cells.  It binds to the kinase, 
interfering with the ability form the cyclinB1 – cdc2 complex and hence progress through 
normal mitosis. This finding suggests that the accumulation of polyploid cells in Nalm 6 
and TOM -1 was likely due to foretinib – induced disruption of the cyclin B1 – cdc2 
complex.  The failure of cyclin B1 degradation, normally required for the exit of cell from 
mitosis, results in cells skipping mitosis and the accumulation of a population of cells with 
increased DNA content (8n). The decrease in cyclin B1 correlates with the progression of 
cells through a new cell cycle. These data suggest that the inhibition of the G2/M is not 
complete, and some cells slip through mitosis.  
 
The cells lines in which G2/M arrest was induced also demonstrated an early accumulation 
of p53 after 24 hours of foretinib treatment, with induction of p21. The 2 cell lines in which 
G2/M arrest was not induced (Nalm17 and SD -1) did not demonstrate significant early p53 
accumulation.  Both p53 and p21 are involved in the regulation of the G2/M checkpoint, 
with p53 reducing cyclin B1 production by inactivating the cyclin B1 promoter (430); p21 
directly inactivates the cyclinB1 – cdc2 complex thus inhibiting mitosis (431).      
 
These data suggest the effect of foretinib on the cell cycle may be protean, and will depend 
on the cellular context.  Foretinib may inhibit the cyclinB1 – cdc2 complex directly through 
cdc2 inhibition or via p53 – mediated mechanisms or possess the ability to induce JNK – 
activated degradation of cyclin B1 followed by cell death. The mechanism of arrest and 
possible cell death will need further investigation. 
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The G2/M arrest induced by dovitinib in Nalm 6 and TOM -1 has been reported in a FGFR1 
– expressing hepatocellular carcinoma (HCC) cell line and was associated with a reduction 
in cyclin B1 (428). The lack of G2/M arrest in REH and SupB15 might be due to the high 
concentration of dovitinib used for the cell cycle profiling or alternatively that it exerts its 
effect through different pathways. Dovitinib induces G1 arrest in FGFR3 expressing 
Waldenström Macroglobulinaemia (432); thus the effect of the TKIs on the cell cycle most 
likely reflects the particular target it inhibits and is not a function of the drug itself. This 
notion was highlighted by Odgerel et al. (433), who reported differential cell cycle patterns 
in AML cell lines with constitutively activated FLT3 after treatment with the FLT3 inhibitor, 
PKC412.  Cell lines with FLT3 mutations underwent apoptosis, while those with wild type 
receptor arrested in G2/M. 
 
The accumulation of p53 after foretinib – treatment was not DNA damage related, as 
demonstrated by the lack of increase in γH2AX foci.  Increased expression of p53 can result 
from a myriad of stressors, mutations, hypoxia, loss of repression by MDM2, inhibition of 
ubiquitin, deregulation oncogene expression and release from Akt inhibition. The 
accumulation of the tumour suppressor may be explained by the release of p53 repression 
imposed by phospho – Akt when the cell lines are treated with foretinib, as observed in 
Nalm 17.  
 
The accumulation of cells in sub – G1 indicates that the effects of both TKIs were not solely 
due to cell cycle arrest.  Both foretinib and dovitinib induced apoptosis as demonstrated 
PARP– 1 protein cleavage, even at low doses of TKI.  Caspase – dependent apoptosis 
induced by treatment by dovitinib and foretinib as seen in this study has been reported in 
AML and ovarian cell lines (427, 434). While the TKIs induced apoptosis in susceptible 
leukaemias, it is unlikely that a single agent TKI will be effective in eradicating the disease 
in a patient.  
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The impact of combined treatment was assessed since any novel drug would be included in 
a multi – agent regimen in clinical practice. The ultimate goal for the use of TKIs in the 
treatment of cancer is twofold. First, in high risk or relapsed disease, the addition of a TKI 
to an established chemotherapy regimen could sensitise the tumour to the conventional 
cytotoxics. Second, in lower risk disease a successful combination might allow for dose 
reduction of particularly toxic agents. To this end cells were treated with both TKIs in 
combination with a variety of cytotoxic drugs.  Significant synergy was found when 
foretinib was combined with 7 different conventional cytotoxics in both cell lines and 
primary cells. Notably, synergy was observed in cell lines that did not demonstrate 
significant response to the TKI alone. The impact of dovitinib on combination therapy was 
more variable. 
  
The precise mechanisms by which the TKIs sensitise malignancies to conventional 
chemotherapy are uncertain, but the inhibition of pro – survival pathways should result in 
increased susceptibility to chemotherapy.  Successful inhibition of RTKs and their pro – 
survival intracellular signalling cascades, such as activated AKT/PKB, and sensitisation to 
conventional cytotoxics has been reported with combinations of IGF-1R inhibitors and 
chemotherapy in Ewing’s sarcoma (435) and multiple myeloma (436).  
 
Concurrent treatment of the leukaemias with both TKIs and dexamethasone was strongly 
synergistic in all cell lines, including the steroid – resistant Nalm 6, SD -1 and REH, despite 
the latter lacking a glucocorticoid receptor (422) . Bachman et al reported the sensitisation of 
a steroid – resistant primary xenograft to dexamethasone with the inhibitor multikinase 
inhibitor SU11657, although not in the cell lines investigated here (422) .  
  
One possible mechanism of sensitisation to steroids is TKI – induced expression of pro – 
apoptotic Bcl – 2 family members.  Huynh et al (426) reported foretinib induced the 
expression of Bim in hepatocellular xenografts and this protein is essential for the induction 
of GC – induced apoptosis (422, 437). Thus alteration in Bcl-2 proteins may tip the balance 
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in favour of cell death. Sensitisation may also occur through GC receptor – independent 
mechanisms, since the reduction in viability induced by foretinib and dexamethasone co – 
treatment in REH was not via apoptosis, as demonstrated by the lack of increase in 
Annexin V – staining cells or increased PARP – 1 cleavage in comparison with foretinib 
alone.  The lack of GR expression in REH supports potentiation via GR – independent 
mechanism, unless the TKI itself induces the expression of the receptor protein.   
 
The interaction between foretinib and dovitinib in combination with the DNA – damaging 
agents is of significant clinical interest.  Foretinib sensitised cells to mitoxantrone, which is 
used in the re – induction phase in relapsed ALL (438). The synergy displayed between 
foretinib and the anthracyclines might allow a reduction in the dose of anthracycline 
required for patients who have received a significant cumulative dose of cardiotoxic drugs.  
However, TKI – induced cardiotoxicity in adults is well described (439), which could limit 
the use of TKIs in combination with anthracycline/anthraquinones.   
 
The impact of sequential exposure to TKI and chemotherapy was not explored in this 
study, although timing of administration might affect the quality of the interaction. Brown 
et al.. (397)  demonstrated the sequence – specific nature of the FLT3 inhibitor CEP – 701 
and conventional cytotoxic in childhood ALL.  Cells which were pre – treated with CEP – 
701 and followed by chemotherapy demonstrated significantly less response compared to 
the samples initially treated with chemotherapy and subsequent exposure to CEP – 701.   It 
has  been suggested the sequence – specificity is due to the effect CEP – 701 exerts on the 
cell cycle, which might interfere with subsequent cell – phase specific chemotherapy. In 
general the addition of FLT3 inhibitors prior to chemotherapy induces antagonism, 
whereas the addition of the TKIs after or at the same time as the conventional cytotoxic 
results in a synergistic interaction (440, 441).  The sequential timing of dovitinib in 
relationship to chemotherapy could be realised as it has a half – life of 13 hours (417), which 
would allow flexibility in dosing. The half – life of foretinib is approximately 40 hours (413), 
which would diminish the feasibility of meaningful sequential dosing. 
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The synergy observed between dovitinib and DNA – damaging agents or dexamethasone 
has previously been described in Waldenström's macroglobulinemia cells (432), where 
melphalan and dexamethasone exerted a moderate synergistic effect.  The results described 
here are the first evidence of interaction between foretinib and conventional 
chemotherapeutic agents.  
 
To investigate the in vivo efficacy of both TKIs, a murine xenograft of an in vitro sensitive 
primary cell was created. While the in vivo experiments did not confirm an objective 
response to the TKIs, foretinib induced a statistically significant reduction in peripheral 
hCD45 cells and dovitinib demonstrated a trend to increased survival (p = 0.08).  
 
A reason for this lack of objective response may be the aggressive nature of the ALL - 20 
xenograft model. The rapid rates of engraftment might have led to too great a tumour load 
by the time treatment started. The in vivo efficacy of dovitinib has been investigated in a 
xenograft model of the myeloid FLT3 - ITD cell line MV4;11 (434).  The myeloid leukaemia 
took 23 days to engraft in comparison to the 4 – 8 days in this study. The MV4;11 control 
mice displayed a median survival time of 51 days with median survival 134 days in the 
dovitinib – treated mice. The untreated mice in the present study survived for 25 – 36 days. 
The engraftment in the untreated mice was also low, 2 – 19% at day 51, while up to 95% 
engraftment reported here. The effects of dovitinib in slower engrafting models might be 
more promising. Foretinib has not been examined in a leukaemic model. 
 
Another limiting factor in this study was the small numbers of mice in each cohort and 
attrition because of misgavage of the TKIs. The decision to continue with oral treatment 
was based on the lack of evidence for administration of either agent by the intraperitoneal 
route. The further loss of viable organs for FACS analysis limits the veracity of tumour load 
comparison in the dovitinib experiment.   It seems likely though, that the necrosis was due 
to thrombosis and haemorrhage induced by massive tumour infiltration. Using the 
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untreated and vehicle cohorts of the foretinib and kinetics experiment as historical controls, 
the level of hCD45 engraftment is similar to that of the dovitinib – treated mice.   
 
The dose schedule used for the dovitinib experiments (65mg/kg/day) has demonstrated 
good responses in myeloid and solid tumour xenografts (428, 434). The dose chosen for 
foretinib, 30mg/kg/day, has been used in solid tumour xenografts with good response (297, 
426), although it was given daily.  The 5 days on/ 9 days off schedule was identified as the 
maximum tolerated dose (MTD) in a recent phase 1 study in adult solid tumours.  Excellent 
pharmacodynamic activity was demonstrated (413), with significant post – exposure 
reduction in phosphorylated RTKs. The limited response in this study may be attributable 
to an inadequate dosing schedule and a higher dose given continuously might have 
provided a better response. Neither foretinib nor dovitinib significantly altered the 
maturity of the engrafting population.  The bulk cell population after treatment were still 
the CD34-CD1910+ B – precursor, thus indicating that these TKIs do not induce 
differentiation in in vivo models.     
  
In conclusion, in vitro efficacy of 2 TKI as single agents and in combination with 
conventional chemotherapies has been demonstrated in the childhood ALLs in this study.  
Objective responses to either TKI could not be in an established and validated primagraft 
model. However, further exploration within the murine xenograft with continuous dosing 
and possibly slower engrafting leukaemias would be justified to fully investigate the 
potential clinical use of these agents.    
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6   Conclusions and future work 
The work undertaken in this study has demonstrated that further investigation into the use 
of TKIs in treating childhood ALL is warranted. Using the complementary approaches of 
phospho – protein arrays and an inhibitor library numerous possible targets have been 
identified. 
 
The phospho – RTK array data demonstrated heterogeneous phosphorylation of a 
significant number RTKs in primary ALLs. Data from the R&D array system was consistent 
with published literature in demonstrating increased FLT3 phosphorylation in the 
hyperdiploid ALLs. Novel data included the identification of increased EphA2 
phosphorylation in ALL with normal cytogenetics, increased phosphorylation signals of 
Mer and FGFR2 in ALLs with high white cell count at diagnosis and the presence of 
increased PDGFRβ in ALLs with MRD detectable by flow cytometry at the end of 
induction. In contrast to published data, the Raybiotech array identified increased 
phosphorylation of Axl in primary ALLs with proficient responses to IR – induced 
apoptosis. The hypothesis that (R)TKs are activated in apoptotic defective leukaemias was 
not demonstrated in this study. Further validation these potential targets is required. 
 
The inhibitor library screen of cell lines and primary ALL revealed heterogeneous activity 
of the TKIs screened. While no single inhibitor was active in all samples investigated, 4 
inhibitors (bosutinib, CEP – 701, dovitinib and foretinib) were active in 4 of the 5 cell lines 
screened. These 3 drugs have activity against common targets   FLT3, VEGFR – 1 and 2 and 
PDGFRβ. Similarly, in the primary ALL screen TKIs with multikinase activity against FLT3, 
VEGFR and PDGFR families were the most potent. From the data in this study, the 
inhibitors with a broad spectrum of activity were most active. Other candidate inhibitors 
with a reportedly narrower spectrum of activity included the Met/ALK inhibitors and the 
irreversible EGFR inhibitors.  The most likely mechanism of action for these drugs were via 
off – target effects.   
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The 2 candidates, dovitinib and foretinib taken forward for further preclinical 
investigations demonstrated nanomolar activity in cell line and primary ALL assays. Both 
drugs inhibited cell growth, either via the induction of apoptosis or cytostasis, and revealed 
a predominantly synergistic effect when combined with conventional cytotoxics. The most 
notable interaction was the potent sensitisation of steroid – resistant cell lines to 
dexamethasone when incubated with dovitinib or foretinib. In the murine primagraft 
dovitinib and foretinib did not extend median survival, but limitations to the model have 
been identified.  
 
These data support the on-going investigation into the use of TKIs in non – Ph+ ALL. As 
reported in this study, inhibitors demonstrated significant activity in cell lines resistant to 
conventional chemotherapy and potent sensitisation of cell lines to steroids. The 
sensitisation of REH to dexamethasone via GR – independent mechanisms highlights the 
potential of TKIs to exploit novel pathways to treat resistant leukaemias.  The activity of 
non – Abl inhibitors in the Ph+ ALL cell lines, SD – 1 and SupB15 is of particular interest as 
resistance to TKIs is a particular concern in the management of Ph+ ALL. Further 
investigation into the action of the non – Abl identified in this study would be of interest as 
alternate targets may be identified.   
 
A limitation of the data presented in this study is the lack of evidence demonstrating the 
inhibitors work through the putative targets. In the EGFR/HER2 inhibitors, BIBW – 2992 
and CI – 1033, the mechanism of action is most likely due to off – target effects. In clinical 
practice it could be argued that if the goal of any therapy is the eradication of leukaemia, it 
is debatable whether the concept of on – and off – target is vital, if the drug achieves cell 
death. However, the identification of pathways is important to understand potential 
toxicities, interactions with other drugs in multi – agent regimens and ultimately define the 
“true” targets to understand a drugs mechanism of action.     
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While this study did not identify particular targets, evidence from the arrays and inhibitor 
screen suggest further investigation into the role of RTKs in leukaemias is warranted. 
Approaches to further validate and identify targets include:  
 
6.1 Validation of phosphorylated RTKs identified by phospho – RTK arrays 
The identification of the phosphorylated RTKs, Axl, EphA2, FLT3, FGFR2 and Mer by the 
phospho – RTK arrays need to be validated because inhibitors for all of these RTKs are 
available or coming through the pharmaceutical pipeline. While this project has 
demonstrated a screening approach based on arrays and cell viability can identify 
candidate RTKs and compounds, it has not identified or validated targets. The goal of this 
work would be to confirm the presence of the proposed targets. To fully characterise the 
potential targets, mRNA transcript and protein should be undertaken in original samples 
used in the study, identifying the total and phosphorylated forms of the RTKs. 
Unfortunately, because of limited amount of sample this will not be achievable. If sufficient 
sample were present and this could be performed, validation in a second cohort would be 
vital.    
 
6.2 Genomic characterisation of primaries at baseline and in response to TKIs 
To date, projects undertaking sequencing of the tyrosine kinome have not identified 
obvious gain – of – function mutations in ALL (442). Although very few specific gene 
mutations have been identified leading to kinase activation, investigation of the molecular 
pathways affected by TKIs may identify susceptible gene expression profiles. Microarray 
analysis of the alterations in the gene expression profiles of primary leukaemias in response 
to TKIs identified in the library screen may elucidate the signalling modules/pathways 
involved in determining sensitivity or resistance. The establishment of gene expression 
profiles of primary cells at baseline and after treatment with candidate inhibitors may 
uncover both on – and off – target mechanisms of action.   
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6.3  Target Deconvolution: Identification of protein targets 
The large number of activated RTKs identified by the arrays in this study and the lack of 
universal response of the samples to a single inhibitor suggests that, unlike CML, ALL does 
not express one individual specific activated tyrosine kinase. Alterations in the leukaemia 
cells internal phosphoproteomic environment in response to treatment with an inhibitor by 
would complement any alterations identified in the genomic approach. The combined 
system biological approach would add significant data to our understanding of childhood 
ALL. Preliminary experiments to assess changes in tyrosine phosphorylation in ALL cell 
lines have been undertaken and significant alterations in phosphorylation signals in cell 
lines treated with foretinib 1µM were identified (fig 6.1).                            
 
                                
 
Figure 6.1: Preliminary experiments in pre – B ALL cell lines reveal altered phosphorylation signals in 
response to incubation with foretinib. 5 ALL cell lines were incubated with 1µM foretinib for 4 hours. 
Western blotting with pan – phospho – tyrosine antibody revealed reduction in signal in regions.  
 
The dominant changes were visible in the consistent the region containing RTKs, MW 130 – 
260kDa. To investigate the putative targets in the region between 130 – 260kDa, 
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immunoprecipitation of cell lysates with a pan – phospho – tyrosine antibodies followed by 
liquid chromatography and tandem mass spectrometry (LC – MS/MS) – based proteomic 
approaches may delineate multiple constitutively phosphorylated RTKs and the associated 
activated cellular pathways. 
 
To help generate protein target hypotheses, the quantitative changes in phosphopeptides in 
response to treatment could be assessed by stable isotope labelling amino acids in cell 
culture (SILAC), this reproducible technique is able to compare the proteomic profile of 2 
cell populations. The incorporation of a labelled amino acid analogue into proteins 
synthesised by a cell population allows for quantification of alteration of peptide levels 
after treatment. The labelled cell lines would be incubated with the candidate TKI, samples 
lysed and immunorecipitated with a pan – phospho – tyrosine antibody. Phospho – 
tyrosine enriched peptides would be produced by in – gel digestion. Further enrichment for 
phosphopeptides using immobilised metal affinity chromatography (IMAC), followed by a 
second step for phosphotyrosine peptides with the use of titanium dioxide beads (TiO2). 
The peptide mixture is separated on liquid chromatography gradient followed by tandem 
mass – spectrometry. A drawback of this approach is SILAC requires cycling cells, thus this 
may approach would be limited to cell lines. 
 
A second more complex approach is the compound – centric chemical proteomic approach. 
To investigate the spectrum of proteins interacting with the inhibitor, the drug is 
conjugated to a biochemically inert matrix to capture proteins which will interact with the 
analogue. Detailed structural activity relationships would need undertaking to ensure the 
functionalised molecule has similar properties to the original; any alteration of the drug’s 
structure to act as “bait” may interfere with the protein binding of the original compound 
and change its biological activity. The proteins are subsequently eluted and assessed by LC 
– MS/MS. While more complicated, this technique would be the preferred method for 
further identifying candidate drug targets because this technique could be used in cell lines 
and in non – cycling primary ALLs.   
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The candidate drugs, dovitinib and foretinib, demonstrated significant in vitro activity, but 
the reasons for lack of activity in the murine model is at present uncertain. The primagraft 
work in this study does suggest the compounds may be active if the dosing schedules are 
optimised. Further xenograft work to expand the murine cohort and investigate the 
possible in vivo ability for foretinib and dovitinib to sensitise dexamethaonse – resistant 
leukaemias to dexamethasone should be pursued:     
 
6.4 Xenograft Modelling: 
The most mature paediatric drug testing programme, the NCI PPTP has investigated the 
multikinase inhibitors in ALL xenografts with limited objective response (407, 410, 443). 
Each experiment consists of 6 pre – B ALL xenografts and of the TKIs investigated limited 
objective responses have been described. While no objective response was present in the 
model is this study, the leukaemia engrafted very rapidly and dosing may have been too 
late for a realistic chance of treatment effect. Development of a more comprehensive panel 
of xenografts including a range of different primary ALL samples would facilitate the full 
assessment the potential activity of both TKIs, as would optimisation of the dosing 
schedules.     
 
6.4.1 Identification of dexamethasone – resistant primary sample  
Dexamethasone revealed the greatest synergistic activity with foretinib and dovitinib in the 
cell lines and the primary ALL (ALL – 20). The combination of TKI and steroid requires 
further investigation, not only to explore the clinical potential, but also to elucidate 
mechanisms of dexamethasone resistance and sensitisation. The identification or 
establishment of a dexamethasone – resistant primary ALL may enable further assessment 
whether foretinib and dovitinib can sensitise a dexamethasone – resistant ALL to 
dexamethasone in vitro. To identify the molecular pathways involved in dexamethasone 
resistance/sensitisation, microarray analysis of the dexamethasone – resistant primary 
leukaemia would be performed at baseline, after exposure to sub – IC50 doses of 
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dexamethasone and TKI and after combination of TKI and steroid to identify the alterations 
in gene expression profile.     
 
6.4.2 Combination of dexamethasone and foretinib/dovitinib in dexamethasone – 
resistant murine model  
The combination of foretinib/dovitinib with dexamethasone needs further investigation in 
the in vivo primagraft model. This would enable the comparison of TKI monotherapy, with 
dexamethasone monotherapy and the combination of the 2 agents. To assess sensitisation to 
dexamethasone, a suggested experiment would compare cohorts of mice treated with 
steroid, TKI or in combination. The first cohort of mice would receive dexamethasone at an 
anti-leukaemic dose reflecting that used in the clinical if possible, while a second cohort 
would receive the TKI. Both cohorts of mice would receive TKI and dexamethasone at 
clinically relevant equivalent doses. The third and fourth cohorts would receive reduced 
(50%) doses of foretinib/dovitinib and reduced (50%) doses of the dexamethasone, 
respectively at same scheduling. The fifth cohort would receive a combination of 50% TKI 
and 50% dexamethasone.  
 
The median survival of each cohort would be documented to assess the impact of each 
treatment. If the combination of the TKI and dexamethasone were to add a survival benefit, 
differences in the gene expression profiles of leukaemia cells harvested from the murine 
organs may be able to identify the molecular pathways involved in the sensitisation.  
 
On basis of the work in this thesis, TKIs are worthy of further investigation as the data 
presented hints at the role of several as potential therapeutic agents, particularly in the 
context of combination therapy with conventional chemotherapies.  
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Abstract 1509  
Acute lymphoblastic leukaemia (ALL) is the most frequent malignancy in childhood with resistance 
or relapse occurring in up to 20% of patients. The precise mechanisms of resistance to conventional 
therapy leading to relapse have not been elucidated. Deregulation of tyrosine kinases (TKs) have 
been implicated in resistant solid tumours and the of aetiology haemopoietic tumours, Philadelphia – 
chromosome positive ALL (Ph+ ALL), FLT3 in MLL+ infant ALL and FLT3-ITD subset in acute 
myeloid leukaemia. The role of TK inhibitors (TKIs) has not been extensively investigated in non-Ph 
+ ALL.  
We screened 5 B-cell precursor ALL cell lines and 20 primary samples with a library of 34 TKIs. 
Nalm 6 (t(5;12)), Nalm 17 (normal karyotype), REH (t(12;21)), SD1 and Sup15 (Ph+ ALL) and 
primary cells were tested at 1μM and 10μM and alterations in cell viability assessed with the 
Promega CellTiter-Glo assay. A drug was considered to be effective if it induced >50% reduction in 
cell viability at 1μM.  
While we demonstrated significant heterogeneity in response to many of the TKIs, we observed 
reduction in viability to lestaurtinib (FLT3/JAK2), dovitinib (FLT3/FGFR/PDGFR/VEGFR) and 
bosutinib (Abl/Src) in all cell lines. Compared with Nalm 6 and Nalm 17 which only exhibited 
sensitivity to these 3 TKIs, REH demonstrated additional sensitivity to crizotinib (ALK/Met) and the 
quinazoline pan-EGFR inhibitors, afatinib and canertinib. The Ph+ cell lines SupB15 and SD1 
responded to the highest number of TKIs, 12 and 14 respectively. These included the expected 
Bcr/Abl and Aurora kinase inhibitors. Activity of the putative PDGFR/VEGFR TKIs axitinib, 
linifanib, vargatef and also foretinib (MET/VEGFR2/FLT3) appeared limited to Ph+ cell lines.  
The cell lines, REH and SD-1, which are resistant to ionizing radiation–induced apoptosis, were 
selectively inhibited by both the quinazolines. Baseline mRNA expression of the ErbB family was 
present in all cell lines and therefore did not correlate with response.  
TKIs inducing the greatest reduction in cell viability across the cell lines were those that target class 
III/IV/V RTKs. Although all cell lines expressed FLT3 mRNA, reduction in cell viability was not 
universally induced by the specific FLT3 inhibitor tandutinib at doses of up to 10μM. As observed in 
previous studies, the level of mRNA transcript did not predict or directly correlate with the response 
to TKI.  
A panel of 20 primary ALL samples, representative of common biological features, were screened. 
We found no correlation between cytogenetics, age, white cell count, post – induction MRD status 
and response to TKI groups or individual inhibitor. Only 5/20 did not respond to any of the tested 
TKIs. Lestaurtinib, dovitinib and foretinib reduced cell viability in 7/20 primary ALLs. In addition, 
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canertinib reduced cell viabililty in 6/20 primary ALL samples, afatinib and TAE684 (ALK/MET) 
both in 5/20 ALL samples respectively and vargatef in 4/20 samples.  
Based on our preliminary screen, the multikinase inhibitor foretinib was selected as one of several 
promising candidates for further pre-clinical testing. Recent adult phase 1 solid tumor trials have 
shown limited toxicity and good bioavailability.  
Foretinib inhibited leukaemia proliferation with LD50 in nanomolar and low micromolar range; 
SupB15 (333nM ±49), SD-1 (381nM ±239), Nalm 17 (484nM ±124), REH (689nM ±92) and Nalm 
6 (1.84μM ±0.25). Annexin/PI staining, DNA fragmentation and PARP protein cleavage confirmed 
that the mechanism of cell death was apoptosis.  
We next investigated whether foretinib could sensitise ALL cell lines to dexamethasone, cytarabine, 
methotrexate, doxorubicin or mitoxantrone. Drug interactions were modelled using the Biosoft 
Calcusyn software package. We found that the addition of foretinib resulted in predominantly 
synergistic interactions in all cell lines (CI<1). The most striking example of synergism was in the 
dexamethasone-resistant cell line, REH. Addition of a sub–LD50 dose of foretinib led to >50% 
reduction in cell viability when combined with 1nM dexamethasone compared with no response at 
10μM dexamethasone alone.  
Overall these data support further exploration of TKIs as potential therapeutic agents in childhood 
ALL. Specifically, we are currently investigating the direct anti-leukemic activity of foretinib in 
childhood ALL and its synergistic activity with dexamethasone in vivo using our NOG mouse 
primograft model for ALL.  
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Purpose: Deregulation of tyrosine kinases (TKs) has been implicated in high risk non- 
Philadelphia chromosome positive ALL. This project investigated the role of TK inhibitors 
(TKIs) in childhood ALL. 
 
Methods: We screened 5 pre – B ALL cell lines and a panel of 20 primary samples 
representative of common biological features for sensitivity to a library of 33 TKIs. Active 
compounds were defined as reducing cell viability >50% at 1 mM with a concomitant dose -
dependent reduction at 10 mM. 
 
Results: Significant heterogeneity in sensitivity was observed in the panel of leukaemia 
cells.No correlation was evident between response to TKIs and current clinical or biological 
stratification parameters in the primary cell panel. In both cell lines and primary cells, 
categories of TKIs were most effective: (i) the FLT3/PDGFR/VEGFR multikinase inhibitors 
(vargatef, lestaurtinib, dovitinib, foretinib), (ii) the irreversible pan – EGFR quinazoline 
inhibitors (canertinib, afatinib) and (iii) dual Met/ALK inhibitors (NVPTAE684, crizotinib). 
As observed in previous studies, the expression of a putative target at mRNA level did not 
predict or directly correlate with the response to a TKI. Based on our preliminary screen, 
the multikinase inhibitor dovitinib was selected as one of several promising candidates for 
further pre-clinical testing. Dovitinib inhibited leukaemia proliferation with IC50 in 
nanomolar range (0.19–0.84 mM) in cell lines. Cell cycle analysis revealed dovitinib induced 
cytostasis and cell death in the cell lines. PARP protein cleavage confirmed that the 
mechanism of cell death was by apoptosis. Co-incubation with dovitinib sensitised ALL cell 
lines to dexamethasone and doxorubicin, with predominantly synergistic drug interactions. 
 
Conclusion: Overall these data support further exploration of TKIs as potential therapeutic 
agents in childhood ALL.We are currently investigating the direct anti-leukaemic activity of 
dovitinib in childhood ALL in vivo using our NOG mouse primograft model for ALL. 
 
